<SEC-DOCUMENT>0001104659-21-138192.txt : 20211112
<SEC-HEADER>0001104659-21-138192.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112170059
ACCESSION NUMBER:		0001104659-21-138192
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211105
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CBTX, Inc.
		CENTRAL INDEX KEY:			0001473844
		STANDARD INDUSTRIAL CLASSIFICATION:	NATIONAL COMMERCIAL BANKS [6021]
		IRS NUMBER:				208339782
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38280
		FILM NUMBER:		211404617

	BUSINESS ADDRESS:	
		STREET 1:		9 GREENWAY PLAZA, SUITE 110
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77046
		BUSINESS PHONE:		(713) 210-7600

	MAIL ADDRESS:	
		STREET 1:		9 GREENWAY PLAZA, SUITE 110
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77046

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CBFH, Inc.
		DATE OF NAME CHANGE:	20091005
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2131964d8_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:CBTX="http://cbtx.com/20211105">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_CBTX_cbtx.com_20211105 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20211105_20211105 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001473844 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityCentralIndexKey">0001473844</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cbtx-20211105.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-11-05to2021-11-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001473844</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-05</xbrli:startDate>
        <xbrli:endDate>2021-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20211105__20211105_zJfqLutnLHJ9"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PURSUANT TO SECTION 13 OR
15(d) OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
 <span id="xdx_907_edei--DocumentPeriodEndDate_c20211105__20211105_zVaJ1rwNP7Ch"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 5, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--EntityRegistrantName_c20211105__20211105_zZ1JRmcYbcNf" style="font-size: 14pt"><b><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityRegistrantName">CBTX,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20211105__20211105_zIttWIt0tmQ5"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityFileNumber_c20211105__20211105_zDbumrSgv5ah"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityFileNumber">001-38280</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: top; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20211105__20211105_z9XcX6diuZFd"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityTaxIdentificationNumber">20-8339782</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation or organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20211105__20211105_zeOfEkCqaGX9"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressAddressLine1">9 Greenway Plaza</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20211105__20211105_zNJz1WhDoPbh"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressAddressLine2">Suite 110</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20211105__20211105_zSrPTun6FPT"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressCityOrTown">Houston</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20211105__20211105_zyZ618dSObUe"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20211105__20211105_zrvCBlPhiYyd"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressPostalZipCode">77046</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--CityAreaCode_c20211105__20211105_zv0vhnUhB4f1"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:CityAreaCode">(713)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20211105__20211105_zfMy9j40uoJ4"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:LocalPhoneNumber">210-7600</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20211105__20211105_zL3VZ1D5Dbqg"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleantrue" name="dei:WrittenCommunications">&#120;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Wingdings"><span id="xdx_907_edei--SolicitingMaterial_c20211105__20211105_zW44h9KXbwU3"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Wingdings"><span id="xdx_909_edei--PreCommencementTenderOffer_c20211105__20211105_zvVFlXSJw0Zc"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
                                                                                                                                                240.14d-2(b))</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20211105__20211105_zhuejhZzRO29"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
                                                                                                                                                240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid; text-align: center; width: 37%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 43%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--Security12bTitle_c20211105__20211105_zZtJd2aOvmXg"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:Security12bTitle">Common stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--TradingSymbol_c20211105__20211105_zjrDIDZgsZ1c"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:TradingSymbol">CBTX</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--SecurityExchangeName_c20211105__20211105_zqkwrP2SMmf1"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;230.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt">Emerging growth
company </span><span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20211105__20211105_z0c5DsfjIQGg"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityExTransitionPeriod_c20211105__20211105_ztr34QDwj6df"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Item 1.01. Entry into a Material
Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November&#160;5, 2021, CBTX,&#160;Inc., a Texas corporation (&#8220;CBTX&#8221;),
and Allegiance Bancshares,&#160;Inc., a Texas corporation (&#8220;Allegiance&#8221;), entered into an Agreement and Plan of Merger (the
&#8220;Merger Agreement&#8221;), pursuant to which Allegiance and CBTX have agreed to effect a merger-of-equals transaction. The Merger
Agreement provides that, upon the terms and subject to the conditions set forth therein, Allegiance will merge with and into CBTX (the
&#8220;Merger&#8221;), with CBTX as the surviving entity in the Merger. Immediately following the Merger, Allegiance Bank, a Texas state-charted
bank and a wholly-owned subsidiary of Allegiance (&#8220;Allegiance Bank&#8221;), and CommunityBank of Texas, N.A., a national banking
association and a wholly-owned subsidiary of CBTX (&#8220;CommunityBank of Texas&#8221;) will merge with and into Allegiance Bank (the
&#8220;Bank Merger&#8221;), with Allegiance Bank as the surviving bank in the Bank Merger. The Merger Agreement was approved by the board
of directors of each of Allegiance and CBTX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the terms and subject to the conditions set forth in the Merger
Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of common stock, par value $1.00 per share,
of Allegiance (&#8220;Allegiance Common Stock&#8221;) outstanding immediately prior to the Effective Time, other than certain shares held
by Allegiance or CBTX, will be converted into the right to receive the merger consideration of 1.4184 (the &#8220;Exchange Ratio&#8221;)
shares of common stock, par value $0.01 per share, of CBTX (&#8220;CBTX Common Stock&#8221;). Holders of Allegiance Common Stock will
receive cash in lieu of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the Effective Time, each option to purchase shares of Allegiance
Common Stock will vest and be converted into an option to purchase a number of shares of CBTX Common Stock equal to the product of (1)&#160;the
total number of shares of Allegiance Common Stock subject to such option immediately prior to the Effective Time multiplied by (2)&#160;the
Exchange Ratio, with any fractional shares rounded down to the next lower whole number of shares. Each such converted option will have
an exercise price per share of CBTX Common Stock (rounded up to the nearest whole cent) equal to (a)&#160;the per share exercise price
for the shares of Allegiance Common Stock subject to such option immediately prior to the Effective Time divided by (b)&#160;the Exchange
Ratio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the Effective Time, (1)&#160;generally each unvested performance
unit award in respect of shares of Allegiance Common Stock will vest to the extent applicable performance goals have been achieved on
a pro rata basis as of the Effective Time and be converted into the right to receive the merger consideration in respect of the applicable
number of shares of Allegiance Common Stock, except that each unvested performance unit award granted less than one year prior to the
closing date of the Merger will be forfeited, and (2)&#160;each other outstanding Allegiance restricted stock award under Allegiance&#8217;s
equity compensation plans will vest and be converted into the right to receive the merger consideration. At the Effective Time, generally
each outstanding CBTX equity award under CBTX&#8217;s equity compensation plans will vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Certain Governance Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement also provides, among other things, that effective
as of the Effective Time, Steven F. Retzloff, the current Chief Executive Officer of Allegiance, will serve as the Executive Chairman
of the board of directors of the surviving entity, and Robert R. Franklin,&#160;Jr., the current Chairman, President and Chief Executive
Officer of CBTX, will serve as the Chief Executive Officer of the surviving entity. Within 180 days following the Effective Time, the
surviving entity&#8217;s board of directors will select an independent director from among the Board of Directors to serve as the lead
independent director of the board of directors of the surviving entity. In addition, the Merger Agreement provides that Ramon A. Vitulli,&#160;III
will be appointed to serve as the Chief Executive Officer of the surviving bank in the Bank Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board of directors of the surviving entity will be comprised of
14 directors, of which seven will be former members of the board of directors of CBTX (one of whom, as of the Effective Time, will be
Robert R. Franklin,&#160;Jr.) and of which seven will be former members of the Board of Directors of Allegiance (one of whom, as of the
Effective Time, will be Steven F. Retzloff). Until the third anniversary of the closing of the Merger, the board of directors of the surviving
entity will have the following four committees: (1)&#160;Audit Committee, (2)&#160;Compensation Committee, (3)&#160;Corporate Governance
and Nominating Committee, and (4)&#160;Risk Committee. At the Effective Time and until the third anniversary of the closing of the Merger,
the chairpersons of two of such committees will be designated from among the continuing CBTX directors (and their successors), and the
chairpersons of the other two of such committees will be designated from among the continuing Allegiance directors (and their successors),
and the membership of each of the foregoing committees will be, as practicably as possible, evenly split between continuing CBTX directors
(and their successors) and continuing Allegiance directors (and their successors).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Effective
as of the Effective Time, the bylaws of CBTX will be amended to reflect the foregoing and certain related governance </span>matters. In
connection with the completion of the Merger, CBTX&#8217;s certificate of formation will also be amended to increase the number of authorized
shares of CBTX Common Stock from 90 million to 140 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Merger Agreement provides that the corporate headquarters
of the surviving entity will be located in Houston, Texas. CBTX and Allegiance will determine the names of the surviving entity and the
surviving bank prior to the Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Certain Other Terms and Conditions of the Merger Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement contains customary representations and warranties
from both Allegiance and CBTX, and each party has agreed to customary covenants, including, among others, covenants relating to (1)&#160;the
conduct of its business during the interim period between the execution of the Merger Agreement and the Effective Time, (2)&#160;its obligations
to call a meeting of its shareholders to approve the Merger Agreement and, subject to certain exceptions, to recommend that its shareholders
approve the Merger Agreement, and (3)&#160;its non-solicitation obligations relating to alternative acquisition proposals. Allegiance
and CBTX have also agreed to use their reasonable best efforts to prepare and file all applications, notices and other documents to obtain
all necessary consents and approvals for consummation of the transactions contemplated by the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The completion of the Merger is subject to customary conditions, including
(1)&#160;approval of the Merger Agreement by Allegiance&#8217;s shareholders, (2)&#160;approval of the Merger Agreement by CBTX&#8217;s
shareholders, (3)&#160;authorization for listing on the NASDAQ Stock Market LLC of the shares of CBTX Common Stock to be issued in the
Merger, (4)&#160;the receipt of required regulatory approvals, including the approval of the Board of Governors of the Federal Reserve
System, the Federal Deposit Insurance Corporation and the Texas Department of Banking, (5)&#160;effectiveness of the registration statement
on Form&#160;S-4 registering the CBTX Common Stock to be issued in the Merger, and (6)&#160;the absence of any order, injunction, decree
or other legal restraint preventing the completion of the Merger or making the completion of the Merger illegal. Each party&#8217;s obligation
to complete the Merger is also subject to certain additional customary conditions, including (a)&#160;subject to certain exceptions, the
accuracy of the representations and warranties of the other party, (b)&#160;performance in all material respects by the other party of
its obligations under the Merger Agreement and (c)&#160;receipt by such party of an opinion from its counsel to the effect that the Merger
will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as
amended. In addition, Allegiance&#8217;s obligation to complete the Merger is subject to the resolution of the investigation of CommunityBank
of Texas&#8217; BSA/AML Program by the Financial Crimes Enforcement Network of the U.S. Department of the Treasury (&#8220;FinCen&#8221;)
and the payment or accrual by CommunityBank of Texas of any monetary penalties assessed by FinCen or the Office of the Comptroller of
the Currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement provides certain termination rights for both Allegiance
and CBTX and further provides that a termination fee of $32.5 million will be payable by either Allegiance or CBTX, as applicable, upon
termination of the Merger Agreement under certain circumstances. In addition, the Merger Agreement provides for reimbursement of up to
$1.0 million of Allegiance&#8217;s expenses associated with the Merger payable by CBTX upon termination of the Merger Agreement under
certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Merger Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached hereto as Exhibit&#160;2.1
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The representations, warranties and covenants of each party set forth
in the Merger Agreement have been made only for the purposes of, and were and are solely for the benefit of the parties to, the Merger
Agreement; may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures
made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters
as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors.
Accordingly, the representations and warranties may not describe the actual state of affairs at the date they were made or at any other
time, and investors should not rely on them as statements of fact. In addition, such representations and warranties (1)&#160;will not
survive consummation of the Merger and (2)&#160;were made only as of the date of the Merger Agreement or such other date as is specified
in the Merger Agreement. Moreover, information concerning the subject matter of the representations and warranties may change after the
date of the Merger Agreement, which subsequent information may or may not be fully reflected in the parties&#8217; public disclosures.
Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding the terms of the Merger
Agreement, and not to provide investors with any factual information regarding Allegiance or CBTX, their respective affiliates or their
respective businesses. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information
regarding Allegiance, CBTX, their respective affiliates or their respective businesses, the Merger Agreement and the Merger that will
be contained in, or incorporated by reference into, the registration statement on Form&#160;S-4 that will include a joint proxy statement
of Allegiance and CBTX and a prospectus of CBTX, as well as in the Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q,
Current Reports on Form&#160;8-K and other filings that each of Allegiance and CBTX makes with the Securities and Exchange Commission
(&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting Agreement and Director Support Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of the directors, executive officers and shareholders of Allegiance
(holding approximately 5.5% of the outstanding Allegiance Common Stock) and certain directors, executive officers and shareholders of
CBTX (holding approximately 20.9% of the outstanding CBTX Common Stock) have executed a voting agreement (the &#8220;Voting Agreement&#8221;)
in which they have agreed to vote their shares of Allegiance Common Stock and CBTX Common Stock, respectively, in favor of approval of
the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger Agreement, certain directors of Allegiance
and CBTX have entered into Director Support Agreements with their respective company (the &#8220;Director Support Agreements&#8221;) pursuant
to which they have agreed to support the transaction and to certain additional restrictive covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Voting Agreement and the Director
Support Agreements do not purport to be complete and are qualified in their entirety by reference to the form of the Voting Agreement,
which is attached hereto as Exhibit&#160;10.1 and incorporated by reference herein, and the form of the Director Support Agreement, which
is attached hereto as Exhibit&#160;10.2 and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"><b>Item 9.01</b></td>
    <td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;<span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-decoration: underline; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Exhibit&#160;Number</span></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-decoration: underline; text-align: justify; width: 88%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Description of Exhibit</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2131964d8_ex2-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">2.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2131964d8_ex2-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger, dated November&#160;5, 2021, by and between CBTX,&#160;Inc. and Allegiance Bancshares,&#160;Inc.*</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2131964d8_ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2131964d8_ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Form&#160;of Voting Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2131964d8_ex10-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2131964d8_ex10-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Form&#160;of Director Support Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page&#160;Interactive Data File &#8211; the cover page&#160;interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded with the Inline XBRL document.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Schedules have been omitted pursuant to Item
601(a)(5)&#160;of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request&#894; provided,
however, that the parties may request confidential treatment pursuant to Rule&#160;24b-2 of the Securities Exchange Act of 1934, as amended,
for any document so furnished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this communication which
are not historical in nature are intended to be, and are hereby identified as, &#8220;forward-looking statements&#8221; for purposes of
the safe harbor provided by Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange
Act of 1934, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statements include, but are not limited
to, statements about the benefits of the proposed merger of Allegiance and CBTX, including future financial and operating results (including
the anticipated impact of the transaction on Allegiance&#8217;s and CBTX&#8217;s respective earnings and book value), statements related
to the expected timing of the completion of the merger, the combined company&#8217;s plans, objectives, expectations and intentions, and
other statements that are not historical facts. Forward-looking statements may be identified by terminology such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;scheduled,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221;
&#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or negatives
of such terms or other comparable terminology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements are subject to
risks, uncertainties and other factors that may cause the actual results, performance or achievements of Allegiance or CBTX to differ
materially from any results expressed or implied by such forward-looking statements. Such factors include, among others: (1)&#160;the
risk that the cost savings and any revenue synergies from the merger may not be fully realized or may take longer than anticipated to
be realized; (2)&#160;disruption to the parties&#8217; businesses as a result of the announcement and pendency of the merger; (3)&#160;the
occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (4)&#160;the risk
that the integration of each party&#8217;s operations will be materially delayed or will be more costly or difficult than expected or
that the parties are otherwise unable to successfully integrate each party&#8217;s businesses into the other&#8217;s businesses; (5)&#160;the
failure to obtain the necessary approvals by the shareholders of Allegiance or CBTX; (6)&#160;the amount of the costs, fees, expenses
and charges related to the merger; (7)&#160;the ability by each of Allegiance and CBTX to obtain required governmental approvals of the
merger (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or
the expected benefits of the transaction); (8)&#160;reputational risk and the reaction of each company&#8217;s customers, suppliers, employees
or other business partners to the merger; (9)&#160;the failure of the closing conditions in the merger agreement to be satisfied, or any
unexpected delay in closing the merger; (10)&#160;the possibility that the merger may be more expensive to complete than anticipated,
including as a result of unexpected factors or events; (11) the dilution caused by CBTX&#8217;s issuance of additional shares of its common
stock in the merger; (12) general competitive, economic, political and market conditions; (13) the costs, effects and results of regulatory
examinations, investigations, including the ongoing investigation by the Financial Crimes Enforcement Network of the U.S. Department of
Treasury, or FinCEN, of CBTX or the ability of CBTX to obtain required regulatory approvals; (14) the possible results and amount of civil
money penalties related to such FinCEN investigation and CBTX&#8217;s BSA/AML program; and (15) other factors that may affect future results
of CBTX and Allegiance including changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes
in interest rates and capital markets; inflation; customer borrowing, repayment, investment and deposit practices; the impact, extent
and timing of technological changes; capital management activities; and other actions of the Board of Governors of the Federal Reserve
System, Federal Deposit Insurance Corporation and Office of the Comptroller of the Currency and legislative and regulatory actions and reforms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional factors which could affect future results
of Allegiance and CBTX can be found in Allegiance&#8217;s Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, and the
Current Reports on Form&#160;8-K, and CBTX&#8217;s Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, and Current Reports
on Form&#160;8-K, in each case filed with the SEC and available on the SEC&#8217;s website at https://www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allegiance and CBTX disclaim any obligation and
do not intend to update or revise any forward-looking statements contained in this communication, which speak only as of the date hereof,
whether as a result of new information, future events or otherwise, except as required by federal securities laws. As forward-looking
statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Information about the Merger and Where to Find
It</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication does not constitute an offer
to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the proposed merger, CBTX intends
to file a registration statement on Form&#160;S-4 with the SEC to register the shares of CBTX common stock that will be issued to Allegiance
shareholders in connection with the merger. The registration statement will include a joint proxy statement/prospectus and other relevant
materials in connection with the proposed merger, which will be sent to the shareholders of CBTX and Allegiance seeking their approval
of the proposed merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WE URGE INVESTORS AND SECURITY HOLDERS TO READ
THE REGISTRATION STATEMENT ON FORM&#160;S-4, THE JOINT PROXY STATEMENT/PROSPECTUS INCLUDED WITHIN THE REGISTRATION STATEMENT ON FORM&#160;S-4
AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IN CONNECTION WITH THE PROPOSED MERGER
BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ALLEGIANCE, CBTX AND THE PROPOSED MERGER.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and security holders may obtain free
copies of these documents, once they are filed, and other documents filed with the SEC by Allegiance or CBTX through the website maintained
by the SEC at https://www.sec.gov. Documents filed with the SEC by CBTX will be available free of charge by accessing the CBTX&#8217;s
website at www.communitybankoftx.com under the heading &#8220;Investor Relations&#8221; or, alternatively, by directing a request by mail
or telephone to CBTX,&#160;Inc., 9 Greenway Plaza, Suite&#160;110, Houston, Texas 77046, Attn: Investor Relations, (713) 210-7600, and
documents filed with the SEC by Allegiance will be available free of charge by accessing Allegiance&#8217;s website at www.allegiancebank.com
under the heading &#8220;Investor Relations&#8221; or, alternatively, by directing a request by mail or telephone to Allegiance Bancshares,&#160;Inc.,
8847 West Sam Houston Parkway, N., Suite&#160;200, Houston, Texas 77040, (281) 894-3200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Participants in the Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CBTX, Allegiance and certain of their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of CBTX and Allegiance
in connection with the proposed merger. Certain information regarding the interests of these participants and a description of their direct
or indirect interests, by security holdings or otherwise, will be included in the joint proxy statement/prospectus regarding the proposed
merger when it becomes available. Additional information about the directors and executive officers of CBTX and their ownership of CBTX&#8217;s
common stock is set forth in CBTX&#8217;s proxy statement for its annual meeting of shareholders, filed with the SEC on April&#160;14,
2021. Additional information about the directors and executive officers of Allegiance and their ownership of Allegiance&#8217;s common
stock is set forth in Allegiance&#8217;s proxy statement for its annual meeting of shareholders, filed with the SEC on March&#160;10,
2021. These documents can be obtained free of charge from the sources described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>CBTX,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Date: November&#160;12, 2021</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Robert T. Pigott,&#160;Jr.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Robert T. Pigott,&#160;Jr.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Senior Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lpq0iNBHi4pYRYqIr9FuJdhmyyb+HclbGlvEZWFZZr4ZIUZiSQvTIMNxVhawx7ZrtEcosUZGe8bgyFfrDMIt8WKcZ219//7AnAKDgZnESp6C0FvvxmGVgVJjOR0nCmSapRPYbUT01XOytanQeqMb0LaCHVPHBr3m15Cw10+y1L76qgOyM2RDXCwH+Q2JVAls6a4fxFcHRZGLaNRPJJZMt+5bc3OeWpg32IYuN6D/jT4VI0lF -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2131964d8_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by and between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CBTX,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ALLEGIANCE BANCSHARES,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of November&nbsp;5, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>table
of contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 81%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><U>Page</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;I</FONT></TD>
    <TD STYLE="padding-left: 0.25in; padding-right: 6pt"><FONT STYLE="font-size: 10pt">THE MERGER</FONT></TD>
    <TD STYLE="text-align: right">2</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Effects of the Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conversion of Allegiance Common Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CBTX Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Treatment of Equity Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Formation of Surviving Entity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Bylaws of Surviving Entity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Consequences</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">1.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Bank Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;II</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">EXCHANGE OF SHARES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CBTX to Make Merger Consideration Available</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exchange of Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;III</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">REPRESENTATIONS AND WARRANTIES OF CBTX</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Corporate Organization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capitalization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authority&#894; No Violation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Broker&rsquo;s Fees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Legal and Regulatory Proceedings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Taxes and Tax Returns</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Benefit Plans; Employees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEC Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance with Applicable Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certain Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Agreements with Regulatory Agencies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investment Securities and Commodities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Real Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Related Party Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">State Takeover Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.22</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Reorganization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 9%"><FONT STYLE="font-size: 10pt">3.23</FONT></TD>
    <TD STYLE="width: 81%"><FONT STYLE="font-size: 10pt">Opinions of Financial Advisors</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.24</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Loan Portfolio</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.26</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Investment Advisor Subsidiary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.27</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Broker-Dealer Subsidiary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.28</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CBTX Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.29</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;IV</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">REPRESENTATIONS AND WARRANTIES OF ALLEGIANCE</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Corporate Organization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capitalization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authority&#894; No Violation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Broker&rsquo;s Fees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Legal and Regulatory Proceedings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Taxes and Tax Returns</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Benefit Plans; Employees</FONT></TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SEC Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance with Applicable Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certain Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Agreements with Regulatory Agencies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investment Securities and Commodities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Real Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Related Party Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">State Takeover Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.22</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Reorganization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.23</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Opinions of Financial Advisors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.24</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Loan Portfolio</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.26</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Investment Advisor Subsidiary</FONT></TD>
    <TD STYLE="text-align: right">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.27</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Broker-Dealer Subsidiary</FONT></TD>
    <TD STYLE="text-align: right">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.28</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Allegiance Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.29</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;V</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">COVENANTS RELATING TO CONDUCT OF BUSINESS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conduct of Businesses Prior to the Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Forbearances</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;VI</FONT></TD>
    <TD STYLE="padding-left: 0.25in; width: 81%"><FONT STYLE="font-size: 10pt">ADDITIONAL AGREEMENTS</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Access to Information&#894; Confidentiality</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Shareholders&rsquo; Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Legal Conditions to Merger</FONT></TD>
    <TD STYLE="text-align: right">58</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Stock Exchange Listing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employee Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Indemnification&#894; Directors&rsquo; and Officers&rsquo; Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Additional Agreements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Advice of Changes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Shareholder Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Corporate Governance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Acquisition Proposals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Public Announcements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Change of Method</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restructuring Efforts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Takeover Restrictions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Treatment of Certain Indebtedness</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exemption from Liability Under Section&nbsp;16(b)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certain Tax Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;VII</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">CONDITIONS PRECEDENT</FONT></TD>
    <TD STYLE="text-align: right">69</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">7.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to Each Party&rsquo;s Obligation to Effect the Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">7.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to Obligations of Allegiance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">7.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to Obligations of CBTX</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;VIII</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">TERMINATION AND AMENDMENT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;IX</FONT></TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">GENERAL PROVISIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Extension&#894; Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Nonsurvival of Representations, Warranties and Agreements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="text-align: right">7<FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right">7<FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: right">7<FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Governing Law&#894; Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right">79</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: right">79</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assignment&#894; Third-Party Beneficiaries</FONT></TD>
    <TD STYLE="text-align: right">79</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Specific Performance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 9%"><FONT STYLE="font-size: 10pt">9.13</FONT></TD>
    <TD STYLE="width: 81%"><FONT STYLE="font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Confidential Supervisory Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Delivery by Electronic Transmission</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">81</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit&nbsp;A &ndash; Form&nbsp;of Voting Agreement<BR>
Exhibit&nbsp;B &ndash; Form&nbsp;of Director Support Agreement<BR>
Exhibit&nbsp;C &ndash; Form&nbsp;of CBTX Certificate Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit&nbsp;D &ndash; Form&nbsp;of CBTX Bylaw Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>INDEX
OF DEFINED TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Acquisition Proposal</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Adjusted Stock Option</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance 401(k)&nbsp;Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Board Recommendation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Bylaws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Certificate of Formation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Common Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Contract</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Credit Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Director</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Disclosure Schedule</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Equity Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Equity Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance ERISA Affiliate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Indemnified Parties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Insiders</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Meeting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Owned Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance PSU</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Qualified Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Real Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Regulatory Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Restricted Stock Award</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Stock Option</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Subsidiary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Subsidiary Bank</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Subsidiary Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Tax Certificate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Allegiance Trust Preferred Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Bank Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Bank Merger Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Bank Merger Certificates</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">BHC Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX 401(k)&nbsp;Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Board Recommendation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Bylaw Amendment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

</DIV>

<P STYLE="margin: 0"></P>

<DIV STYLE="float: right; width: 48%">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">CBTX Bylaws</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Certificate Amendment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Certificate of Formation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Common Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Contract</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Credit Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Director</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Disclosure Schedule</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Equity Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX ERISA Affiliate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Meeting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Owned Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Qualified Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Real Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Regulatory Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Reports</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Restricted Stock Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Stock Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Subsidiary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Subsidiary Bank</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Subsidiary Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">CBTX Tax Certificate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Certificate of Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Closing Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Code</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Committees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Confidentiality Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Continuing 401(k)&nbsp;Plan(s)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Continuing Allegiance Employees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Continuing CBTX Employees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Continuing Employees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">COVID-19</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">COVID-19 Measures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Deferred Compensation Arrangements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Enforceability Exceptions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Environmental Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ERISA</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ESPP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Excess Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exchange Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

</DIV>

<P STYLE="margin: 0"></P>

<DIV STYLE="clear: both; width: 100%">

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">Exchange Agent</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exchange Fund</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exchange Ratio</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Expense Reimbursement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">FDIC</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Federal Reserve Board</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">FinCEN</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">FinCEN Matter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">GAAP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Governmental Entity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Investment Advisors Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">IRS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Joint Proxy Statement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Liens</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Loans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Material Adverse Effect</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Materially Burdensome Regulatory Condition</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Merger Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">NASDAQ</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">New Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">New Certificates</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">OCC</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Old Certificate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Permitted Encumbrances</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

</DIV>

<P STYLE="margin: 0"></P>

<DIV STYLE="float: right; width: 48%">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">Personal Data</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Recommendation Change</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Regulatory Agencies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Representatives</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Requisite Allegiance Vote</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Requisite CBTX Vote</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Requisite Regulatory Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">S-4</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Sarbanes-Oxley Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">SEC</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Securities Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Security Breach</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">SRO</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Subsidiary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Surviving Entity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Takeover Restrictions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tax</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tax Return</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">TBOC</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Terminated 401(k)&nbsp;Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Terminated Credit Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Terminated Credit Agreement Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Termination Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Termination Fee</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Texas Secretary of State</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">WARN Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="clear: both; width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AGREEMENT
AND PLAN OF MERGER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AGREEMENT AND PLAN OF MERGER,
dated as of November&nbsp;5, 2021 (this &ldquo;<U>Agreement</U>&rdquo;), by and between CBTX,&nbsp;Inc., a Texas corporation (&ldquo;<U>CBTX</U>&rdquo;),
and Allegiance Bancshares,&nbsp;Inc., a Texas corporation (&ldquo;<U>Allegiance</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Boards of Directors
of Allegiance and CBTX have determined that it is in the best interests of their respective companies and their shareholders to consummate
the strategic business combination transaction provided for herein, pursuant to which Allegiance will, subject to the terms and conditions
set forth herein, merge with and into CBTX (the &ldquo;<U>Merger</U>&rdquo;), so that CBTX is the surviving entity (hereinafter sometimes
referred to in such capacity as the &ldquo;<U>Surviving Entity</U>&rdquo;) in the Merger&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, in furtherance thereof,
the respective Boards of Directors of Allegiance and CBTX have approved the Merger and this Agreement&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition to each party&rsquo;s willingness to enter into this Agreement, certain
directors and executive officers of Allegiance who are also Allegiance shareholders and certain directors and executive officers of CBTX
who are also shareholders of CBTX are entering into a voting agreement in the form attached hereto as <U>Exhibit&nbsp;A</U>, pursuant
to which, among other things, such shareholder has agreed to vote to approve this Agreement, upon the terms and subject to the conditions
set forth therein&#894;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition to each party&rsquo;s willingness to enter into this Agreement, certain
directors of Allegiance and CBTX are entering into Director Support Agreements in the form attached hereto as <U>Exhibit&nbsp;B</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, for U.S. federal
income tax purposes, it is intended that the Merger shall qualify as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of
the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), and this Agreement is intended to be and is adopted as
a plan of reorganization for purposes of Sections 354 and 361 of the Code&#894; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the parties desire
to make certain representations, warranties and agreements in connection with the Merger and also to prescribe certain conditions to the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, representations, warranties and agreements contained herein, and intending to be legally bound hereby, the parties
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;I</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
THE MERGER</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>The
Merger</U>. Subject to the terms and conditions of this Agreement, in accordance with the Texas Business Organizations Code (the &ldquo;<U>TBOC</U>&rdquo;),
at the Effective Time, Allegiance shall merge with and into CBTX pursuant to this Agreement. CBTX shall be the Surviving Entity in the
Merger, and shall continue its corporate existence under the laws of the State of Texas. Upon the consummation of the Merger, the separate
corporate existence of Allegiance shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
Subject to the terms and conditions of this Agreement, the closing of the Merger (the &ldquo;<U>Closing</U>&rdquo;) will take place by
electronic exchange of documents at 10:00 a.m., Houston, Texas time, on such date as may be agreed upon between parties, no later than
thirty days after the satisfaction or waiver (subject to applicable law) of all the conditions set forth in <U>ARTICLE&nbsp;VII</U> (other
than those conditions that by their nature can only be satisfied at the Closing, but subject to the satisfaction or waiver thereof), unless
another date, time or place is agreed to in writing by CBTX and Allegiance. The date on which the Closing occurs is referred to as the
&ldquo;<U>Closing Date</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Effective
Time</U>. On or (if agreed by CBTX and Allegiance) prior to the Closing Date, Allegiance and CBTX, respectively, shall cause to be filed
a certificate of merger (the &ldquo;<U>Certificate of Merger</U>&rdquo;) with the Secretary of State of the State of Texas (the &ldquo;<U>Texas
Secretary of State</U>&rdquo;). The Merger shall become effective on the date and at the time specified in the Certificate of Merger
in accordance with the applicable provisions of the TBOC (such time hereinafter referred to as the &ldquo;<U>Effective Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Effects
of the Merger</U>. At and after the Effective Time, the Merger shall have the effects set forth in the applicable provisions of the TBOC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conversion
of Allegiance Common Stock</U>. At the Effective Time, by virtue of the Merger and without any action on the part of Allegiance, CBTX
or the holder of any securities of Allegiance or CBTX:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;2.2(e)</U>, each share of the common stock, par value $1.00 per share, of Allegiance issued and outstanding immediately
prior to the Effective Time (the &ldquo;<U>Allegiance Common Stock</U>&rdquo;), except for shares of Allegiance Common Stock owned by
CBTX or Allegiance (in each case other than shares of Allegiance Common Stock (i)&nbsp;held in trust accounts, managed accounts, mutual
funds and the like, or otherwise held in a fiduciary or agency capacity that are beneficially owned by third parties or (ii)&nbsp;held,
directly or indirectly, by CBTX or Allegiance in respect of debts previously contracted), shall be converted into the right to receive
1.4184 shares (the &ldquo;<U>Exchange Ratio</U>&rdquo; and such shares the &ldquo;<U>Merger Consideration</U>&rdquo;) of the common stock,
par value $0.01 per share, of CBTX (the &ldquo;<U>CBTX Common Stock</U>&rdquo;)&#894; it being understood that upon the Effective Time,
pursuant to <U>Section&nbsp;1.6</U>, the CBTX Common Stock, including the shares issued to former holders of Allegiance Common Stock,
shall be the common stock of the Surviving Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
the shares of Allegiance Common Stock converted into the right to receive the Merger Consideration pursuant to this <U>ARTICLE&nbsp;I
</U>shall no longer be outstanding and shall automatically be cancelled and shall cease to exist as of the Effective Time, and each certificate
(each, an &ldquo;<U>Old Certificate</U>,&rdquo; it being understood that any reference herein to &ldquo;Old Certificate&rdquo; shall
be deemed to include reference to book-entry account statements relating to the ownership of shares of Allegiance Common Stock) previously
representing any such shares of Allegiance Common Stock shall thereafter represent only the right to receive (i)&nbsp;a New Certificate
representing the number of whole shares of CBTX Common Stock which such shares of Allegiance Common Stock have been converted into the
right to receive; (ii)&nbsp;cash in lieu of fractional shares which the shares of Allegiance Common Stock represented by such Old Certificate
have been converted into the right to receive pursuant to this <U>Section&nbsp;1.5</U> and <U>Section&nbsp;2.2(e)</U>, without any interest
thereon; and (iii)&nbsp;any dividends or distributions which the holder thereof has the right to receive pursuant to <U>Section&nbsp;2.2</U>,
in each case, without any interest thereon. If, prior to the Effective Time, the outstanding shares of Allegiance Common Stock or CBTX
Common Stock shall have been increased, decreased, changed into or exchanged for a different number or kind of shares or securities as
a result of a reorganization, recapitalization, reclassification, stock dividend, stock split or reverse stock split, or there shall
be any extraordinary dividend or distribution, an appropriate and proportionate adjustment shall be made to the Exchange Ratio to give
CBTX and the holders of Allegiance Common Stock the same economic effect as contemplated by this Agreement prior to such event&#894;
<U>provided</U> that nothing contained in this sentence shall be construed to permit CBTX or Allegiance to take any action with respect
to its securities or otherwise that is prohibited by the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Agreement to the contrary, at the Effective Time, all shares of Allegiance Common Stock that are owned by CBTX or Allegiance
(in each case other than shares of Allegiance Common Stock (i)&nbsp;held in trust accounts, managed accounts, mutual funds and the like,
or otherwise held in a fiduciary or agency capacity that are beneficially owned by third parties or (ii)&nbsp;held, directly or indirectly,
by CBTX or Allegiance in respect of debts previously contracted) shall be cancelled and shall cease to exist and no CBTX Common Stock
or other consideration shall be delivered in exchange therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>CBTX
Stock</U>. At and after the Effective Time, each share of CBTX Common Stock issued and outstanding immediately prior to the Effective
Time shall remain an issued and outstanding share of common stock of the Surviving Entity and shall not be affected by the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of Equity Awards</U>. This <U>Section&nbsp;1.7</U> shall govern the treatment of the Allegiance Equity Awards and the CBTX Equity Awards
in connection with the transactions contemplated hereby:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of Allegiance Equity Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each option, whether vested or unvested, granted under the Post Oak Bancshares,&nbsp;Inc. Stock Option Plan, as amended,
the Allegiance Bancshares,&nbsp;Inc. 2015 Stock Awards and Incentive Plan, as amended, and the Allegiance Bancshares,&nbsp;Inc. 2019
Amended and Restated Stock Awards and Incentive Plan, as amended (each an &ldquo;<U>Allegiance Equity Plan</U>&rdquo;), to purchase a
number of shares of Allegiance Common Stock (an &ldquo;<U>Allegiance Stock Option</U>&rdquo;) that is outstanding as of immediately prior
to the Effective Time shall, by virtue of the Merger and without any action on the part of the holder thereof, fully vest, to the extent
not previously vested, shall cease to represent a right to purchase shares of Allegiance Common Stock and shall be converted automatically
into an option to purchase a number of shares of CBTX Common Stock (each, an &ldquo;<U>Adjusted Stock Option</U>&rdquo;) equal to the
product obtained by multiplying (x)&nbsp;the total number of shares of Allegiance Common Stock subject to such Allegiance Stock Option
immediately prior to the Effective Time by (y)&nbsp;the Exchange Ratio, with any fractional shares rounded down to the next lower whole
number of shares. Each Adjusted Stock Option shall have an exercise price per share of CBTX Common Stock (rounded up to the nearest whole
cent) equal to (1)&nbsp;the per share exercise price for the shares of Allegiance Common Stock subject to such Allegiance Stock Option
divided by (2)&nbsp;the Exchange Ratio. In the case of any Allegiance Stock Option that is intended to qualify as an incentive stock
option under Section&nbsp;421 of the Code, on a share-by-share comparison, the ratio of the purchase price to the fair market value of
the shares subject to the Adjusted Stock Option immediately after the Merger shall not be more favorable to the optionee than the ratio
of the purchase price to the fair market value of the shares subject to the Allegiance Stock Option immediately prior to the Merger.
In the case of any Allegiance Stock Option that is intended to qualify as an incentive stock option under Section&nbsp;421 of the Code,
the adjustments described above will be made in accordance with Treas. Reg. 1.424-1(a)&nbsp;so that the conversion does not constitute
a &ldquo;modification&rdquo; within the meaning of Treas. Reg. 1.424-1(e), and for each other Allegiance Stock Option in accordance with
Treas. Reg. 1.409A-1(b)(5)(v)(D)&nbsp;so that the conversion does not constitute the grant of a new stock right or a change in the form
of payment for purposes of Section&nbsp;409A of the Code. Except as specifically provided above, following the Effective Time, each Adjusted
Stock Option shall otherwise be subject to the same terms and conditions applicable to the converted Allegiance Stock Option under the
applicable Allegiance Equity Plan and the agreements evidencing grants thereunder, other than with respect to vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each award in respect of a share of Allegiance Common Stock subject to vesting, repurchase or other lapse restriction
(an &ldquo;<U>Allegiance Restricted Stock Award</U>&rdquo;) that is outstanding immediately prior to the Effective Time shall, automatically
and without any required action on the part of the holder thereof, immediately and fully vest and be converted into the right to receive
the Merger Consideration, less applicable Tax withholding, which shall be delivered as soon as reasonably practicable following the Closing
Date and in no event later than ten (10)&nbsp;business days following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each performance unit award in respect of shares of Allegiance Common Stock (an &ldquo;<U>Allegiance PSU</U>&rdquo;)
that is outstanding immediately prior to the Effective Time shall, subject to the terms of the award agreement related to and governing
each such Allegiance PSU, (i)&nbsp;with respect to unvested Allegiance PSUs granted less than one year prior to the Closing Date, automatically
be forfeited; (ii)&nbsp;with respect to unvested Allegiance PSUs granted at least one year but not more than 18 months prior to the Closing
Date, vest to the extent applicable performance goals have been achieved on a pro rata basis as of the Effective Time based on such audited
and unaudited financial information then available, provided that no more than the target number of such Allegiance PSUs may vest; (iii)&nbsp;with
respect to unvested Allegiance PSUs granted at least 18 months prior to the Closing Date but for which the performance period would not
otherwise end until after the Closing Date, vest to the extent applicable performance goals have been achieved on a pro rata basis as
of the Effective Time based on such audited and unaudited financial information then available; and (iv)&nbsp;with respect to unvested
Allegiance PSUs for which the performance period has ended vest to the extent earned based on applicable performance goals have been
achieved. At the Effective Time, all vested Allegiance PSUs shall be converted into the right to receive the Merger Consideration in
respect of the applicable number of shares of Allegiance Common Stock as determined pursuant to the immediately preceding sentence, less
applicable Tax withholding, which shall be delivered as soon as reasonably practicable following the Closing Date and in no event later
than ten (10)&nbsp;business days following the Closing Date&#894; <U>provided</U>, that with respect to any Allegiance PSU that constitutes
&ldquo;deferred compensation&rdquo; subject to Section&nbsp;409A of the Code, settlement of such award shall be made on the earliest
permissible date that such delivery would not trigger a Tax or penalty under Section&nbsp;409A of the Code. Any Allegiance PSUs that
are unvested as of the Effective Time (after giving effect to the foregoing) shall automatically be forfeited at the Effective Time for
no consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Allegiance Board of Directors (or appropriate committee thereof) shall take such action as is necessary to ensure that (i)&nbsp;the Purchase
Period commencing on January&nbsp;1, 2022, under and as defined in the Allegiance Employee Stock Purchase Plan, as amended (the &ldquo;<U>ESPP</U>&rdquo;),
shall be terminated prior to the Effective Time;(ii)&nbsp;at the time of termination of such Purchase Period, accumulated payroll deductions
shall, in the Allegiance Board of Directors&rsquo; discretion, either be refunded to participants or used to purchase shares of Allegiance
Common Stock, with the date of such termination being the Date of Purchase (as defined in the ESPP), (iii)&nbsp;all participation in,
and any actions taken under, the ESPP shall be in accordance with the terms of the ESPP; and (iv)&nbsp;effective as of the Effective Time,
the ESPP shall be suspended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Effective Time, Allegiance, the Board of Directors of Allegiance and the Allegiance Compensation Committee, as applicable, shall
adopt any resolutions and take any actions that are necessary or appropriate to effectuate the provisions of this <U>Section&nbsp;1.7(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of CBTX Equity Awards</U>. At the Effective Time (i)&nbsp;any vesting conditions applicable to each outstanding CBTX Stock Option, whether
vested or unvested, shall, automatically and without any action on the part of the holder thereof, be deemed satisfied and accelerated
in full, and (ii)&nbsp;any vesting conditions applicable to each outstanding CBTX Restricted Stock Award shall, automatically and without
any action on the part of the holder thereof, be deemed satisfied and accelerated in full. Any CBTX dividend equivalent rights associated
with any CBTX Restricted Stock Award shall either be paid in cash or treated in the same manner as the CBTX Restricted Stock Award to
which such dividend equivalent rights relate in accordance with this <U>Section&nbsp;1.7(b)</U>, in each case, pursuant to the terms of
the relevant CBTX Benefit Plan immediately prior to the Effective Time. Prior to the Effective Time, CBTX, the Board of Directors of CBTX
and the CBTX Compensation Committee, as applicable, shall adopt any resolutions and take any actions that are necessary or appropriate
to effectuate the provisions of this <U>Section&nbsp;1.7(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Future
Grants of Equity Awards</U>. Notwithstanding anything in <U>Section&nbsp;1.7(a)</U>&nbsp;or <U>Section&nbsp;1.7(b)</U>&nbsp;to the contrary,
but subject to <U>Section&nbsp;5.1</U>, (i)&nbsp;to the extent the terms of any Allegiance Equity Award or CBTX Equity Award granted
on or after the date of this Agreement and not in violation of this Agreement expressly provide for treatment in connection with the
occurrence of the Effective Time that is different from the treatment prescribed by this <U>Section&nbsp;1.7</U>, or (ii)&nbsp;as mutually
agreed by Allegiance and CBTX and a holder of any Allegiance Equity Award or CBTX Equity Award, then in each case, the terms of such
Allegiance Equity Award or CBTX Equity Award, as applicable, shall control (and the applicable provisions of this <U>Section&nbsp;1.7
</U>shall not apply).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certificate
of Formation of Surviving Entity</U>. At the Effective Time, the certificate of formation of CBTX, as in effect immediately prior to
the Effective Time, as amended as set forth in <U>Exhibit&nbsp;C</U> (the &ldquo;<U>CBTX Certificate Amendment</U>&rdquo;), shall be
the certificate of formation of the Surviving Entity until thereafter amended in accordance with applicable law; <U>provided</U>, <U>however</U>,
that if the CBTX Certificate Amendment is not approved by the shareholders of CBTX at the CBTX Meeting, then the certificate of formation
of CBTX, as in effect immediately prior to the Effective Time, shall be the certificate of formation of the Surviving Entity until thereafter
amended in accordance with applicable law, unless otherwise agreed to by Allegiance and CBTX prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bylaws
of Surviving Entity</U>. At the Effective Time, the bylaws of CBTX, as amended as set forth in <U>Exhibit&nbsp;D</U> (such amendment,
the &ldquo;<U>CBTX Bylaw Amendment</U>&rdquo;), shall be the bylaws of the Surviving Entity until thereafter amended in accordance with
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Consequences</U>. For U.S. federal income tax purposes, it is intended that the Merger shall qualify as a &ldquo;reorganization&rdquo;
within the meaning of Section&nbsp;368(a)&nbsp;of the Code, and that this Agreement is intended to be and is adopted as a plan of reorganization
within the meaning of Treasury Regulation Sections 1.368-2(g)&nbsp;and 1.368-3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Bank
Merger</U>. Immediately following the Merger, CommunityBank of Texas, National Association, a federally-chartered national association
and wholly-owned Subsidiary of CBTX (&ldquo;<U>CBTX Subsidiary Bank</U>&rdquo;), will merge (the &ldquo;<U>Bank Merger</U>&rdquo;) with
and into Allegiance Bank, a Texas-chartered state bank and wholly-owned Subsidiary of Allegiance (&ldquo;<U>Allegiance Subsidiary Bank</U>&rdquo;).
Allegiance Subsidiary Bank shall be the surviving entity in the Bank Merger and, following the Bank Merger, the separate corporate existence
of CBTX Subsidiary Bank shall cease. Promptly after the date of this Agreement, Allegiance Subsidiary Bank and CBTX Subsidiary Bank will
enter into an agreement and plan of merger in form and substance agreed by Allegiance and CBTX, which shall be customary for mergers
similar to the Bank Merger (the &ldquo;<U>Bank Merger Agreement</U>&rdquo;). Each of Allegiance and CBTX shall approve the Bank Merger
Agreement and the Bank Merger as the sole shareholder of Allegiance Subsidiary Bank and CBTX Subsidiary Bank, respectively, and Allegiance
and CBTX shall, and shall cause Allegiance Subsidiary Bank and CBTX Subsidiary Bank, respectively, to, execute certificates or Articles
of Merger and such other documents and certificates as are necessary to make the Bank Merger effective (&ldquo;<U>Bank Merger Certificates</U>&rdquo;)
immediately following the Effective Time. The Bank Merger shall become effective at such time and date as specified in the Bank Merger
Agreement in accordance with applicable law, or at such other time as shall be provided by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;II</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
EXCHANGE OF SHARES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>CBTX
to Make Merger Consideration Available</U>. At or prior to the Effective Time, CBTX shall deposit, or shall cause to be deposited, with
a bank or trust company mutually agreed upon by CBTX and Allegiance (the &ldquo;<U>Exchange Agent</U>&rdquo;), for exchange in accordance
with this <U>ARTICLE&nbsp;II</U> for the benefit of the holders of Old Certificates evidence in book-entry form representing shares of
CBTX Common Stock to be issued pursuant to <U>Section&nbsp;1.5</U> (referred to herein as &ldquo;<U>New Certificates</U>&rdquo;), and
cash in lieu of any fractional shares to be paid pursuant to <U>Section&nbsp;2.2(e)</U>&nbsp;(such cash and New Certificates, together
with any dividends or distributions with respect to shares of CBTX Common Stock payable in accordance with <U>Section&nbsp;2.2(b)</U>,
being hereinafter referred to as the &ldquo;<U>Exchange Fund</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exchange
of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
promptly as practicable after the Effective Time, but in no event later than ten (10)&nbsp;days thereafter, CBTX and Allegiance shall
cause the Exchange Agent to mail to each holder of record of one or more Old Certificates representing shares of Allegiance Common Stock
immediately prior to the Effective Time that have been converted at the Effective Time into the right to receive CBTX Common Stock pursuant
to <U>ARTICLE&nbsp;I</U>, a letter of transmittal (which shall specify that delivery shall be effected, and risk of loss and title to
the Old Certificates shall pass, only upon proper delivery of the Old Certificates to the Exchange Agent) and instructions for use in
effecting the surrender of the Old Certificates in exchange for New Certificates representing the number of whole shares of CBTX Common
Stock and any cash in lieu of fractional shares which the shares of Allegiance Common Stock represented by such Old Certificate or Old
Certificates shall have been converted into the right to receive pursuant to this Agreement as well as any dividends or distributions
to be paid pursuant to <U>Section&nbsp;2.2(b)</U>. Upon proper surrender of an Old Certificate or Old Certificates for exchange and cancellation
to the Exchange Agent, together with such properly completed letter of transmittal, duly executed, the holder of such Old Certificate
or Old Certificates shall be entitled to receive in exchange therefor, as applicable, (i)&nbsp;a New Certificate representing that number
of whole shares of CBTX Common Stock to which such holder of Allegiance Common Stock shall have become entitled pursuant to the provisions
of <U>ARTICLE&nbsp;I</U> and (ii)&nbsp;a check representing the amount of (x)&nbsp;any cash in lieu of fractional shares which such holder
has the right to receive in respect of the Old Certificate or Old Certificates surrendered pursuant to the provisions of this <U>ARTICLE&nbsp;II</U>
and (y)&nbsp;any dividends or distributions which the holder thereof has the right to receive pursuant to <U>Section&nbsp;2.2(b)</U>.
No interest will be paid or accrued on any cash in lieu of fractional shares or dividends or distributions payable to holders of Old Certificates.
Until surrendered as contemplated by this <U>Section&nbsp;2.2</U>, each Old Certificate shall be deemed at any time after the Effective
Time to represent only the right to receive, upon surrender, the number of whole shares of CBTX Common Stock which the shares of Allegiance
Common Stock represented by such Old Certificate have been converted into the right to receive and any cash in lieu of fractional shares
or in respect of dividends or distributions as contemplated by this <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
dividends or other distributions declared with respect to CBTX Common Stock shall be paid to the holder of any unsurrendered Old Certificate
until the holder thereof shall surrender such Old Certificate in accordance with this <U>ARTICLE&nbsp;II</U>. After the surrender of
an Old Certificate in accordance with this <U>ARTICLE&nbsp;II</U>, the record holder thereof shall be entitled to receive any such dividends
or other distributions, without any interest thereon, which theretofore had become payable with respect to the whole shares of CBTX Common
Stock that the shares of Allegiance Common Stock represented by such Old Certificate have been converted into the right to receive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
any New Certificate representing shares of CBTX Common Stock is to be issued in a name other than that in which the Old Certificate or
Old Certificates surrendered in exchange therefor is or are registered, it shall be a condition of the issuance thereof that the Old Certificate
or Old Certificates so surrendered shall be properly endorsed (or accompanied by an appropriate instrument of transfer) and otherwise
in proper form for transfer, and that the person requesting such exchange shall pay to the Exchange Agent in advance any transfer or other
similar Taxes required by reason of the issuance of a New Certificate representing shares of CBTX Common Stock in any name other than
that of the registered holder of the Old Certificate or Old Certificates surrendered, or required for any other reason, or shall establish
to the satisfaction of the Exchange Agent that such Tax has been paid or is not payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">After
the Effective Time, there shall be no transfers on the stock transfer books of Allegiance of the shares of Allegiance Common Stock that
were issued and outstanding immediately prior to the Effective Time. If, after the Effective Time, Old Certificates representing such
shares are presented for transfer to the Exchange Agent, they shall be cancelled and exchanged for New Certificates representing shares
of CBTX Common Stock as provided in this <U>ARTICLE&nbsp;II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary contained herein, no New Certificates or scrip representing fractional shares of CBTX Common Stock shall be
issued upon the surrender for exchange of Old Certificates (or in satisfaction of the obligations set forth in <U>Section&nbsp;1.7</U>
in respect of Allegiance Equity Awards), no dividend or distribution with respect to CBTX Common Stock shall be payable on or with respect
to any fractional share, and such fractional share interests shall not entitle the owner thereof to vote or to any other rights of a
shareholder of CBTX. In lieu of the issuance of any such fractional share, CBTX shall pay to each former holder of Allegiance Common
Stock or any Allegiance Equity Awards who otherwise would be entitled to receive such fractional share an amount in cash (rounded to
the nearest cent) determined by multiplying (i)&nbsp;the average of the closing-sale prices of CBTX Common Stock on the NASDAQ Stock
Market,&nbsp;Inc. Global Select Market System (the &ldquo;<U>NASDAQ</U>&rdquo;) as reported by NASDAQ for the consecutive period of five
(5)&nbsp;full trading days ending on the day preceding the Closing Date by (ii)&nbsp;the fraction of a share (after taking into account
all shares of Allegiance Common Stock held by such holder immediately prior to the Effective Time and rounded to the nearest one-thousandth
when expressed in decimal form) of CBTX Common Stock which such holder would otherwise be entitled to receive pursuant to <U>Section&nbsp;1.5
</U>or <U>Section&nbsp;1.7</U>. The parties acknowledge that payment of such cash consideration in lieu of issuing fractional shares
is not separately bargained-for consideration, but merely represents a mechanical rounding off for purposes of avoiding the expense and
inconvenience that would otherwise be caused by the issuance of fractional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
portion of the Exchange Fund that remains unclaimed by the shareholders of Allegiance for twelve (12) months after the Effective Time
shall be paid to the Surviving Entity. Any former holders of Allegiance Common Stock who have not theretofore complied with this <U>ARTICLE&nbsp;II</U>
shall thereafter look only to the Surviving Entity for payment of the shares of CBTX Common Stock, cash in lieu of any fractional shares
and any unpaid dividends and distributions on the CBTX Common Stock deliverable in respect of each former share of Allegiance Common Stock
such holder holds as determined pursuant to this Agreement without any interest thereon. Notwithstanding the foregoing, none of CBTX,
Allegiance, the Surviving Entity, the Exchange Agent or any other person shall be liable to any former holder of shares of Allegiance
Common Stock for any amount delivered in good faith to a public official pursuant to applicable abandoned property, escheat or similar
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Agreement to the contrary, CBTX shall be entitled to deduct and withhold, or cause the Exchange Agent to deduct and withhold,
from any cash in lieu of fractional shares of CBTX Common Stock, any cash dividends or distributions payable pursuant to this <U>Section&nbsp;2.2</U>
or any other amounts otherwise payable pursuant to this Agreement to any holder of Allegiance Common Stock or Allegiance Equity Awards,
such amounts as it is required to deduct and withhold with respect to the making of such payment under the Code or any provision of state,
local or non-U.S. Tax law. To the extent that amounts are so withheld by CBTX or the Exchange Agent, as the case may be, and paid over
to the appropriate taxing authority, the withheld amounts shall be treated for all purposes of this Agreement as having been paid to the
holder of Allegiance Common Stock or Allegiance Equity Awards in respect of which the deduction and withholding was made by CBTX or the
Exchange Agent, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event any Old Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming
such Old Certificate to be lost, stolen or destroyed and, if required by CBTX or the Exchange Agent, the posting by such person of a bond
in such amount and on such terms as CBTX or the Exchange Agent may determine is reasonably necessary as indemnity against any claim that
may be made against it with respect to such Old Certificate, the Exchange Agent will issue in exchange for such lost, stolen or destroyed
Old Certificate the shares of CBTX Common Stock and any cash in lieu of fractional shares deliverable in respect thereof pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;III</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF CBTX</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except (a)&nbsp;as disclosed
in the disclosure schedule delivered by CBTX to Allegiance concurrently herewith (the &ldquo;<U>CBTX Disclosure Schedule</U>&rdquo;)&#894;
<U>provided</U>, that (i)&nbsp;no such item is required to be set forth as an exception to a representation or warranty if its absence
would not result in the related representation or warranty being deemed untrue or incorrect; (ii)&nbsp;the mere inclusion of an item
in the CBTX Disclosure Schedule as an exception to a representation or warranty shall not be deemed an admission by CBTX that such item
represents a material exception or fact, event or circumstance or that such item would reasonably be expected to have a Material Adverse
Effect; and (iii)&nbsp;any disclosures made with respect to a section of <U>ARTICLE&nbsp;III</U> shall be deemed to qualify (1)&nbsp;any
other section of <U>ARTICLE&nbsp;III</U> specifically referenced or cross-referenced and (2)&nbsp;other sections of <U>ARTICLE&nbsp;III
</U>to the extent it is reasonably apparent on its face (notwithstanding the absence of a specific cross reference) from a reading of
the disclosure that such disclosure applies to such other sections or (b)&nbsp;as disclosed in any CBTX Reports filed by CBTX since December&nbsp;31,
2019, and prior to the date hereof (but disregarding risk factor disclosures contained under the heading &ldquo;Risk Factors,&rdquo;
or disclosures of risks set forth in any &ldquo;forward-looking statements&rdquo; disclaimer or any other statements that are similarly
non-specific or cautionary, predictive or forward-looking in nature), CBTX hereby represents and warrants to Allegiance as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Corporate
Organization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
is a corporation duly organized, validly existing and in good standing under the laws of the State of Texas, and is a bank holding company
duly registered under the Bank Holding Company Act of 1956, as amended (the &ldquo;<U>BHC Act</U>&rdquo;). CBTX has the corporate power
and authority to own, lease or operate all of its properties and assets and to carry on its business as it is now being conducted. CBTX
is duly licensed or qualified to do business and in good standing in each jurisdiction in which the nature of the business conducted
by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing, qualification or
standing necessary, except where the failure to be so licensed or qualified or to be in good standing would not, either individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX. As used in this Agreement, the term &ldquo;<U>Material
Adverse Effect</U>&rdquo; means, with respect to Allegiance, CBTX or the Surviving Entity, as the case may be, any effect, change, event,
circumstance, condition, occurrence or development that, either individually or in the aggregate, has had or would reasonably be expected
to have a material adverse effect on (i)&nbsp;the business, properties, assets, liabilities, results of operations or financial condition
of such party and its Subsidiaries taken as a whole (<U>provided</U>, <U>however</U>, that, with respect to this clause (i), Material
Adverse Effect shall not be deemed to include the impact of (A)&nbsp;changes, after the date hereof, in U.S. generally accepted accounting
principles (&ldquo;<U>GAAP</U>&rdquo;) or applicable regulatory accounting requirements, (B)&nbsp;changes, after the date hereof, in
laws, rules&nbsp;or regulations of general applicability to companies in the industries in which such party and its Subsidiaries operate,
or interpretations thereof by courts or Governmental Entities, (C)&nbsp;changes, after the date hereof, in global, national or regional
political conditions (including the outbreak of war or acts of terrorism) or in economic or market (including equity, credit and debt
markets, as well as changes in interest rates) conditions affecting the financial services industry generally and not specifically relating
to such party or its Subsidiaries, (D)&nbsp;public disclosure of the transactions contemplated hereby or actions expressly required by
this Agreement or that are taken with the prior written consent of the other party in contemplation of the transactions contemplated
hereby, (E)&nbsp;a decline in the trading price of a party&rsquo;s common stock or the failure, in and of itself, to meet earnings projections
or internal financial forecasts, but not, in either case, including any underlying causes thereof, (F)&nbsp;any local, regional, national
or global health conditions (including any epidemic, pandemic or disease outbreak (including SARS-CoV-2 or COVID-19, and any evolutions
thereof (&ldquo;<U>COVID-19</U>&rdquo;)), including any material worsening of such conditions or any law, directive, guidelines or recommendations
issued by a Governmental Entity, the Centers for Disease Control and Prevention, the World Health Organization, any other Governmental
Entity providing for business closures, &ldquo;sheltering-in-place,&rdquo; curfews or other restrictions that relate to, or arise out
of, an epidemic, pandemic or disease outbreak (including COVID-19), or any change in such law, directive, guidelines, recommendations
or interpretation thereof, or (G)&nbsp;the payment or accrual of any monetary penalties assessed or issued by FinCEN or the OCC in connection
with the FinCEN Matter&#894; except, with respect to subclause (A), (B), (C)&nbsp;or (F)&nbsp;to the extent that the effects of such
change are materially disproportionately adverse to the business, properties, assets, liabilities, results of operations or financial
condition of such party and its Subsidiaries, taken as a whole, as compared to other companies in the industry in which such party and
its Subsidiaries operate) or (ii)&nbsp;the ability of such party to timely consummate the transactions contemplated hereby. As used in
this Agreement, the word &ldquo;<U>Subsidiary</U>&rdquo; when used with respect to any person, means any corporation, partnership, limited
liability company, bank or other organization, whether incorporated or unincorporated, or person of which (x)&nbsp;such first person
directly or indirectly owns or controls at least a majority of the securities or other interests having by their terms ordinary voting
power to elect a majority of the board of directors or others performing similar functions or (y)&nbsp;such first person is or directly
or indirectly has the power to appoint a general partner, manager or managing member or others performing similar functions. True and
complete copies of the amended and restated certificate of formation of CBTX, as amended (the &ldquo;<U>CBTX Certificate of Formation&rdquo;</U>)
and the amended and restated bylaws of CBTX, as amended (the &ldquo;<U>CBTX Bylaws</U>&rdquo;), in each case as in effect as of the date
of this Agreement, have previously been made available by CBTX to Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX, each Subsidiary
of CBTX (a &ldquo;<U>CBTX Subsidiary</U>&rdquo;) (i)&nbsp;is duly organized and validly existing under the laws of its jurisdiction of
organization; (ii)&nbsp;is duly licensed or qualified to do business and, where such concept is recognized under applicable law, in good
standing in all jurisdictions (whether federal, state, local or foreign) where its ownership, leasing or operation of property or the
conduct of its business requires it to be so licensed or qualified or in good standing; and (iii)&nbsp;has all requisite corporate power
and authority to own, lease or operate its properties and assets and to carry on its business as now conducted. There are no restrictions
on the ability of CBTX or any CBTX Subsidiary to pay dividends or distributions except, in the case of CBTX or a CBTX Subsidiary that
is a regulated entity, for restrictions on dividends or distributions generally applicable to all similarly regulated entities. The deposit
accounts of each CBTX Subsidiary that is an insured depository institution are insured by the Federal Deposit Insurance Corporation (the
&ldquo;<U>FDIC</U>&rdquo;) through the Deposit Insurance Fund (as defined in Section&nbsp;3(y)&nbsp;of the Federal Deposit Insurance
Act of 1950) to the fullest extent permitted by law, all premiums and assessments required to be paid in connection therewith have been
paid when due, and no proceedings for the termination of such insurance are pending or threatened. <U>Section&nbsp;3.1(b)</U>&nbsp;of
the CBTX Disclosure Schedule sets forth a true and complete list of all CBTX Subsidiaries that would constitute significant subsidiaries
within the meaning of Rule&nbsp;1-02 of Regulation S-X of the SEC as of the date hereof. There is no person whose results of operations,
cash flows, changes in shareholders&rsquo; equity or financial position are consolidated in the financial statements of CBTX other than
the CBTX Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
authorized capital stock of CBTX as of the date of this Agreement consists of 90,000,000 shares of CBTX Common Stock, and 10,000,000 shares
of preferred stock, par value $0.01 per share. As of November&nbsp;1, 2021, there were (i)&nbsp;24,579,355 shares of CBTX Common Stock
issued and outstanding, including 158,961 shares of CBTX Common Stock granted in respect of outstanding restricted stock awards (&ldquo;<U>CBTX
Restricted Stock Awards</U>&rdquo;); (ii)&nbsp;843,956 shares of CBTX Common Stock held in treasury; (iii)&nbsp;199,688 shares of CBTX
Common Stock reserved for issuance upon the exercise of outstanding CBTX Stock Options (&ldquo;<U>CBTX Stock Options</U>&rdquo;); and
(iv)&nbsp;no shares of CBTX preferred stock issued and outstanding or held by CBTX in its treasury. As of the date of this Agreement,
except as set forth in the immediately preceding sentence, and for changes since November&nbsp;1, 2021 resulting from the exercise, vesting
or settlement of any CBTX Equity Awards described in the immediately preceding sentence, there are no shares of capital stock or other
voting securities or equity interests of CBTX issued, reserved for issuance or outstanding. All the issued and outstanding shares of CBTX
Common Stock have been duly authorized and validly issued and are fully paid, nonassessable and free of preemptive rights, with no personal
liability attaching to the ownership thereof. There are no bonds, debentures, notes or other indebtedness that have the right to vote
on any matters on which shareholders of CBTX may vote. Other than CBTX Restricted Stock Awards and the CBTX Stock Options (collectively,
&ldquo;<U>CBTX Equity Awards</U>&rdquo;) issued prior to the date of this Agreement as described in this <U>Section&nbsp;3.2</U>, as of
the date of this Agreement there are no outstanding subscriptions, options, warrants, stock appreciation rights, phantom units, scrip,
rights to subscribe to, preemptive rights, anti- dilutive rights, or rights of first refusal or similar rights, puts, calls, commitments
or agreements of any character to which CBTX or any CBTX Subsidiary is a party relating to, or securities or rights convertible or exchangeable
into or exercisable for, shares of capital stock or other voting or equity securities of or ownership interest in CBTX, or contracts,
commitments, understandings or arrangements by which CBTX may become bound to issue additional shares of its capital stock or other equity
or voting securities of or ownership interests in CBTX, or that otherwise obligate CBTX to issue, transfer, sell, purchase, redeem or
otherwise acquire, any of the foregoing (collectively, &ldquo;<U>CBTX Securities</U>&rdquo;, and any of the foregoing in respect of CBTX
Subsidiaries, collectively, &ldquo;<U>CBTX Subsidiary Securities</U>&rdquo;). Other than CBTX Equity Awards, no equity-based awards (including
any cash awards where the amount of payment is determined, in whole or in part, based on the price of any capital stock of CBTX or any
CBTX Subsidiary) are outstanding. There are no voting trusts, shareholder agreements, proxies or other agreements in effect to which CBTX
or any CBTX Subsidiary is a party with respect to the voting or transfer of CBTX Common Stock, capital stock or other voting or equity
securities or ownership interests of CBTX or granting any shareholder or other person any registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX, CBTX owns, directly
or indirectly, all the issued and outstanding shares of capital stock or other equity ownership interests of each of the CBTX Subsidiaries,
free and clear of any liens, claims, title defects, mortgages, pledges, charges, encumbrances and security interests whatsoever (&ldquo;<U>Liens</U>&rdquo;),
and all such shares or equity ownership interests are duly authorized and validly issued and are fully paid, nonassessable (except, with
respect to Subsidiaries that are depository institutions, as provided under 12 U.S.C. &sect; 55) and free of preemptive rights, with
no personal liability attaching to the ownership thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
CBTX Subsidiary has or is bound by any outstanding subscriptions, options, warrants, calls, rights, commitments or agreements of any character
calling for the purchase or issuance of any shares of capital stock or any other equity security of such Subsidiary or any securities
representing the right to purchase or otherwise receive any shares of capital stock or any other equity security of such Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authority&#894;
No Violation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
has full corporate power and authority to execute and deliver this Agreement and, subject to obtaining the Requisite CBTX Vote and the
adoption and approval of the Bank Merger Agreement by CBTX as CBTX Subsidiary Bank&rsquo;s sole shareholder, to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement and the consummation of the Merger have been duly and validly approved
by the Board of Directors of CBTX. The Board of Directors of CBTX has determined that the Merger, on the terms and conditions set forth
in this Agreement, is advisable and in the best interests of CBTX and its shareholders, has adopted and approved this Agreement and the
transactions contemplated hereby (including the Merger), and has directed that this Agreement be submitted to CBTX&rsquo;s shareholders
for approval at a meeting of such shareholders and has adopted a resolution to the foregoing effect. Except for (i)&nbsp;the approval
of this Agreement and the transactions contemplated hereby by the affirmative vote of two-thirds of the outstanding shares of CBTX Common
Stock entitled to vote on this Agreement, and (ii)&nbsp;the approval of the CBTX Certificate Amendment by the affirmative vote of two-thirds
of the outstanding shares of CBTX Common Stock entitled to vote thereon (the &ldquo;<U>Requisite CBTX Vote</U>&rdquo;), and subject to
the adoption and approval of the Bank Merger Agreement by CBTX as CBTX Subsidiary Bank&rsquo;s sole shareholder, no other corporate proceedings
on the part of CBTX are necessary to approve this Agreement or to consummate the transactions contemplated hereby. This Agreement has
been duly and validly executed and delivered by CBTX and (assuming due authorization, execution and delivery by Allegiance) constitutes
a valid and binding obligation of CBTX, enforceable against CBTX in accordance with its terms (except in all cases as such enforceability
may be limited by bankruptcy, insolvency, moratorium, reorganization or similar laws of general applicability affecting the rights of
creditors generally and the availability of equitable remedies (the &ldquo;<U>Enforceability Exceptions</U>&rdquo;)). The shares of CBTX
Common Stock to be issued in the Merger have been validly authorized (subject to the receipt of the Requisite CBTX Vote), and when issued,
will be validly issued, fully paid and nonassessable, and no current or past shareholder of CBTX will have any preemptive right or similar
rights in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution and delivery of this Agreement by CBTX nor the consummation by CBTX of the transactions contemplated hereby (including
the Merger and the Bank Merger), nor compliance by CBTX with any of the terms or provisions hereof, will (i)&nbsp;violate any provision
of the CBTX Certificate of Formation or the CBTX Bylaws or (ii)&nbsp;assuming that the consents and approvals referred to in <U>Section&nbsp;3.4
</U>are duly obtained, (x)&nbsp;violate any law, statute, code, ordinance, rule, regulation, judgment, order, writ, decree or injunction
applicable to CBTX or any of its Subsidiaries or any of their respective properties or assets or (y)&nbsp;violate, conflict with, result
in a breach of any provision of or the loss of any benefit under, constitute a default (or an event which, with notice or lapse of time,
or both, would constitute a default) under, result in the termination of or a right of termination or cancellation under, accelerate
the performance required by, or result in the creation of any Lien upon any of the respective properties or assets of CBTX or any of
its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, lease,
agreement or other instrument or obligation to which CBTX or any of its Subsidiaries is a party, or by which they or any of their respective
properties or assets may be bound, except (in the case of clauses (x)&nbsp;and (y)&nbsp;above) for such violations, conflicts, breaches
or defaults that, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consents
and Approvals</U>. Except for (a)&nbsp;the filing of any required applications, filings, notices and requests for waiver, as applicable,
with the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal Reserve Board</U>&rdquo;) under the BHC Act and approval
of such applications, filings and notices or granting of such waivers, as applicable, (b)&nbsp;the filing of any required applications,
filings and notices, as applicable, with the FDIC and the Texas Department of Banking in connection with the Bank Merger and approval
of such applications, filings and notices, (c)&nbsp;the filing of an exit notice with the Office of the Comptroller of the Currency (the
&ldquo;<U>OCC</U>&rdquo;) pursuant to 12 C.F.R. &sect; 5.33(k)&nbsp;with respect to the Bank Merger and the filing of any other required
applications, filings or notices with any federal or state banking authorities listed on <U>Section&nbsp;3.4</U> of the CBTX Disclosure
Schedule or <U>Section&nbsp;4.4</U> of the Allegiance Disclosure Schedule and approval of such applications, filings and notices, as
applicable, (d)&nbsp;the filing of any required applications, filings and notices, as applicable, with the NASDAQ, (e)&nbsp;the filing
by CBTX with the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) of a joint proxy statement in definitive form relating
to meetings of CBTX&rsquo;s shareholders and Allegiance&rsquo;s shareholders to be held in connection with this Agreement and the transactions
contemplated hereby (including any amendments or supplements thereto, the &ldquo;<U>Joint Proxy Statement</U>&rdquo;), and of the registration
statement on Form&nbsp;S-4 in which the Joint Proxy Statement will be included as a prospectus, to be filed with the SEC by CBTX in connection
with the transactions contemplated by this Agreement (the &ldquo;<U>S-4</U>&rdquo;) and the declaration of effectiveness of the S-4,
(f)&nbsp;the filing of the Certificate of Merger with the Texas Secretary of State pursuant to the TBOC, (g)&nbsp;the filing of the Bank
Merger Certificates with the applicable Governmental Entities as required by applicable law and (h)&nbsp;such filings and approvals as
are required to be made or obtained under the securities or &ldquo;Blue Sky&rdquo; laws of various states in connection with the issuance
of the shares of CBTX Common Stock pursuant to this Agreement and the approval of the listing of such CBTX Common Stock on the NASDAQ,
no consents or approvals of or filings or registrations with any court, administrative agency or commission or other governmental or
regulatory authority or instrumentality or SRO (each a &ldquo;<U>Governmental Entity</U>&rdquo;) are necessary in connection with (i)&nbsp;the
execution and delivery by CBTX of this Agreement or (ii)&nbsp;the consummation by CBTX of the Merger and the other transactions contemplated
hereby (including the Bank Merger). As of the date hereof, CBTX has no knowledge of any reason why the necessary regulatory approvals
and consents will not be received by CBTX to permit consummation of the Merger and Bank Merger on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reports</U>.
CBTX and each of its Subsidiaries have timely filed (or furnished) all reports, forms, correspondence, registrations and statements, together
with any amendments required to be made with respect thereto, that they were required to file (or furnish, as applicable) since January&nbsp;1,
2019 with (i)&nbsp;any state regulatory authority; (ii)&nbsp;the SEC; (iii)&nbsp;the Federal Reserve Board; (iv)&nbsp;the FDIC; (v)&nbsp;the
OCC; (vi)&nbsp;any foreign regulatory authority; and (vii)&nbsp;any self-regulatory organization (an &ldquo;<U>SRO</U>&rdquo;) (clauses
(i)&nbsp;- (vii), collectively &ldquo;<U>Regulatory Agencies</U>&rdquo;), including any report, form, correspondence, registration or
statement required to be filed (or furnished, as applicable) pursuant to the laws, rules&nbsp;or regulations of the United States, any
state, any foreign entity, or any Regulatory Agency, and have paid all fees and assessments due and payable in connection therewith, except
where the failure to file (or furnish, as applicable) such report, form, correspondence, registration or statement or to pay such fees
and assessments, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on CBTX.
Subject to <U>Section&nbsp;9.14</U>, except for normal examinations conducted by a Regulatory Agency in the ordinary course of business
of CBTX and its Subsidiaries, no Regulatory Agency has initiated or has pending any proceeding or, to the knowledge of CBTX, investigation
into the business or operations of CBTX or any of its Subsidiaries since January&nbsp;1, 2019, except as where such proceedings or investigations
would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX. Subject to <U>Section&nbsp;9.14</U>,
there (i)&nbsp;is no unresolved violation, criticism, or exception by any Regulatory Agency with respect to any report or statement relating
to any examinations or inspections of CBTX or any of its Subsidiaries and (ii)&nbsp;has been no formal or informal inquiries by, or disagreements
or disputes with, any Regulatory Agency with respect to the business, operations, policies or procedures of CBTX or any of its Subsidiaries
since January&nbsp;1, 2019, in each case, which would reasonably be expected to have, either individually or in the aggregate, a Material
Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
financial statements of CBTX and its Subsidiaries included (or incorporated by reference) in the CBTX Reports (including the related notes,
where applicable) (i)&nbsp;have been prepared from, and are in accordance with, the books and records of CBTX and its Subsidiaries; (ii)&nbsp;fairly
present in all material respects the consolidated results of operations, cash flows, changes in shareholders&rsquo; equity and consolidated
financial position of CBTX and its Subsidiaries for the respective fiscal periods or as of the respective dates therein set forth (subject
in the case of unaudited statements to year-end audit adjustments normal in nature and amount); (iii)&nbsp;complied, as of their respective
dates of filing with the SEC, in all material respects with applicable accounting requirements and with the published rules&nbsp;and regulations
of the SEC with respect thereto; and (iv)&nbsp;have been prepared in accordance with GAAP consistently applied during the periods involved,
except, in each case, as indicated in such statements or in the notes thereto. Since December&nbsp;31, 2018, no independent public accounting
firm of CBTX has resigned (or informed CBTX that it intends to resign) or been dismissed as independent public accountants of CBTX as
a result of or in connection with any disagreements with CBTX on a matter of accounting principles or practices, financial statement disclosure
or auditing scope or procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, neither CBTX
nor any of its Subsidiaries has any liability of any nature whatsoever (whether absolute, accrued, contingent or otherwise and whether
due or to become due), and except for those liabilities that are reflected or reserved against on the consolidated balance sheet of CBTX
included in its Quarterly Report on Form&nbsp;10-Q for the fiscal quarter ended September&nbsp;30, 2021 (including any notes thereto)
and for liabilities incurred in the ordinary course of business consistent with past practice since September&nbsp;30, 2021, or in connection
with this Agreement and the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
records, systems, controls, data and information of CBTX and its Subsidiaries are recorded, stored, maintained and operated under means
(including any electronic, mechanical or photographic process, whether computerized or not) that are under the exclusive ownership of
CBTX or its Subsidiaries or accountants (including all means of access thereto and therefrom), except for any non-exclusive ownership
that would not reasonably be expected to have a Material Adverse Effect on CBTX. CBTX (x)&nbsp;has implemented and maintains disclosure
controls and procedures (as defined in Rule&nbsp;13a-15(e)&nbsp;of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;)) to ensure that material information relating to CBTX, including its Subsidiaries, is made known to the chief executive
officer and the chief financial officer of CBTX by others within those entities as appropriate to allow timely decisions regarding required
disclosures and to make the certifications required by the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 (the
&ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), and (y)&nbsp;has disclosed, based on its most recent evaluation prior to the date hereof, to
CBTX&rsquo;s outside auditors and the audit committee of CBTX&rsquo;s Board of Directors (i)&nbsp;any significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting (as defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange
Act) which are reasonably likely to adversely affect CBTX&rsquo;s ability to record, process, summarize and report financial information,
and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in CBTX&rsquo;s
internal controls over financial reporting. These disclosures were made in writing by management to CBTX&rsquo;s auditors and audit committee
and true, correct and complete copies of such disclosures have previously been made available by CBTX to Allegiance. There is no reason
to believe that CBTX&rsquo;s outside auditors and its chief executive officer and chief financial officer will not be able to give the
certifications and attestations required pursuant to the rules&nbsp;and regulations adopted pursuant to Section&nbsp;404 of the Sarbanes-Oxley
Act, without qualification, when next due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, (i)&nbsp;neither CBTX nor any CBTX Subsidiary, nor, to the knowledge of CBTX, any director, officer, auditor, accountant
or representative of CBTX or any CBTX Subsidiary, has received or otherwise had or obtained knowledge of any material complaint, allegation,
assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods (including
with respect to loan loss reserves, write-downs, charge-offs and accruals) of CBTX or any CBTX Subsidiary or their respective internal
accounting controls, including any material complaint, allegation, assertion or claim that CBTX or any CBTX Subsidiary has engaged in
questionable accounting or auditing practices, and (ii)&nbsp;no employee of or attorney representing CBTX or any CBTX Subsidiary, whether
or not employed by CBTX or any CBTX Subsidiary, has reported evidence of a material violation of securities laws or banking laws, breach
of fiduciary duty or similar violation by CBTX or any CBTX Subsidiary or any of their respective officers, directors, employees or agents
to the Board of Directors of CBTX or any committee thereof or the Board of Directors or similar governing body of any CBTX Subsidiary
or any committee thereof, or to the knowledge of CBTX, to any director or officer of CBTX or any CBTX Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Broker&rsquo;s
Fees</U>. With the exception of the engagement of Stephens Inc. neither CBTX nor any CBTX Subsidiary nor any of their respective officers
or directors has employed any broker, finder or financial advisor or incurred any liability for any broker&rsquo;s fees, commissions or
finder&rsquo;s fees in connection with the Merger or related transactions contemplated by this Agreement. CBTX has made available to Allegiance
the engagement letter by and between CBTX and Stephens Inc. related to the Merger and the other transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes or Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
December&nbsp;31, 2020, there has not been any effect, change, event, circumstance, condition, occurrence or development that has had
or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
in connection with the transactions contemplated by this Agreement, since December&nbsp;31, 2020, CBTX and its Subsidiaries have carried
on their respective businesses in all material respects in the ordinary course.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legal
and Regulatory Proceedings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to, either individually or in the aggregate, have a Material Adverse Effect on CBTX, neither CBTX
nor any CBTX Subsidiary is a party to any, and there are no outstanding or pending or, to the knowledge of CBTX, threatened, legal, administrative,
arbitral or other proceedings, claims, actions or governmental or regulatory investigations of any nature against CBTX or any CBTX Subsidiary
or any of their current or former directors or executive officers or challenging the validity or propriety of the transactions contemplated
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;9.14</U>, there is no material injunction, order, judgment, decree, or regulatory restriction imposed upon CBTX, any
of its Subsidiaries or the assets of CBTX or any of its Subsidiaries (or that, upon consummation of the Merger, would apply to the Surviving
Entity or any of its affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Taxes
and Tax Returns</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of CBTX and its Subsidiaries has duly and timely filed (including all applicable extensions) all material Tax Returns in all jurisdictions
in which Tax Returns are required to be filed by it, and all such Tax Returns are true, correct, and complete in all material respects.
Neither CBTX nor any of its Subsidiaries is the beneficiary of any extension of time within which to file any material Tax Return (other
than extensions to file Tax Returns obtained in the ordinary course). All material Taxes of CBTX and its Subsidiaries (whether or not
shown on any Tax Returns) that are due have been fully and timely paid (other than Taxes being contested in good faith by appropriate
proceedings and for which reserves have been established in accordance with GAAP). Each of CBTX and its Subsidiaries has withheld and
paid all material Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, creditor, shareholder,
independent contractor or other third party. Neither CBTX nor any of its Subsidiaries has granted any extension or waiver of the limitation
period applicable to any material Tax or Tax Return that remains in effect (other than extension or waiver granted in the ordinary course
of business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
CBTX nor any of its Subsidiaries has received written notice of assessment or proposed assessment in connection with any material amount
of Taxes, and there are no threatened in writing or pending disputes, claims, audits, examinations or other proceedings regarding any
material Tax or Tax Return of CBTX and its Subsidiaries or Taxes imposed on the assets of CBTX and its Subsidiaries. Neither CBTX nor
any of its Subsidiaries is a party to or is bound by any Tax sharing, allocation or indemnification agreement or arrangement (other than
such an agreement or arrangement (i)&nbsp;exclusively between or among CBTX and its Subsidiaries, or (ii)&nbsp;contained in commercial
agreements entered into in the ordinary course of business the primary purpose of which does not relate to Taxes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no pending or proposed changes in the income Tax accounting methods (including any method for determining reserves for bad debts)
of CBTX or any of its Subsidiaries. Neither CBTX nor any of its Subsidiaries will be required to include any item of income or gain in,
or exclude any item of deduction or loss from, taxable income for any taxable period ending after the Closing Date as a result of any:
(i)&nbsp;adjustment required by a change in method of accounting made prior to the Closing Date; (ii)&nbsp;closing agreement entered into
prior to the Closing Date; or (iii)&nbsp;installment sale or open transaction disposition made prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2017, neither CBTX nor any of its Subsidiaries (i)&nbsp;has been a member of an affiliated group filing a consolidated
federal income Tax Return for which the statute of limitations is open (other than a group the common parent of which was CBTX) or (ii)&nbsp;has
any liability for the Taxes of any person (other than CBTX or any of its Subsidiaries) under Treasury Regulation Section&nbsp;1.1502-6
(or any similar provision of state, local or foreign law), as a transferee or successor or by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
CBTX nor any of its Subsidiaries has been, within the past two (2)&nbsp;years or otherwise as part of a &ldquo;plan (or series of related
transactions)&rdquo; within the meaning of Section&nbsp;355(e)&nbsp;of the Code of which the Merger is also a part, a &ldquo;distributing
corporation&rdquo; or a &ldquo;controlled corporation&rdquo; (within the meaning of Section&nbsp;355(a)(1)(A)&nbsp;of the Code) in a distribution
of stock intending to qualify for tax-free treatment under Section&nbsp;355 of the Code. Neither CBTX nor any of its Subsidiaries has
participated in a &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulation Section&nbsp;1.6011-4(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
CBTX nor any of its Subsidiaries has taken any action or has knowledge of any facts or circumstances that, in either case, would reasonably
be expected to prevent or impede the Merger from being treated as a transaction that qualifies as a &ldquo;reorganization&rdquo; within
the meaning of Section&nbsp;368(a)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
used in this Agreement, (i)&nbsp;the term &ldquo;<U>Tax</U>&rdquo; or &ldquo;<U>Taxes</U>&rdquo; means all federal, state, local, and
non-U.S. taxes, including income, excise, gross receipts, ad valorem, profits, gains, property, turnover, production, stamp, documentary,
goods and services, registration, disability, capital, sales, transfer, use, license, payroll, employment, social security, severance,
unemployment, withholding, duties, excise, windfall profits, intangibles, franchise, backup withholding, value added, alternative or add-on
minimum, estimated and other like charges, levies or assessments that are in the nature of a tax together with all penalties and additions
to tax and interest thereon, and (ii)&nbsp;term &ldquo;<U>Tax Return</U>&rdquo; means any return, declaration, report, form, filing, election,
notice, claim for refund, or information return , including any schedule, statement or attachment thereto, and including any amendment
thereof, filed or required to be filed with a Governmental Entity with respect to Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Benefit
Plans; Employees</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, each CBTX Benefit
Plan has been established, operated, maintained and administered in accordance with its terms and the requirements of all applicable laws,
including ERISA and the Code. For purposes of this Agreement, the term &ldquo;<U>CBTX Benefit Plans</U>&rdquo; means all employee benefit
plans (as defined in Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;)),
whether or not subject to ERISA, and all equity, equity-related, bonus or incentive, deferred compensation, retiree medical or life insurance,
supplemental retirement, severance, termination, change in control, retention, employment, consulting, welfare, insurance, medical, dental,
disability, cafeteria, flexible spending, dependent care, fringe benefit or other compensation or benefit plans, programs, agreements,
contracts, policies, arrangements or remuneration of any kind with respect to which CBTX, any Subsidiary thereof or any trade or business,
whether or not incorporated, which would be deemed a single employer with CBTX or any of its Subsidiaries pursuant to Section&nbsp;414(b),
(c), (m)&nbsp;or (o)&nbsp;of the Code (a &ldquo;<U>CBTX ERISA Affiliate</U>&rdquo;), is a party or has any current or future obligation
or liability (whether actual, contingent or otherwise) or that are sponsored, maintained, contributed to by or required to be contributed
to by CBTX, any of its Subsidiaries, or any CBTX ERISA Affiliate for the benefit of any current or former employee, officer, director
or independent contractor (or the dependents, beneficiaries or designees of any of the foregoing) of CBTX, any of its Subsidiaries, or
any CBTX ERISA Affiliate. <U>Section&nbsp;3.11(a)</U>&nbsp;of the CBTX Disclosure Schedule lists each CBTX Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
has made available to Allegiance true and complete copies of each material CBTX Benefit Plan (and all amendments thereto) (or, in the
case of an unwritten material CBTX Benefit Plan, a written summary of the material terms thereof) and the following related documents,
to the extent applicable: (i)&nbsp;all summary plan descriptions, amendments, modifications or material supplements; (ii)&nbsp;the most
recent annual report (Form&nbsp;5500) filed with the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;); (iii)&nbsp;the most recently
received IRS determination, advisory or opinion letter; and (iv)&nbsp;the most recently prepared actuarial report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
IRS has issued a favorable determination, advisory or opinion with respect to the form of each CBTX Benefit Plan that is intended to be
qualified under Section&nbsp;401(a)&nbsp;of the Code (the &ldquo;<U>CBTX Qualified Plans</U>&rdquo;) and the related trust, which letter
has not been revoked (nor has revocation been threatened), and, to CBTX&rsquo;s knowledge, there are no existing circumstances and no
events have occurred that would reasonably be expected to adversely affect the qualified status of any CBTX Qualified Plan or the related
trust.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
CBTX Benefit Plan is (i)&nbsp;subject to Title IV of ERISA of Section&nbsp;412 of the Code; (ii)&nbsp;a &ldquo;multiemployer plan&rdquo;
as defined in Section&nbsp;3(37) of ERISA; (iii)&nbsp;a multiple employer plan as described in Section&nbsp;413(d)&nbsp;of the Code; or
(iv)&nbsp;a &ldquo;multiple employer welfare arrangement&rdquo; as defined in Section&nbsp;3(40)(A)&nbsp;of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, no CBTX Benefit
Plan provides for any post-employment, post-retirement or post-service health or medical or life insurance benefits for retired, former
or current employees, directors or consultants (or beneficiaries or dependents thereof), except (i)&nbsp;as required by Section&nbsp;4980B
of the Code; (ii)&nbsp;through the end of the month of termination of employment; or (iii)&nbsp;pursuant to conversion rights at sole
expense of converting former employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, all contributions
required to be made by CBTX, its Subsidiaries or any CBTX ERISA Affiliate to any CBTX Benefit Plan by applicable law or by any plan document
or other contractual undertaking, and all premiums due or payable by CBTX, its Subsidiaries or any CBTX ERISA Affiliate with respect to
insurance policies funding any CBTX Benefit Plan, for any period through the date hereof, have been timely made or paid in full or, to
the extent not required to be made or paid on or before the date hereof, have been fully reflected on the books and records of CBTX in
accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no pending or, to CBTX&rsquo;s knowledge, threatened claims (other than claims for benefits in the ordinary course), lawsuits, arbitrations
or governmental audits or investigations that have been asserted or instituted, and, to CBTX&rsquo;s knowledge, no set of circumstances
exists which may reasonably give rise to a claim, lawsuit, arbitration, audit or investigation, against or of the CBTX Benefit Plans,
any fiduciaries thereof with respect to their duties to the CBTX Benefit Plans or the assets of any of the trusts under any of the CBTX
Benefit Plans that would reasonably be expected to result in any material liability to CBTX or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, none of CBTX,
its Subsidiaries or any CBTX ERISA Affiliate (or, to CBTX&rsquo;s knowledge, any other party) has engaged in any &ldquo;prohibited transaction&rdquo;
(as defined in Section&nbsp;4975 of the Code or Section&nbsp;406 of ERISA) with respect to a CBTX Benefit Plan that would reasonably
be expected to subject any of the CBTX Benefit Plans or their related trusts, CBTX, any of its Subsidiaries or any CBTX ERISA Affiliate
to any material Tax, penalty or liability imposed under Section&nbsp;4975 of the Code or Section&nbsp;502 of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as contemplated by <U>Section&nbsp;1.7</U>, neither the execution and delivery of this Agreement nor the consummation of the transactions
contemplated hereby will (either alone or in conjunction with any other event) result or has resulted in the acceleration of vesting,
exercisability, funding or delivery of, or increase in the amount or value of, any payment, right or other benefit to any current or former
employee, officer, director or other service provider of CBTX or any of its Subsidiaries, or result in any limitation on the right of
CBTX or any of its Subsidiaries to amend, merge, terminate or receive a reversion of assets from any CBTX Benefit Plan or related trust
on or after the Effective Time. Without limiting the generality of the foregoing, no amount paid or payable (whether in cash, in property,
or in the form of benefits) by CBTX or any of its Subsidiaries in connection with the transactions contemplated hereby (either solely
as a result thereof or as a result of such transactions in conjunction with any other event) will be an &ldquo;excess parachute payment&rdquo;
within the meaning of Section&nbsp;280G of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
CBTX Benefit Plan provides for the gross-up or reimbursement of Taxes under Section&nbsp;409A or 4999 of the Code, or otherwise. Except
as would not reasonably be expected to result in material liability to CBTX, each CBTX Benefit Plan required to comply with Section&nbsp;409A
of the Code complies in both form and operation therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, there are no
pending or, to CBTX&rsquo;s knowledge, threatened labor grievances or unfair labor practice claims or charges against CBTX or any of its
Subsidiaries, or any strikes or other labor disputes against CBTX or any of its Subsidiaries. Neither CBTX nor any of its Subsidiaries
is party to or bound by any collective bargaining or similar agreement with any labor organization, or work rules&nbsp;or practices agreed
to with any labor organization or employee association applicable to employees of CBTX or any of its Subsidiaries and there are no pending
or, to the CBTX&rsquo;s knowledge, threatened organizing efforts by any union or other group seeking to represent any employees of CBTX
or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
has provided to Allegiance a list of individuals employed by CBTX or any of its Subsidiaries as of the date hereof, and the following
information for each such individual: (i)&nbsp;name; (ii)&nbsp;title; (iii)&nbsp;hire date; (iv)&nbsp;office location; (v)&nbsp;annual
salary or hourly wage rate, as applicable; (vi)&nbsp;incentive compensation; and (vii)&nbsp;total annual compensation. As of the date
hereof, all compensation payable to all employees of CBTX or any of its Subsidiaries for services performed on or prior to the date hereof
have been paid in full (or accrued in full on the interim financial statements) and there are no outstanding agreements, understandings
or commitments of CBTX or any of its Subsidiaries with respect to any compensation to employees. Neither CBTX nor any of its Subsidiaries
is a party to an agreement with a professional employer organization or staffing services agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
CBTX nor any of its Subsidiaries has, in the past ninety (90) days, engaged in any employment termination action requiring notice pursuant
to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Section&nbsp;2101 et seq. similar provision of any state or local
law (the &ldquo;<U>WARN Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>SEC
Reports</U>. CBTX has previously made available to Allegiance an accurate and complete copy of each (a)&nbsp;final registration statement,
prospectus, report, schedule and definitive proxy statement filed with or furnished to the SEC since December&nbsp;31, 2019 by CBTX pursuant
to the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), or the Exchange Act (the &ldquo;<U>CBTX Reports</U>&rdquo;)
and (b)&nbsp;communication mailed by CBTX to its shareholders since December&nbsp;31, 2019 and prior to the date hereof, and no such
CBTX Report or communication, as of the date thereof (and, in the case of registration statements and proxy statements, on the dates
of effectiveness and the dates of the relevant meetings, respectively), contained any untrue statement of a material fact or omitted
to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
in which they were made, not misleading, except that information filed or furnished as of a later date (but before the date of this Agreement)
shall be deemed to modify information as of an earlier date. Since December&nbsp;31, 2019, as of their respective dates, all CBTX Reports
filed or furnished under the Securities Act and the Exchange Act complied in all material respects with the published rules&nbsp;and
regulations of the SEC with respect thereto. No executive officer of CBTX has failed in any respect to make the certifications required
of him or her under Section&nbsp;302 or 906 of the Sarbanes-Oxley Act. As of the date of this Agreement, there are no outstanding comments
from, or unresolved issued raised by, the SEC with respect to any of the CBTX Reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Applicable Law</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
and each of its Subsidiaries hold, and have at all times since December&nbsp;31, 2020, held, all licenses, registrations, franchises,
certificates, variances, permits, charters and authorizations necessary for the lawful conduct of their respective businesses and ownership
of their respective properties, rights and assets under and pursuant to each (and have paid all fees and assessments due and payable in
connection therewith), except where neither the cost of failure to hold nor the cost of obtaining and holding such license, registration,
franchise, certificate, variance, permit, charter or authorization (nor the failure to pay any fees or assessments) would, either individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX, and to the knowledge of CBTX, no suspension or
cancellation of any such necessary license, registration, franchise, certificate, variance, permit, charter or authorization is threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX, CBTX and each
of its Subsidiaries have complied with and are not in default or violation under any applicable law, statute, order, rule, regulation,
policy and/or guideline of any Governmental Entity relating to CBTX or any of its Subsidiaries, including all laws related to data protection
or privacy (including laws relating to the privacy and security of data or information that constitutes personal data or personal information
under applicable law (&ldquo;<U>Personal Data</U>&rdquo;)), the USA PATRIOT Act, the Bank Secrecy Act, the Equal Credit Opportunity Act
and Regulation B, the Fair Housing Act, the Community Reinvestment Act, the Fair Credit Reporting Act, the Truth in Lending Act and Regulation
Z, the Home Mortgage Disclosure Act, the Fair Debt Collection Practices Act, the Electronic Fund Transfer Act, the Dodd-Frank Wall Street
Reform and Consumer Protection Act, any regulations promulgated by the Consumer Financial Protection Bureau, the Interagency Policy Statement
on Retail Sales of Nondeposit Investment Products, the SAFE Mortgage Licensing Act of 2008, the Real Estate Settlement Procedures Act
and Regulation X, Title V of the Gramm-Leach-Bliley Act, any and all sanctions or regulations enforced by the Office of Foreign Assets
Control of the United States Department of Treasury and any other law, policy or guideline relating to bank secrecy, discriminatory lending,
financing or leasing practices, consumer protection, money laundering prevention, foreign assets control, U.S. sanctions laws and regulations,
Sections 23A and 23B of the Federal Reserve Act, the Sarbanes-Oxley Act, and all agency requirements relating to the origination, sale
and servicing of mortgage and consumer loans. CBTX and its Subsidiaries have established and maintain a system of internal controls designed
to ensure compliance in all material respects by CBTX and its Subsidiaries with applicable financial recordkeeping and reporting requirements
of applicable money laundering prevention laws in jurisdictions where CBTX and its Subsidiaries conduct business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
Subsidiary Bank has a Community Reinvestment Act rating of &ldquo;satisfactory&rdquo; or better.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
maintains a written information privacy and security program that maintains reasonable measures to protect the privacy, confidentiality
and security of all Personal Data against any (i)&nbsp;loss or misuse of Personal Data; (ii)&nbsp;unauthorized or unlawful operations
performed upon Personal Data; or (iii)&nbsp;other act or omission that compromises the security or confidentiality of Personal Data (clauses
(i)&nbsp;through (iii), a &ldquo;<U>Security Breach</U>&rdquo;). To the knowledge of CBTX, CBTX has not experienced any Security Breach
that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX. To the knowledge of CBTX,
there are no data security or other technological vulnerabilities with respect to its information technology systems or networks that,
individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limitation, none of CBTX or any of its Subsidiaries, or to the knowledge of CBTX, any director, officer, employee, agent or other person
acting on behalf of CBTX or any of its Subsidiaries has, directly or indirectly, (i)&nbsp;used any funds of CBTX or any of its Subsidiaries
for unlawful contributions, unlawful gifts, unlawful entertainment or other expenses relating to political activity; (ii)&nbsp;made any
unlawful payment to foreign or domestic governmental officials or employees or to foreign or domestic political parties or campaigns
from funds of CBTX or any of its Subsidiaries; (iii)&nbsp;violated any provision that would result in the violation of the Foreign Corrupt
Practices Act of 1977, as amended, or any similar law; (iv)&nbsp;established or maintained any unlawful fund of monies or other assets
of CBTX or any of its Subsidiaries; (v)&nbsp;made any fraudulent entry on the books or records of CBTX or any of its Subsidiaries; or
(vi)&nbsp;made any unlawful bribe, unlawful rebate, unlawful payoff, unlawful influence payment, unlawful kickback or other unlawful
payment to any person, private or public, regardless of form, whether in money, property or services, to obtain favorable treatment in
securing business, to obtain special concessions for CBTX or any of its Subsidiaries, to pay for favorable treatment for business secured
or to pay for special concessions already obtained for CBTX or any of its Subsidiaries, or is currently subject to any United States
sanctions administered by the Office of Foreign Assets Control of the United States Treasury Department, except in each case as would
not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, CBTX, CBTX Subsidiary Bank and each other insured depository institution CBTX Subsidiary is &ldquo;well-capitalized&rdquo;
(as such term is defined in the relevant regulation of the institution&rsquo;s primary bank regulator).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX, (i)&nbsp;CBTX
and each of its Subsidiaries have properly administered all accounts for which it acts as a fiduciary, including accounts for which it
serves as a trustee, agent, custodian, personal representative, guardian, conservator or investment advisor, in accordance with the terms
of the governing documents and applicable state, federal and foreign law&#894; and (ii)&nbsp;none of CBTX, any of its Subsidiaries, or
any of its or its Subsidiaries&rsquo; directors, officers or employees, has committed any breach of trust or fiduciary duty with respect
to any such fiduciary account, and the accountings for each such fiduciary account are true and correct and accurately reflect the assets
and results of such fiduciary account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14</FONT>&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Contracts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, neither CBTX nor any of its Subsidiaries is a party to or bound by any contract, arrangement, commitment or understanding
(whether written or oral, but excluding any CBTX Benefit Plan):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">which
is a &ldquo;material contract&rdquo; (as such term is defined in Item 601(b)(10)&nbsp;of Regulation S-K of the SEC)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">which
contains a provision that materially restricts the conduct of any line of business by CBTX or any of its Subsidiaries or upon consummation
of the Merger will materially restrict the ability of the Surviving Entity or any of its affiliates to engage in any line of business
or in any geographic region&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">with
or to a labor union, labor organization or other employee organization (including any collective bargaining agreement)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
of the benefits of or obligations under which will arise or be increased or accelerated by the occurrence of the execution and delivery
of this Agreement, receipt of the Requisite CBTX Vote or the announcement or consummation of any of the transactions contemplated by this
Agreement, or under which a right of cancellation or termination will arise as a result thereof, or the value of any of the benefits of
which will be calculated on the basis of any of the transactions contemplated by this Agreement, where such increase or acceleration of
benefits or obligations, right of cancellation or termination, or change in calculation of value of benefits would, either individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on CBTX&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;that
relates to the incurrence of indebtedness by CBTX or any of its Subsidiaries, including any sale and leaseback transactions, capitalized
leases and other similar financing arrangements (other than deposit liabilities, trade payables, federal funds purchased, advances and
loans from the Federal Home Loan Bank and securities sold under agreements to repurchase, in each case incurred in the ordinary course
of business consistent with past practice), or (B)&nbsp;that provides for the guarantee, support, indemnification, assumption or endorsement
by CBTX or any CBTX Subsidiary of, or any similar commitment by CBTX or any of its Subsidiaries with respect to, the obligations, liabilities
or indebtedness of any other person, in the case of each of clauses (A)&nbsp;and (B), in outstanding principal amount of $5,000,000 or
more&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
grants any right of first refusal, right of first offer or similar right with respect to any material assets, rights or properties of
CBTX or its Subsidiaries, taken as a whole&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
alters the at-will employment status of an employee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">with
independent contractors or consultants providing for payments of at least $250,000 in any twelve (12)-month period or that are not terminable
by CBTX or any of its Subsidiaries on notice of sixty (60) days or less without termination obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
is a consulting agreement or data processing, software programming or licensing contract involving the payment of more than $250,000 per
annum (other than any such contracts which are terminable by CBTX or any of its Subsidiaries on sixty (60) days or less notice without
any required payment or other conditions, other than the condition of notice)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
is a settlement, consent or similar agreement and contains any material continuing obligations of CBTX or any of its Subsidiaries&#894;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
relates to the acquisition or disposition of any person, business or asset and under which CBTX or its Subsidiaries have or may have a
material obligation or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each contract, arrangement, commitment or understanding
of the type described in this <U>Section&nbsp;3.14(a)</U>, whether or not set forth in the CBTX Disclosure Schedule, is referred to herein
as a &ldquo;<U>CBTX Contract</U>.&rdquo; CBTX has made available to Allegiance true, correct and complete copies of each CBTX Contract
in effect as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
CBTX Contract is valid and binding on CBTX or one of its Subsidiaries, as applicable, and in full force and effect, except as, either
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on CBTX. CBTX and each of its Subsidiaries
have in all material respects complied with and performed all obligations required to be complied with or performed by any of them to
date under each CBTX Contract, except where such noncompliance or nonperformance, either individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect on CBTX. To the knowledge of CBTX, each third-party counterparty to each CBTX
Contract has in all material respects complied with and performed all obligations required to be complied with and performed by it to
date under such CBTX Contract, except where such noncompliance or nonperformance, either individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect on CBTX. Neither CBTX nor any of its Subsidiaries has knowledge of, or has received
notice of, any violation of any CBTX Contract by any of the other parties thereto which would reasonably be expected to have, either
individually or in the aggregate, a Material Adverse Effect on CBTX. No event or condition exists which constitutes or, after notice
or lapse of time or both, will constitute, a material breach or default on the part of CBTX or any of its Subsidiaries, or to the knowledge
of CBTX, any other party thereto, of or under any such CBTX Contract, except where such breach or default, either individually or in
the aggregate, would not reasonably be expected to have a Material Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Agreements
with Regulatory Agencies</U>. Subject to <U>Section&nbsp;9.14</U>, neither CBTX nor any of its Subsidiaries is subject to any
cease-and-desist or other order or enforcement action issued by, or is a party to any written agreement, consent agreement or
memorandum of understanding with, or is a party to any commitment letter or similar undertaking to, or is subject to any order or
directive by, or has been ordered to pay any civil money penalty by, or has been since December&nbsp;31, 2019, a recipient of any
supervisory letter from, or since December&nbsp;31, 2019, has adopted any policies, procedures or board resolutions at the request
or suggestion of, any Regulatory Agency or other Governmental Entity that currently restricts in any material respect or would
reasonably be expected to restrict in any material respect the conduct of its business or that in any material manner relates to its
capital adequacy, its ability to pay dividends, its credit or risk management policies, its management or its business (each,
whether or not set forth in the CBTX Disclosure Schedule, a &ldquo;<U>CBTX Regulatory Agreement</U>&rdquo;), nor has CBTX or any of
its Subsidiaries been advised in writing or, to the knowledge of CBTX, threatened since January&nbsp;1, 2019, by any Regulatory
Agency or other Governmental Entity that it is considering issuing, initiating, ordering, or requesting any such CBTX Regulatory
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Matters</U>. Except as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on
CBTX, CBTX and its Subsidiaries are in compliance, and have complied since January&nbsp;1, 2020, with all federal, state or local law,
regulation, order, decree, permit, authorization, common law or agency requirement relating to: (a)&nbsp;the protection or restoration
of the environment, health and safety as it relates to hazardous substance exposure or natural resource damages, (b)&nbsp;the handling,
use, presence, disposal, release or threatened release of, or exposure to, any hazardous substance, or (c)&nbsp;noise, odor, wetlands,
indoor air, pollution, contamination or any injury to persons or property from exposure to any hazardous substance (collectively, &ldquo;<U>Environmental
Laws</U>&rdquo;). There are no legal, administrative, arbitral or other proceedings, claims or actions, or to the knowledge of CBTX, any
private environmental investigations or remediation activities or governmental investigations of any nature seeking to impose, or that
could reasonably be expected to result in the imposition, on CBTX or any CBTX Subsidiary of any liability or obligation arising under
any Environmental Law pending or threatened against CBTX, which liability or obligation would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect on CBTX. To the knowledge of CBTX, there is no reasonable basis for any such proceeding,
claim, action or governmental investigation that would impose any liability or obligation that would reasonably be expected to have, either
individually or in the aggregate, a Material Adverse Effect on CBTX. CBTX is not subject to any agreement, order, judgment, decree, letter
agreement or memorandum of agreement by or with any court, Governmental Entity, Regulatory Agency or other third party imposing any liability
or obligation with respect to the foregoing that would reasonably be expected to have, either individually or in the aggregate, a Material
Adverse Effect on CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Securities and Commodities</U>. Each of CBTX and its Subsidiaries has good title to all securities and commodities owned by it (except
those sold under repurchase agreements) which are material to CBTX&rsquo;s business on a consolidated basis, free and clear of any Lien,
except as set forth in the financial statements included in the CBTX Reports or to the extent such securities or commodities are pledged
in the ordinary course of business to secure obligations of CBTX or its Subsidiaries. Such securities and commodities are valued on the
books of CBTX in accordance with GAAP in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Real
Property</U>. Except as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on
CBTX, CBTX or a CBTX Subsidiary (a)&nbsp;has good and marketable title to all the real property reflected in the latest audited balance
sheet included in the CBTX Reports as being owned by CBTX or a CBTX Subsidiary or acquired after the date thereof which are material to
CBTX on a consolidated basis (except properties sold or otherwise disposed of since the date thereof in the ordinary course of business)
(the &ldquo;<U>CBTX Owned Properties</U>&rdquo;), free and clear of all material Liens, except (i)&nbsp;statutory Liens securing payments
not yet due; (ii)&nbsp;Liens for property or ad valorem Taxes not yet due and payable; (iii)&nbsp;easements, rights of way, and other
similar encumbrances that do not materially affect the value or use of the properties or assets subject thereto or affected thereby or
otherwise materially impair business operations at such properties; and (iv)&nbsp;such imperfections or irregularities of title or Liens
as do not materially affect the value or use of the properties or assets subject thereto or affected thereby or otherwise materially impair
business operations at such properties (clauses (i)&nbsp;through (iv)&nbsp;collectively, &ldquo;<U>Permitted Encumbrances</U>&rdquo;),
and (b)&nbsp;is the lessee of all leasehold estates reflected in the latest audited financial statements included in such CBTX Reports
or acquired after the date thereof which are material to CBTX on a consolidated basis (except for leases that have expired by their terms
since the date thereof) (such leasehold estates, collectively with the CBTX Owned Properties, the &ldquo;<U>CBTX Real Property</U>&rdquo;),
free and clear of all material Liens, except for Permitted Encumbrances, and is in possession of the properties purported to be leased
thereunder, and each such lease is valid without default thereunder by the lessee or, to the knowledge of CBTX, the lessor. There are
no pending or, to the knowledge of CBTX, threatened condemnation proceedings against the CBTX Real Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. CBTX and each of its Subsidiaries owns, or is licensed to use (in each case, free and clear of any material Liens), all
Intellectual Property necessary for the conduct of its business as currently conducted. Except as would not reasonably be expected to
have, either individually or in the aggregate, a Material Adverse Effect on CBTX: (a)&nbsp;(i)&nbsp;to the knowledge of CBTX, the use
of any Intellectual Property by CBTX and its Subsidiaries does not infringe, misappropriate or otherwise violate the rights of any person
and is in accordance with any applicable license pursuant to which CBTX or any CBTX Subsidiary acquired the right to use any Intellectual
Property, and (ii)&nbsp;no person has asserted in writing to CBTX that CBTX or any of its Subsidiaries has infringed, misappropriated
or otherwise violated the Intellectual Property rights of such person, (b)&nbsp;to the knowledge of CBTX, no person is challenging, infringing
on or otherwise violating any right of CBTX or any of its Subsidiaries with respect to any Intellectual Property owned by and/or licensed
to CBTX or its Subsidiaries, and (c)&nbsp;neither CBTX nor any CBTX Subsidiary has received any written notice of any pending claim with
respect to any Intellectual Property owned by CBTX or any CBTX Subsidiary, and CBTX and its Subsidiaries have taken commercially reasonable
actions to avoid the abandonment, cancellation or unenforceability of all Intellectual Property owned or licensed, respectively, by CBTX
and its Subsidiaries. For purposes of this Agreement, &ldquo;<U>Intellectual Property</U>&rdquo; means trademarks, service marks, brand
names, internet domain names, logos, symbols, certification marks, trade dress and other indications of origin, the goodwill associated
with the foregoing and registrations in any jurisdiction of, and applications in any jurisdiction to register, the foregoing, including
any extension, modification or renewal of any such registration or application&#894; inventions, discoveries and ideas, whether patentable
or not, in any jurisdiction&#894; patents, applications for patents (including divisions, continuations, continuations in part and renewal
applications), all improvements thereto, and any renewals, extensions or reissues thereof, in any jurisdiction&#894; nonpublic information,
trade secrets and know-how, including processes, technologies, protocols, formulae, prototypes and confidential information and rights
in any jurisdiction to limit the use or disclosure thereof by any person&#894; writings and other works, whether copyrightable or not
and whether in published or unpublished works, in any jurisdiction&#894; and registrations or applications for registration of copyrights
in any jurisdiction, and any renewals or extensions thereof&#894; and any similar intellectual property or proprietary rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Related
Party Transactions</U>. As of the date hereof, there are no transactions or series of related transactions, agreements, arrangements or
understandings, nor are there any currently proposed transactions or series of related transactions, between CBTX or any of its Subsidiaries,
on the one hand, and any current or former director or &ldquo;executive officer&rdquo; (as defined in Rule&nbsp;3b-7 under the Exchange
Act) of CBTX or any of its Subsidiaries or any person who beneficially owns (as defined in Rules&nbsp;13d-3 and 13d-5 of the Exchange
Act) five percent (5%) or more of the outstanding CBTX Common Stock (or any of such person&rsquo;s immediate family members or affiliates)
(other than CBTX Subsidiaries) on the other hand, of the type required to be reported in any CBTX Report pursuant to Item 404 of Regulation
S-K promulgated under the Exchange Act that have not been disclosed therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>State
Takeover Laws</U>. The Board of Directors of CBTX has approved this Agreement and the transactions contemplated hereby and has taken all
such other necessary actions as required to render inapplicable to such agreements and transactions the provisions of any potentially
applicable takeover laws of any state, including any &ldquo;moratorium,&rdquo; &ldquo;control share,&rdquo; &ldquo;fair price,&rdquo;
&ldquo;takeover&rdquo; or &ldquo;interested shareholder&rdquo; law or any similar provisions of the CBTX Certificate of Formation or CBTX
Bylaws (collectively, with any similar provisions of the Allegiance Certificate of Formation or Allegiance Bylaws &ldquo;<U>Takeover Restrictions</U>&rdquo;).
In accordance with Section&nbsp;10.354 of the TBOC, no appraisal or dissenters&rsquo; rights will be available to the holders of CBTX
Common Stock in connection with the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reorganization</U>.
CBTX has not taken any action and is not aware of any fact or circumstance that could reasonably be expected to prevent the Merger from
qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Opinions
of Financial Advisors</U>. Prior to the execution of this Agreement, the Board of Directors of CBTX has received the opinion (which if
initially rendered orally, has been or will be confirmed by written opinion of the same date) from Stephens Inc. to the effect that as
of the date of such opinion and based upon and subject to the assumptions, limitations, qualifications and other matters set forth in
the written opinion, the Exchange Ratio pursuant to this Agreement is fair, from a financial point of view, to the holders of CBTX Common
Stock (other than, as applicable, Allegiance and its affiliates). Such opinion has not been amended or rescinded as of the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.24</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loan
Portfolio</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, neither CBTX nor any of its Subsidiaries is a party to any written or oral loan, loan agreement, note or borrowing
arrangement (including leases, credit enhancements, commitments, guarantees and interest-bearing assets) (collectively, &ldquo;<U>Loans</U>&rdquo;)
in which CBTX or any CBTX Subsidiary is a creditor that, as of September&nbsp;30, 2021, had an outstanding balance of $5,000,000 or more
and under the terms of which the obligor was, as of September&nbsp;30, 2021, over ninety (90) days or more delinquent in payment of principal
or interest. Set forth in <U>Section&nbsp;3.24(a)</U>&nbsp;of the CBTX Disclosure Schedule is a true, correct and complete list of (A)&nbsp;all
the Loans of CBTX and its Subsidiaries that, as of September&nbsp;30, 2021, had an outstanding balance of $5,000,000 and were classified
by CBTX as &ldquo;Other Loans Specially Mentioned,&rdquo; &ldquo;Special Mention,&rdquo; &ldquo;Substandard,&rdquo; &ldquo;Doubtful,&rdquo;
&ldquo;Loss,&rdquo; &ldquo;Classified,&rdquo; &ldquo;Criticized,&rdquo; &ldquo;Credit Risk Assets,&rdquo; &ldquo;Concerned Loans,&rdquo;
&ldquo;Watch List&rdquo; or words of similar import, together with the principal amount of and accrued and unpaid interest on each such
Loan and the identity of the borrower thereunder, together with the aggregate principal amount of and accrued and unpaid interest on
such Loans, by category of Loan (e.g., commercial, consumer,&nbsp;etc.), together with the aggregate principal amount of such Loans by
category and (B)&nbsp;each asset of CBTX or any of its Subsidiaries that, as of September&nbsp;30, 2021, is classified as &ldquo;Other
Real Estate Owned&rdquo; and the book value thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, each Loan of
CBTX or any of its Subsidiaries (i)&nbsp;is evidenced by notes, agreements or other evidences of indebtedness that are true, genuine
and what they purport to be, (ii)&nbsp;to the extent carried on the books and records of CBTX and its Subsidiaries as secured Loans,
has been secured by valid Liens, which have been perfected and (iii)&nbsp;is the legal, valid and binding obligation of the obligor named
therein, enforceable in accordance with its terms, subject to the Enforceability Exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on CBTX, each outstanding
Loan of CBTX or any of its Subsidiaries (including Loans held for resale to investors) was solicited and originated, and is and has been
administered and, where applicable, serviced, and the relevant Loan files are being maintained, in all material respects in accordance
with the relevant notes or other credit or security documents, the written underwriting standards of CBTX and its Subsidiaries (and, in
the case of Loans held for resale to investors, the underwriting standards, if any, of the applicable investors) and with all applicable
federal, state and local laws, regulations and rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Except as would not reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect on CBTX, (a)&nbsp;CBTX
and its Subsidiaries are insured with reputable insurers against such risks and in such amounts as the management of CBTX reasonably has
determined to be prudent and consistent with industry practice, and CBTX and its Subsidiaries are in compliance in all material respects
with their insurance policies and are not in default under any of the terms thereof; (b)&nbsp;each such policy is outstanding and in full
force and effect and, except for policies insuring against potential liabilities of officers, directors and employees of CBTX and its
Subsidiaries, CBTX or the relevant Subsidiary thereof is the sole beneficiary of such policies; (c)&nbsp;all premiums and other payments
due under any such policy have been paid, and all claims thereunder have been filed in due and timely fashion; (d)&nbsp;there is no claim
for coverage by CBTX or any of its Subsidiaries pending under any insurance policy as to which coverage has been questioned, denied or
disputed by the underwriters of such insurance policy and (e)&nbsp;neither CBTX nor any of its Subsidiaries has received notice of any
threatened termination of, material premium increase with respect to, or material alteration of coverage under, any insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.26</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Investment Advisor Subsidiary</U>. Neither CBTX nor any CBTX Subsidiary provides any investment management, investment advisory or sub-advisory
services or is required to register with the SEC as an investment advisor under the Investment Advisers Act of 1940, as amended (the &ldquo;<U>Investment
Advisors Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.27</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Broker-Dealer Subsidiary</U>. Neither CBTX nor any CBTX Subsidiary is a broker-dealer required to be registered under the Exchange Act
with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>CBTX
Information</U>.&nbsp; The information relating to CBTX and the CBTX Subsidiaries to be contained in the Joint Proxy Statement and the
S-4, and the information relating to CBTX and the CBTX Subsidiaries that is provided by CBTX or its representatives for inclusion in any
other document filed with any other Regulatory Agency in connection herewith, will not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in light of the circumstances in which they are made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.29</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Other Representations or Warranties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
for the representations and warranties made by CBTX in this <U>ARTICLE&nbsp;III</U>, neither CBTX nor any other person makes any express
or implied representation or warranty with respect to CBTX, its Subsidiaries, or their respective businesses, operations, assets, liabilities,
conditions (financial or otherwise) or prospects, and CBTX hereby disclaims any such other representations or warranties. In particular,
without limiting the foregoing disclaimer, neither CBTX nor any other person makes or has made any representation or warranty to Allegiance
or any of its affiliates or representatives with respect to (i)&nbsp;any financial projection, forecast, estimate, budget or prospective
information relating to CBTX, any of its Subsidiaries or their respective businesses or (ii)&nbsp;except for the representations and warranties
made by CBTX in this <U>ARTICLE&nbsp;III</U>, any oral or written information presented to Allegiance or any of its affiliates or representatives
in the course of their due diligence investigation of CBTX, the negotiation of this Agreement or in the course of the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
acknowledges and agrees that neither Allegiance nor any other person has made or is making any express or implied representation or warranty
other than those contained in <U>ARTICLE&nbsp;IV</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;IV</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF ALLEGIANCE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except (a)&nbsp;as disclosed
in the disclosure schedule delivered by Allegiance to CBTX concurrently herewith (the &ldquo;<U>Allegiance Disclosure Schedule</U>&rdquo;)&#894;
<U>provided</U>, that (i)&nbsp;no such item is required to be set forth as an exception to a representation or warranty if its absence
would not result in the related representation or warranty being deemed untrue or incorrect; (ii)&nbsp;the mere inclusion of an item in
the Allegiance Disclosure Schedule as an exception to a representation or warranty shall not be deemed an admission by Allegiance that
such item represents a material exception or fact, event or circumstance or that such item would reasonably be expected to have a Material
Adverse Effect; and (iii)&nbsp;any disclosures made with respect to a section of <U>ARTICLE&nbsp;IV</U> shall be deemed to qualify (1)&nbsp;any
other section of <U>ARTICLE&nbsp;IV</U> specifically referenced or cross-referenced and (2)&nbsp;other sections of <U>ARTICLE&nbsp;IV</U>
to the extent it is reasonably apparent on its face (notwithstanding the absence of a specific cross reference) from a reading of the
disclosure that such disclosure applies to such other sections or (b)&nbsp;as disclosed in any Allegiance Reports filed by Allegiance
since December&nbsp;31, 2019, and prior to the date hereof (but disregarding risk factor disclosures contained under the heading &ldquo;Risk
Factors,&rdquo; or disclosures of risks set forth in any &ldquo;forward-looking statements&rdquo; disclaimer or any other statements that
are similarly non-specific or cautionary, predictive or forward-looking in nature), Allegiance hereby represents and warrants to CBTX
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Corporate
Organization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
is a corporation duly organized, validly existing and in good standing under the laws of the State of Texas and is a bank holding company
duly registered under the BHC Act. Allegiance has the corporate power and authority to own, lease or operate all of its properties and
assets and to carry on its business as it is now being conducted. Allegiance is duly licensed or qualified to do business and in good
standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and
assets owned, leased or operated by it makes such licensing, qualification or standing necessary, except where the failure to be so licensed
or qualified or to be in good standing would not, either individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Allegiance. True and complete copies of the amended and restated certificate of formation of Allegiance, as amended
(the &ldquo;<U>Allegiance Certificate of Formation</U>&rdquo;) and the amended and restated bylaws of Allegiance (the &ldquo;<U>Allegiance
Bylaws</U>&rdquo;), in each case as in effect as of the date of this Agreement, have previously been made available by Allegiance to
CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance, each Subsidiary
of Allegiance (an &ldquo;<U>Allegiance Subsidiary</U>&rdquo;) (i)&nbsp;is duly organized and validly existing under the laws of its jurisdiction
of organization; (ii)&nbsp;is duly licensed or qualified to do business and, where such concept is recognized under applicable law, in
good standing in all jurisdictions (whether federal, state, local or foreign) where its ownership, leasing or operation of property or
the conduct of its business requires it to be so licensed or qualified or in good standing and (iii)&nbsp;has all requisite corporate
power and authority to own, lease or operate its properties and assets and to carry on its business as now conducted. There are no restrictions
on the ability of Allegiance or any Allegiance Subsidiary to pay dividends or distributions except, in the case of Allegiance or a Subsidiary
that is a regulated entity, for restrictions on dividends or distributions generally applicable to all similarly regulated entities. The
deposit accounts of each Allegiance Subsidiary that is an insured depository institution are insured by the FDIC through the Deposit Insurance
Fund (as defined in Section&nbsp;3(y)&nbsp;of the Federal Deposit Insurance Act of 1950) to the fullest extent permitted by law, all premiums
and assessments required to be paid in connection therewith have been paid when due, and no proceedings for the termination of such insurance
are pending or threatened. <U>Section&nbsp;4.1(b)</U>&nbsp;of the Allegiance Disclosure Schedule sets forth a true and complete list of
all Allegiance Subsidiaries that would constitute &ldquo;significant subsidiaries&rdquo; within the meaning of Rule&nbsp;1-02 of Regulation
S-X of the SEC as of the date hereof. There is no person whose results of operations, cash flows, changes in shareholders&rsquo; equity
or financial position are consolidated in the financial statements of Allegiance other than the Allegiance Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
authorized capital stock of Allegiance as of the date of this Agreement consists of 80,000,000 shares of Allegiance Common Stock and
1,000,000 shares of preferred stock, par value $1.00 per share. As of November&nbsp;1, 2021, there were (i)&nbsp;20,250,559 shares of
Allegiance Common Stock issued and outstanding, including 168,659 shares of Allegiance Common Stock granted in respect of outstanding
Allegiance Restricted Stock Awards&#894; (ii)&nbsp;no shares of Allegiance Common Stock held in treasury; (iii)&nbsp;157,674 shares of
Allegiance Common Stock reserved for issuance upon the settlement of outstanding Allegiance PSUs (assuming performance goals are satisfied
at the maximum level)&#894; (iv)&nbsp;358,164 shares of Allegiance Common Stock reserved for issuance upon the exercise of outstanding
Allegiance Stock Options; (v)&nbsp;90,540 shares of Allegiance Common Stock reserved for issuance under the ESPP; and (vi)&nbsp;no shares
of Allegiance preferred stock issued and outstanding or held by Allegiance in its treasury. As of the date of this Agreement, except
as set forth in the immediately preceding sentence, and for changes since November&nbsp;1, 2021 resulting from the exercise, vesting
or settlement of any Allegiance Equity Awards described in the immediately preceding sentence, there are no shares of capital stock or
other voting securities or equity interests of Allegiance issued, reserved for issuance or outstanding. All the issued and outstanding
shares of Allegiance Common Stock have been duly authorized and validly issued and are fully paid, nonassessable and free of preemptive
rights, with no personal liability attaching to the ownership thereof. There are no bonds, debentures, notes or other indebtedness that
have the right to vote on any matters on which shareholders of Allegiance may vote. Other than the Allegiance Stock Options, the Allegiance
Restricted Stock Awards and the Allegiance PSUs in each case issued prior to the date of this Agreement as described in this <U>Section&nbsp;4.2(a)</U>,
as of the date of this Agreement there are no outstanding subscriptions, options, warrants, stock appreciation rights, phantom units,
scrip, rights to subscribe to, preemptive rights, anti- dilutive rights, or rights of first refusal or similar rights, puts, calls, commitments
or agreements of any character to which Allegiance or any Allegiance Subsidiary is a party relating to, or securities or rights convertible
or exchangeable into or exercisable for, shares of capital stock or other voting or equity securities of or ownership interest in Allegiance,
or contracts, commitments, understandings or arrangements by which Allegiance may become bound to issue additional shares of its capital
stock or other equity or voting securities of or ownership interests in Allegiance or that otherwise obligate Allegiance to issue, transfer,
sell, purchase, redeem or otherwise acquire, any of the foregoing (collectively, &ldquo;<U>Allegiance Securities</U>&rdquo;, and any
of the foregoing in respect of Allegiance Subsidiaries, collectively, &ldquo;<U>Allegiance Subsidiary Securities</U>&rdquo;). Other than
the Allegiance Restricted Stock Awards, the Allegiance Stock Options, the Allegiance PSUs and the ESPP (collectively, the &ldquo;<U>Allegiance
Equity Awards</U>&rdquo;), no equity-based awards (including any cash awards where the amount of payment is determined in whole or in
part based on the price of any capital stock of Allegiance or any Allegiance Subsidiary) are outstanding. There are no voting trusts,
shareholder agreements, proxies or other agreements in effect to which Allegiance or any Allegiance Subsidiary is a party with respect
to the voting or transfer of Allegiance Common Stock, capital stock or other voting or equity securities or ownership interests of Allegiance
or granting any shareholder or other person any registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance, Allegiance
owns, directly or indirectly, all the issued and outstanding shares of capital stock or other equity ownership interests of each of the
Allegiance Subsidiaries, free and clear of any Liens, and all such shares or equity ownership interests are duly authorized and validly
issued and are fully paid, nonassessable and free of preemptive rights, with no personal liability attaching to the ownership thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.2(c)</U>&nbsp;of
the Allegiance Disclosure Schedule sets forth a true and complete schedule, as of the date hereof, of the outstanding capital securities
(the &ldquo;<U>Allegiance Trust Preferred Securities</U>&rdquo;) issued by F&amp;M Bancshares to each of Farmers&nbsp;&amp; Merchants
Capital Trust II and Farmers&nbsp;&amp; Merchants Capital Trust III that were assumed by Allegiance in its acquisition of F&amp;M Bancshares
on January&nbsp;1, 2015. <U>Section&nbsp;4.2(c)</U>&nbsp;of the Allegiance Disclosure Schedule is in the same form as the table included
in Note 13 of the Notes to Consolidated Financial Statements included in Allegiance&rsquo;s Quarterly Report on Form&nbsp;10-Q for the
quarter ended September&nbsp;30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Allegiance Subsidiary has or is bound by any outstanding subscriptions, options, warrants, calls, rights, commitments or agreements of
any character calling for the purchase or issuance of any shares of capital stock or any other equity security of such Subsidiary or
any securities representing the right to purchase or otherwise receive any shares of capital stock or any other equity security of such
Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authority&#894;
No Violation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
has full corporate power and authority to execute and deliver this Agreement and, subject to obtaining the Requisite Allegiance Vote
and the adoption and approval of the Bank Merger Agreement by Allegiance as Allegiance Subsidiary Bank&rsquo;s sole shareholder, to consummate
the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the Merger have been duly
and validly approved by the Board of Directors of Allegiance. The Board of Directors of Allegiance has determined that the Merger, on
the terms and conditions set forth in this Agreement, is advisable and in the best interests of Allegiance and its shareholders, has
adopted and approved this Agreement and the transactions contemplated hereby (including the Merger), and has directed that this Agreement
be submitted to Allegiance&rsquo;s shareholders for approval at a meeting of such shareholders and has adopted a resolution to the foregoing
effect. Except for the approval of this Agreement by the affirmative vote of two-thirds of the outstanding shares of Allegiance Common
Stock entitled to vote on this Agreement (the &ldquo;<U>Requisite Allegiance Vote</U>&rdquo;), and subject to the adoption and approval
of the Bank Merger Agreement by Allegiance as Allegiance Subsidiary Bank&rsquo;s sole shareholder, no other corporate proceedings on
the part of Allegiance are necessary to approve this Agreement or to consummate the transactions contemplated hereby. This Agreement
has been duly and validly executed and delivered by Allegiance and (assuming due authorization, execution and delivery by CBTX) constitutes
a valid and binding obligation of Allegiance, enforceable against Allegiance in accordance with its terms (except in all cases as such
enforceability may be limited by the Enforceability Exceptions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution and delivery of this Agreement by Allegiance, nor the consummation by Allegiance of the transactions contemplated hereby
(including the Merger and the Bank Merger), nor compliance by Allegiance with any of the terms or provisions hereof, will (i)&nbsp;violate
any provision of the Allegiance Certificate of Formation or the Allegiance Bylaws or (ii)&nbsp;assuming that the consents and approvals
referred to in <U>Section&nbsp;4.4</U> are duly obtained, (x)&nbsp;violate any law, statute, code, ordinance, rule, regulation, judgment,
order, writ, decree or injunction applicable to Allegiance or any of its Subsidiaries or any of their respective properties or assets
or (y)&nbsp;violate, conflict with, result in a breach of any provision of or the loss of any benefit under, constitute a default (or
an event which, with notice or lapse of time, or both, would constitute a default) under, result in the termination of or a right of termination
or cancellation under, accelerate the performance required by, or result in the creation of any Lien upon any of the respective properties
or assets of Allegiance or any of its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture,
deed of trust, license, lease, agreement or other instrument or obligation to which Allegiance or any of its Subsidiaries is a party,
or by which they or any of their respective properties or assets may be bound, except (in the case of clauses (x)&nbsp;and (y)&nbsp;above)
for such violations, conflicts, breaches or defaults that either individually or in the aggregate would not reasonably be expected to
have a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consents
and Approvals</U>. Except for (a)&nbsp;the filing of any required applications, filings, notices and requests for waiver, as applicable,
with the Federal Reserve Board under the BHC Act and approval of such applications, filings and notices or granting of such waivers,
as applicable, (b)&nbsp;the filing of any required applications, filings and notices, as applicable, with the FDIC and the Texas Department
of Banking in connection with the Bank Merger, and approval of such applications, filings and notices, (c)&nbsp;the filing of an exit
notice with the OCC pursuant to 12 C.F.R. &sect; 5.33(k)&nbsp;with respect to the Bank Merger and the filing of any other required applications,
filings or notices with any federal or state banking authorities listed on <U>Section&nbsp;3.4</U> of the CBTX Disclosure Schedule or
<U>Section&nbsp;4.4</U> of the Allegiance Disclosure Schedule and approval of such applications, filings and notices, (d)&nbsp;the filing
of any required applications, filings and notices, as applicable, with the NASDAQ, (e)&nbsp;the filing by CBTX with the SEC of the Joint
Proxy Statement and the S-4 in which the Joint Proxy Statement will be included as a prospectus, and the declaration of effectiveness
of the S-4, (f)&nbsp;the filing of the Certificate of Merger with the Texas Secretary of State pursuant to the TBOC, (g)&nbsp;the filing
of the Bank Merger Certificates with the applicable Governmental Entities as required by applicable law and (h)&nbsp;such filings and
approvals as are required to be made or obtained under the securities or &ldquo;Blue Sky&rdquo; laws of various states in connection
with the issuance of the shares of CBTX Common Stock pursuant to this Agreement and the approval of the listing of such CBTX Common Stock
on the NASDAQ, no consents or approvals of or filings or registrations with any Governmental Entity are necessary in connection with
(i)&nbsp;the execution and delivery by Allegiance of this Agreement or (ii)&nbsp;the consummation by Allegiance of the Merger and the
other transactions contemplated hereby (including the Bank Merger). As of the date hereof, Allegiance has no knowledge of any reason
why the necessary regulatory approvals and consents will not be received by Allegiance to permit consummation of the Merger and Bank
Merger on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reports</U>.
Allegiance and each of its Subsidiaries have timely filed (or furnished) all reports, forms, correspondence, registrations and statements,
together with any amendments required to be made with respect thereto, that they were required to file (or furnish, as applicable) since
January&nbsp;1, 2019 with any Regulatory Agencies, including any report, form, correspondence, registration or statement required to
be filed (or furnished, as applicable) pursuant to the laws, rules&nbsp;or regulations of the United States, any state, any foreign entity,
or any Regulatory Agency, and have paid all fees and assessments due and payable in connection therewith, except where the failure to
file (or furnish, as applicable) such report, form, correspondence, registration or statement or to pay such fees and assessments, either
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on Allegiance. Subject to <U>Section&nbsp;9.14</U>,
except for normal examinations conducted by a Regulatory Agency in the ordinary course of business of Allegiance and its Subsidiaries,
no Regulatory Agency has initiated or has pending any proceeding or, to the knowledge of Allegiance, investigation into the business
or operations of Allegiance or any of its Subsidiaries since January&nbsp;1, 2019, except where such proceedings or investigations would
not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance. Subject to <U>Section&nbsp;9.14</U>,
there (i)&nbsp;is no unresolved violation, criticism, or exception by any Regulatory Agency with respect to any report or statement relating
to any examinations or inspections of Allegiance or any of its Subsidiaries and (ii)&nbsp;has been no formal or informal inquiries by,
or disagreements or disputes with, any Regulatory Agency with respect to the business, operations, policies or procedures of Allegiance
or any of its Subsidiaries since January&nbsp;1, 2019, in each case, which would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
financial statements of Allegiance and its Subsidiaries included (or incorporated by reference) in the Allegiance Reports (including the
related notes, where applicable) (i)&nbsp;have been prepared from, and are in accordance with, the books and records of Allegiance and
its Subsidiaries; (ii)&nbsp;fairly present in all material respects the consolidated results of operations, cash flows, changes in shareholders&rsquo;
equity and consolidated financial position of Allegiance and its Subsidiaries for the respective fiscal periods or as of the respective
dates therein set forth (subject in the case of unaudited statements to year-end audit adjustments normal in nature and amount); (iii)&nbsp;complied,
as of their respective dates of filing with the SEC, in all material respects with applicable accounting requirements and with the published
rules&nbsp;and regulations of the SEC with respect thereto; and (iv)&nbsp;have been prepared in accordance with GAAP consistently applied
during the periods involved, except, in each case, as indicated in such statements or in the notes thereto. Since December&nbsp;31, 2018,
no independent public accounting firm of Allegiance has resigned (or informed Allegiance that it intends to resign) or been dismissed
as independent public accountants of Allegiance as a result of or in connection with any disagreements with Allegiance on a matter of
accounting principles or practices, financial statement disclosure or auditing scope or procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, neither
Allegiance nor any of its Subsidiaries has any liability of any nature whatsoever (whether absolute, accrued, contingent or otherwise
and whether due or to become due), and except for those liabilities that are reflected or reserved against on the consolidated balance
sheet of Allegiance included in its Quarterly Report on Form&nbsp;10-Q for the fiscal quarter ended September&nbsp;30, 2021 (including
any notes thereto) and for liabilities incurred in the ordinary course of business consistent with past practice since September&nbsp;30,
2021, or in connection with this Agreement and the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
records, systems, controls, data and information of Allegiance and its Subsidiaries are recorded, stored, maintained and operated under
means (including any electronic, mechanical or photographic process, whether computerized or not) that are under the exclusive ownership
of Allegiance or its Subsidiaries or accountants (including all means of access thereto and therefrom), except for any non-exclusive
ownership that would not reasonably be expected to have a Material Adverse Effect on Allegiance. Allegiance (x)&nbsp;has implemented
and maintains disclosure controls and procedures (as defined in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) to ensure that material
information relating to Allegiance, including its Subsidiaries, is made known to the chief executive officer and the chief financial
officer of Allegiance by others within those entities as appropriate to allow timely decisions regarding required disclosures and to
make the certifications required by the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act, and (y)&nbsp;has disclosed,
based on its most recent evaluation prior to the date hereof, to Allegiance&rsquo;s outside auditors and the audit committee of Allegiance&rsquo;s
Board of Directors (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting (as defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) which are reasonably likely to adversely affect Allegiance&rsquo;s
ability to record, process, summarize and report financial information, and (ii)&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in Allegiance&rsquo;s internal controls over financial reporting. These disclosures
were made in writing by management to Allegiance&rsquo;s auditors and audit committee and true, correct and complete copies of such disclosures
have previously been made available by Allegiance to CBTX. There is no reason to believe that Allegiance&rsquo;s outside auditors and
its chief executive officer and chief financial officer will not be able to give the certifications and attestations required pursuant
to the rules&nbsp;and regulations adopted pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, without qualification, when next due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, (i)&nbsp;neither Allegiance nor any of its Subsidiaries, nor, to the knowledge of Allegiance, any director, officer,
auditor, accountant or representative of Allegiance or any of its Subsidiaries, has received or otherwise had or obtained knowledge of
any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures,
methodologies or methods (including with respect to loan loss reserves, write-downs, charge-offs and accruals) of Allegiance or any of
its Subsidiaries or their respective internal accounting controls, including any material complaint, allegation, assertion or claim that
Allegiance or any of its Subsidiaries has engaged in questionable accounting or auditing practices, and (ii)&nbsp;no employee of or attorney
representing Allegiance or any of its Subsidiaries, whether or not employed by Allegiance or any of its Subsidiaries, has reported evidence
of a material violation of securities laws or banking laws, breach of fiduciary duty or similar violation by Allegiance or any of its
Subsidiaries or any of their respective officers, directors, employees or agents to the Board of Directors of Allegiance or any committee
thereof or the Board of Directors or similar governing body of any Allegiance Subsidiary or any committee thereof, or to the knowledge
of Allegiance, to any director or officer of Allegiance or any Allegiance Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Broker&rsquo;s
Fees</U>. With the exception of the engagement of Raymond James&nbsp;&amp; Associates,&nbsp;Inc., neither Allegiance nor any Allegiance
Subsidiary nor any of their respective officers or directors has employed any broker, finder or financial advisor or incurred any liability
for any broker&rsquo;s fees, commissions or finder&rsquo;s fees in connection with the Merger or related transactions contemplated by
this Agreement. Allegiance has made available to CBTX the engagement letter by and between Allegiance and Raymond James&nbsp;&amp; Associates,&nbsp;Inc.
related to the Merger and the other transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes or Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
December&nbsp;31, 2020, there has not been any effect, change, event, circumstance, condition, occurrence or development that has had
or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
in connection with the transactions contemplated by this Agreement, since December&nbsp;31, 2020, Allegiance and its Subsidiaries have
carried on their respective businesses in all material respects in the ordinary course.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legal
and Regulatory Proceedings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to, either individually or in the aggregate, have a Material Adverse Effect on Allegiance, neither
Allegiance nor any of its Subsidiaries is a party to any, and there are no outstanding or pending or, to the knowledge of Allegiance,
threatened, legal, administrative, arbitral or other proceedings, claims, actions or governmental or regulatory investigations of any
nature against Allegiance or any of its Subsidiaries or any of their current or former directors or executive officers or challenging
the validity or propriety of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;9.14</U>, there is no material injunction, order, judgment, decree, or regulatory restriction imposed upon Allegiance,
any of its Subsidiaries or the assets of Allegiance or any of its Subsidiaries (or that, upon consummation of the Merger, would apply
to the Surviving Entity or any of its affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Taxes
and Tax Returns</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and its Subsidiaries has duly and timely filed (including all applicable extensions) all material Tax Returns in all jurisdictions
in which Tax Returns are required to be filed by it, and all such Tax Returns are true, correct, and complete in all material respects.
Neither Allegiance nor any of its Subsidiaries is the beneficiary of any extension of time within which to file any material Tax Return
(other than extensions to file Tax Returns obtained in the ordinary course). All material Taxes of Allegiance and its Subsidiaries (whether
or not shown on any Tax Returns) that are due have been fully and timely paid (other than Taxes being contested in good faith by appropriate
proceedings and for which reserves have been established in accordance with GAAP). Each of Allegiance and its Subsidiaries has withheld
and paid all material Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, creditor,
shareholder, independent contractor or other third party. Neither Allegiance nor any of its Subsidiaries has granted any extension or
waiver of the limitation period applicable to any material Tax or Tax Return that remains in effect (other than extension or waiver granted
in the ordinary course of business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Allegiance nor any of its Subsidiaries has received written notice of assessment or proposed assessment in connection with any material
amount of Taxes, and there are no threatened in writing or pending disputes, claims, audits, examinations or other proceedings regarding
any material Tax or Tax Return of Allegiance and its Subsidiaries or Taxes imposed on the assets of Allegiance and its Subsidiaries.
Neither Allegiance nor any of its Subsidiaries is a party to or is bound by any Tax sharing, allocation or indemnification agreement
or arrangement (other than such an agreement or arrangement (i)&nbsp;exclusively between or among Allegiance and its Subsidiaries, or
(ii)&nbsp;contained in commercial agreements entered into in the ordinary course of business the primary purpose of which does not relate
to Taxes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no pending or proposed changes in the income Tax accounting methods (including any method for determining reserves for bad debts)
of Allegiance or any of its Subsidiaries. Neither Allegiance nor any of its Subsidiaries will be required to include any item of income
or gain in, or exclude any item of deduction or loss from, taxable income for any taxable period ending after the Closing Date as a result
of any: (i)&nbsp;adjustment required by a change in method of accounting made prior to the Closing Date; (ii)&nbsp;closing agreement
entered into prior to the Closing Date; or (iii)&nbsp;installment sale or open transaction disposition made prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2017, neither Allegiance nor any of its Subsidiaries (i)&nbsp;has been a member of an affiliated group filing a consolidated
federal income Tax Return for which the statute of limitations is open (other than a group the common parent of which was Allegiance)
or (ii)&nbsp;has any liability for the Taxes of any person (other than Allegiance or any of its Subsidiaries) under Treasury Regulation
Section&nbsp;1.1502-6 (or any similar provision of state, local or foreign law), as a transferee or successor or by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Allegiance nor any of its Subsidiaries has been, within the past two (2)&nbsp;years or otherwise as part of a &ldquo;plan (or series
of related transactions)&rdquo; within the meaning of Section&nbsp;355(e)&nbsp;of the Code of which the Merger is also a part, a &ldquo;distributing
corporation&rdquo; or a &ldquo;controlled corporation&rdquo; (within the meaning of Section&nbsp;355(a)(1)(A)&nbsp;of the Code) in a
distribution of stock intending to qualify for tax-free treatment under Section&nbsp;355 of the Code. Neither Allegiance nor any of its
Subsidiaries has participated in a &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulation Section&nbsp;1.6011-4(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">Neither
Allegiance nor any of its Subsidiaries has taken any action or has knowledge of any facts or circumstances that, in either case, would
reasonably be expected to prevent or impede the Merger from being treated as a transaction that qualifies as a &ldquo;reorganization&rdquo;
within the meaning of Section&nbsp;368(a)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Benefit
Plans; Employees</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, each Allegiance
Benefit Plan has been established, operated, maintained and administered in accordance with its terms and the requirements of all applicable
laws, including ERISA and the Code. For purposes of this Agreement, the term &ldquo;<U>Allegiance Benefit Plans</U>&rdquo; means all employee
benefit plans (as defined in Section&nbsp;3(3)&nbsp;of ERISA), whether or not subject to ERISA, and all equity, equity-related, bonus
or incentive, deferred compensation, retiree medical or life insurance, supplemental retirement, severance, termination, change in control,
retention, employment, consulting, welfare, insurance, medical, dental, disability, cafeteria, flexible spending, dependent care, fringe
benefit or other compensation or benefit plans, programs, agreements, contracts, policies, arrangements or remuneration of any kind with
respect to which Allegiance, any Subsidiary thereof or any trade or business, whether or not incorporated, which would be deemed a single
employer with Allegiance or any of its Subsidiaries pursuant to Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code (an &ldquo;<U>Allegiance
ERISA Affiliate</U>&rdquo;), is a party or has any current or future obligation or liability (whether actual, contingent or otherwise)
or that are sponsored, maintained, contributed to by or required to be contributed to by Allegiance, any of its Subsidiaries, or any Allegiance
ERISA Affiliate for the benefit of any current or former employee, officer, director or independent contractor (or the dependents, beneficiaries
or designees of any of the foregoing) of Allegiance, any of its Subsidiaries, or any Allegiance ERISA Affiliate. <U>Section&nbsp;4.11(a)</U>&nbsp;of
the Allegiance Disclosure Schedule lists each Allegiance Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
has made available to CBTX true and complete copies of each material Allegiance Benefit Plan (and all amendments thereto) (or, in the
case of an unwritten material Allegiance Benefit Plan, a written summary of the material terms thereof) and the following related documents,
to the extent applicable: (i)&nbsp;all summary plan descriptions, amendments, modifications or material supplements; (ii)&nbsp;the most
recent annual report (Form&nbsp;5500) filed with the IRS; (iii)&nbsp;the most recently received IRS determination, advisory or opinion
letter; and (iv)&nbsp;the most recently prepared actuarial report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
IRS has issued a favorable determination, advisory or opinion with respect to the form of each Allegiance Benefit Plan that is intended
to be qualified under Section&nbsp;401(a)&nbsp;of the Code (the &ldquo;<U>Allegiance Qualified Plans</U>&rdquo;) and the related trust,
which letter has not been revoked (nor has revocation been threatened), and, to Allegiance&rsquo;s knowledge, there are no existing circumstances
and no events have occurred that would reasonably be expected to adversely affect the qualified status of any Allegiance Qualified Plan
or the related trust.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Allegiance Benefit Plan is (i)&nbsp;subject to Title IV of ERISA of Section&nbsp;412 of the Code; (ii)&nbsp;a &ldquo;multiemployer plan&rdquo;
as defined in Section&nbsp;3(37) of ERISA; (iii)&nbsp;a multiple employer plan as described in Section&nbsp;413(d)&nbsp;of the Code;
or (iv)&nbsp;a &ldquo;multiple employer welfare arrangement&rdquo; as defined in Section&nbsp;3(40)(A)&nbsp;of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, no Allegiance
Benefit Plan provides for any post-employment, post-retirement or post-service health or medical or life insurance benefits for retired,
former or current employees, directors or consultants (or beneficiaries or dependents thereof), except (i)&nbsp;as required by Section&nbsp;4980B
of the Code; (ii)&nbsp;through the end of the month of termination of employment; or (iii)&nbsp;pursuant to conversion rights at sole
expense of converting former employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, all contributions
required to be made by Allegiance, its Subsidiaries or any Allegiance ERISA Affiliate to any Allegiance Benefit Plan by applicable law
or by any plan document or other contractual undertaking, and all premiums due or payable by Allegiance, its Subsidiaries or any Allegiance
ERISA Affiliate with respect to insurance policies funding any Allegiance Benefit Plan, for any period through the date hereof, have
been timely made or paid in full or, to the extent not required to be made or paid on or before the date hereof, have been fully reflected
on the books and records of Allegiance in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no pending or, to Allegiance&rsquo;s knowledge, threatened claims (other than claims for benefits in the ordinary course), lawsuits,
arbitrations or governmental audits or investigations that have been asserted or instituted, and, to Allegiance&rsquo;s knowledge, no
set of circumstances exists which may reasonably give rise to a claim, lawsuit, arbitration, audit or investigation, against or of the
Allegiance Benefit Plans, any fiduciaries thereof with respect to their duties to the Allegiance Benefit Plans or the assets of any of
the trusts under any of the Allegiance Benefit Plans that would reasonably be expected to result in any material liability to Allegiance
or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, none of
Allegiance, its Subsidiaries or any Allegiance ERISA Affiliate (or, to Allegiance&rsquo;s knowledge, any other party) has engaged in any
&ldquo;prohibited transaction&rdquo; (as defined in Section&nbsp;4975 of the Code or Section&nbsp;406 of ERISA) with respect to an Allegiance
Benefit Plan that would reasonably be expected to subject any of the Allegiance Benefit Plans or their related trusts, Allegiance, any
of its Subsidiaries or any Allegiance ERISA Affiliate to any material Tax, penalty or liability imposed under Section&nbsp;4975 of the
Code or Section&nbsp;502 of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as contemplated by <U>Section&nbsp;1.7</U>, neither the execution and delivery of this Agreement nor the consummation of the transactions
contemplated hereby will (either alone or in conjunction with any other event) result or has resulted in the acceleration of vesting,
exercisability, funding or delivery of, or increase in the amount or value of, any payment, right or other benefit to any current or former
employee, officer, director or other service provider of Allegiance or any of its Subsidiaries, or result in any limitation on the right
of Allegiance or any of its Subsidiaries to amend, merge, terminate or receive a reversion of assets from any Allegiance Benefit Plan
or related trust on or after the Effective Time. Without limiting the generality of the foregoing, no amount paid or payable (whether
in cash, in property, or in the form of benefits) by Allegiance or any of its Subsidiaries in connection with the transactions contemplated
hereby (either solely as a result thereof or as a result of such transactions in conjunction with any other event) will be an &ldquo;excess
parachute payment&rdquo; within the meaning of Section&nbsp;280G of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Allegiance Benefit Plan provides for the gross-up or reimbursement of Taxes under Section&nbsp;409A or 4999 of the Code, or otherwise.
Except as would not reasonably be expected to result in material liability to Allegiance, each Allegiance Benefit Plan required to comply
with Section&nbsp;409A of the Code complies in both form and operation therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, there are
no pending or, to Allegiance&rsquo;s knowledge, threatened labor grievances or unfair labor practice claims or charges against Allegiance
or any of its Subsidiaries, or any strikes or other labor disputes against Allegiance or any of its Subsidiaries. Neither Allegiance nor
any of its Subsidiaries is party to or bound by any collective bargaining or similar agreement with any labor organization, or work rules&nbsp;or
practices agreed to with any labor organization or employee association applicable to employees of Allegiance or any of its Subsidiaries
and there are no pending or, to Allegiance&rsquo;s knowledge, threatened organizing efforts by any union or other group seeking to represent
any employees of Allegiance or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
has provided to CBTX a list of individuals employed by Allegiance or any of its Subsidiaries as of the date hereof, and the following
information for each such individual: (i)&nbsp;name; (ii)&nbsp;title; (iii)&nbsp;hire date; (iv)&nbsp;office location; (v)&nbsp;annual
salary or hourly wage rate, as applicable; (vi)&nbsp;incentive compensation; and (vii)&nbsp;total annual compensation. As of the date
hereof, all compensation payable to all employees of Allegiance or any of its Subsidiaries for services performed on or prior to the
date hereof have been paid in full (or accrued in full on the interim financial statements) and there are no outstanding agreements,
understandings or commitments of Allegiance or any of its Subsidiaries with respect to any compensation to employees. Neither Allegiance
nor any of its Subsidiaries is a party to an agreement with a professional employer organization or staffing services agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Allegiance nor any of its Subsidiaries has, in the past ninety (90) days, engaged in any employment termination action requiring notice
pursuant to WARN Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>SEC
Reports</U>. Allegiance has previously made available to CBTX an accurate and complete copy of each (a)&nbsp;final registration statement,
prospectus, report, schedule and definitive proxy statement filed with or furnished to the SEC since December&nbsp;31, 2019 by Allegiance
pursuant to the Securities Act or the Exchange Act (the &ldquo;<U>Allegiance Reports</U>&rdquo;) and (b)&nbsp;communication mailed by
Allegiance to its shareholders since December&nbsp;31, 2019 and prior to the date hereof, and no such Allegiance Report or communication,
as of the date thereof (and, in the case of registration statements and proxy statements, on the dates of effectiveness and the dates
of the relevant meetings, respectively), contained any untrue statement of a material fact or omitted to state any material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances in which they were made, not
misleading, except that information filed or furnished as of a later date (but before the date of this Agreement) shall be deemed to modify
information as of an earlier date. Since December&nbsp;31, 2019, as of their respective dates, all Allegiance Reports filed or furnished
under the Securities Act and the Exchange Act complied in all material respects with the published rules&nbsp;and regulations of the SEC
with respect thereto. No executive officer of Allegiance has failed in any respect to make the certifications required of him or her under
Section&nbsp;302 or 906 of the Sarbanes-Oxley Act. As of the date of this Agreement, there are no outstanding comments from, or unresolved
issued raised by, the SEC with respect to any of the Allegiance Reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Applicable Law</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
and each of its Subsidiaries hold, and have at all times since December&nbsp;31, 2020, held, all licenses, registrations, franchises,
certificates, variances, permits charters and authorizations necessary for the lawful conduct of their respective businesses and ownership
of their respective properties, rights and assets under and pursuant to each (and have paid all fees and assessments due and payable
in connection therewith), except where neither the cost of failure to hold nor the cost of obtaining and holding such license, registration,
franchise, certificate, variance, permit, charter or authorization (nor the failure to pay any fees or assessments) would, either individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance, and to the knowledge of Allegiance, no suspension
or cancellation of any such necessary license, registration, franchise, certificate, variance, permit, charter or authorization is threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance, Allegiance
and each of its Subsidiaries have complied with and are not in default or violation under any applicable law, statute, order, rule, regulation,
policy and/or guideline of any Governmental Entity relating to Allegiance or any of its Subsidiaries, including all laws related to data
protection or privacy (including laws relating to the privacy and security of Personal Data), the USA PATRIOT Act, the Bank Secrecy Act,
the Equal Credit Opportunity Act and Regulation B, the Fair Housing Act, the Community Reinvestment Act, the Fair Credit Reporting Act,
the Truth in Lending Act and Regulation Z, the Home Mortgage Disclosure Act, the Fair Debt Collection Practices Act, the Electronic Fund
Transfer Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, any regulations promulgated by the Consumer Financial Protection
Bureau, the Interagency Policy Statement on Retail Sales of Nondeposit Investment Products, the SAFE Mortgage Licensing Act of 2008, the
Real Estate Settlement Procedures Act and Regulation X, Title V of the Gramm-Leach-Bliley Act, any and all sanctions or regulations enforced
by the Office of Foreign Assets Control of the United States Department of Treasury and any other law, policy or guideline relating to
bank secrecy, discriminatory lending, financing or leasing practices, consumer protection, money laundering prevention, foreign assets
control, U.S. sanctions laws and regulations, Sections 23A and 23B of the Federal Reserve Act, the Sarbanes-Oxley Act, and all agency
requirements relating to the origination, sale and servicing of mortgage and consumer loans. Allegiance and its Subsidiaries have established
and maintain a system of internal controls designed to ensure compliance in all material respects by Allegiance and its Subsidiaries with
applicable financial recordkeeping and reporting requirements of applicable money laundering prevention laws in jurisdictions where Allegiance
and its Subsidiaries conduct business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
Subsidiary Bank has a Community Reinvestment Act rating of &ldquo;satisfactory&rdquo; or better.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
maintains a written information privacy and security program that maintains reasonable measures to protect the privacy, confidentiality
and security of all Personal Data against any Security Breach. To the knowledge of Allegiance, Allegiance has not experienced any Security
Breach that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance. To the knowledge
of Allegiance, there are no data security or other technological vulnerabilities with respect to its information technology systems or
networks that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limitation, none of Allegiance, or any of its Subsidiaries, or to the knowledge of Allegiance, any director, officer, employee, agent
or other person acting on behalf of Allegiance or any of its Subsidiaries has, directly or indirectly, (i)&nbsp;used any funds of Allegiance
or any of its Subsidiaries for unlawful contributions, unlawful gifts, unlawful entertainment or other expenses relating to political
activity; (ii)&nbsp;made any unlawful payment to foreign or domestic governmental officials or employees or to foreign or domestic political
parties or campaigns from funds of Allegiance or any of its Subsidiaries; (iii)&nbsp;violated any provision that would result in the
violation of the Foreign Corrupt Practices Act of 1977, as amended, or any similar law; (iv)&nbsp;established or maintained any unlawful
fund of monies or other assets of Allegiance or any of its Subsidiaries; (v)&nbsp;made any fraudulent entry on the books or records of
Allegiance or any of its Subsidiaries; or (vi)&nbsp;made any unlawful bribe, unlawful rebate, unlawful payoff, unlawful influence payment,
unlawful kickback or other unlawful payment to any person, private or public, regardless of form, whether in money, property or services,
to obtain favorable treatment in securing business, to obtain special concessions for Allegiance or any of its Subsidiaries, to pay for
favorable treatment for business secured or to pay for special concessions already obtained for Allegiance or any of its Subsidiaries,
or is currently subject to any United States sanctions administered by the Office of Foreign Assets Control of the United States Treasury
Department, except in each case as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, Allegiance, Allegiance Subsidiary Bank and each other insured depository institution Allegiance Subsidiary is &ldquo;well-capitalized&rdquo;
(as such term is defined in the relevant regulation of the institution&rsquo;s primary bank regulator).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance, (i)&nbsp;Allegiance
and each of its Subsidiaries have properly administered all accounts for which it acts as a fiduciary, including accounts for which it
serves as a trustee, agent, custodian, personal representative, guardian, conservator or investment advisor, in accordance with the terms
of the governing documents and applicable state, federal and foreign law&#894; and (ii)&nbsp;none of Allegiance, any of its Subsidiaries,
or any of its or its Subsidiaries&rsquo; directors, officers or employees, has committed any breach of trust or fiduciary duty with respect
to any such fiduciary account, and the accountings for each such fiduciary account are true and correct and accurately reflect the assets
and results of such fiduciary account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Contracts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, neither Allegiance nor any of its Subsidiaries is a party to or bound by any contract, arrangement, commitment or
understanding (whether written or oral, but excluding any Allegiance Benefit Plan):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">which
is a &ldquo;material contract&rdquo; (as such term is defined in Item 601(b)(10)&nbsp;of Regulation S-K of the SEC)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">which
contains a provision that materially restricts the conduct of any line of business by Allegiance or any of its Subsidiaries or upon consummation
of the Merger will materially restrict the ability of the Surviving Entity or any of its affiliates to engage in any line of business
or in any geographic region&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">with
or to a labor union, labor organization or other employee organization (including any collective bargaining agreement)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
of the benefits of or obligations under which will arise or be increased or accelerated by the occurrence of the execution and delivery
of this Agreement, receipt of the Requisite Allegiance Vote or the announcement or consummation of any of the transactions contemplated
by this Agreement, or under which a right of cancellation or termination will arise as a result thereof, or the value of any of the benefits
of which will be calculated on the basis of any of the transactions contemplated by this Agreement, where such increase or acceleration
of benefits or obligations, right of cancellation or termination, or change in calculation of value of benefits would, either individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on Allegiance&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;that
relates to the incurrence of indebtedness by Allegiance or any of its Subsidiaries, including any sale and leaseback transactions, capitalized
leases and other similar financing arrangements (other than deposit liabilities, trade payables, federal funds purchased, advances and
loans from the Federal Home Loan Bank, securities sold under agreements to repurchase and any contract relating to the Allegiance Trust
Preferred Securities, in each case incurred in the ordinary course of business consistent with past practice), or (B)&nbsp;that provides
for the guarantee, support, indemnification, assumption or endorsement by Allegiance or any of Allegiance Subsidiary of, or any similar
commitment by Allegiance or any of its Subsidiaries with respect to, the obligations, liabilities or indebtedness of any other person,
in the case of each of clauses (A)&nbsp;and (B), in the outstanding principal amount of $5,000,000 or more&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
grants any right of first refusal, right of first offer or similar right with respect to any material assets, rights or properties of
Allegiance or its Subsidiaries, taken as a whole&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
alters the at-will employment status of an employee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">with
independent contractors or consultants providing for payments of at least $250,000 in any twelve (12)-month period or that are not terminable
by Allegiance or any of its Subsidiaries on notice of sixty (60) days or less without termination obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
is a consulting agreement or data processing, software programming or licensing contract involving the payment of more than $250,000
per annum (other than any such contracts which are terminable by Allegiance or any of its Subsidiaries on sixty (60) days or less notice
without any required payment or other conditions, other than the condition of notice)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
is a settlement, consent or similar agreement and contains any material continuing obligations of Allegiance or any of its Subsidiaries&#894;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
relates to the acquisition or disposition of any person, business or asset and under which Allegiance or its Subsidiaries have or may
have a material obligation or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each contract, arrangement, commitment or understanding
of the type described in this <U>Section&nbsp;4.14(a)</U>, whether or not set forth in the Allegiance Disclosure Schedule, is referred
to herein as an &ldquo;<U>Allegiance Contract</U>.&rdquo; Allegiance has made available to CBTX true, correct and complete copies of each
Allegiance Contract in effect as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Allegiance Contract is valid and binding on Allegiance or one of its Subsidiaries, as applicable, and in full force and effect, except
as, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on Allegiance. Allegiance
and each of its Subsidiaries have in all material respects complied with and performed all obligations required to be complied with or
performed by any of them to date under each Allegiance Contract, except where such noncompliance or nonperformance, either individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on Allegiance. To the knowledge of Allegiance,
each third-party counterparty to each Allegiance Contract has in all material respects complied with and performed all obligations required
to be complied with and performed by it to date under such Allegiance Contract, except where such noncompliance or nonperformance, either
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect on Allegiance. Neither Allegiance
nor any of its Subsidiaries has knowledge of, or has received notice of, any violation of any Allegiance Contract by any of the other
parties thereto which would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance.
No event or condition exists which constitutes or, after notice or lapse of time or both, will constitute, a material breach or default
on the part of Allegiance or any of its Subsidiaries or, to the knowledge of Allegiance, any other party thereto, of or under any such
Allegiance Contract, except where such breach or default, either individually or in the aggregate, would not reasonably be expected to
have a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Agreements
with Regulatory Agencies</U>. Subject to <U>Section&nbsp;9.14</U>, neither Allegiance nor any of its Subsidiaries is subject to any cease-and-desist
or other order or enforcement action issued by, or is a party to any written agreement, consent agreement or memorandum of understanding
with, or is a party to any commitment letter or similar undertaking to, or is subject to any order or directive by, or has been ordered
to pay any civil money penalty by, or has been since December&nbsp;31, 2019, a recipient of any supervisory letter from, or since December&nbsp;31,
2019, has adopted any policies, procedures or board resolutions at the request or suggestion of, any Regulatory Agency or other Governmental
Entity that currently restricts in any material respect or would reasonably be expected to restrict in any material respect the conduct
of its business or that in any material manner relates to its capital adequacy, its ability to pay dividends, its credit or risk management
policies, its management or its business (each, whether or not set forth in the Allegiance Disclosure Schedule, an &ldquo;<U>Allegiance
Regulatory Agreement</U>&rdquo;), nor has Allegiance or any of its Subsidiaries been advised in writing or, to the knowledge of Allegiance,
threatened since January&nbsp;1, 2019, by any Regulatory Agency or other Governmental Entity that it is considering issuing, initiating,
ordering or requesting any such Allegiance Regulatory Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Matters</U>. Except as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on
Allegiance, Allegiance and its Subsidiaries are in compliance, and have complied since January&nbsp;1, 2020, with all Environmental Laws.
There are no legal, administrative, arbitral or other proceedings, claims or actions or, to the knowledge of Allegiance, any private environmental
investigations or remediation activities or governmental investigations of any nature seeking to impose, or that could reasonably be expected
to result in the imposition, on Allegiance or any Allegiance Subsidiary of any liability or obligation arising under any Environmental
Law pending or threatened against Allegiance, which liability or obligation would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect on Allegiance. To the knowledge of Allegiance, there is no reasonable basis for any such
proceeding, claim, action or governmental investigation that would impose any liability or obligation that would reasonably be expected
to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance. Allegiance is not subject to any agreement,
order, judgment, decree, letter agreement or memorandum of agreement by or with any court, Governmental Entity, Regulatory Agency or other
third party imposing any liability or obligation with respect to the foregoing that would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect on Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Securities and Commodities</U>. Each of Allegiance and its Subsidiaries has good title to all securities and commodities owned by it (except
those sold under repurchase agreements) which are material to Allegiance&rsquo;s business on a consolidated basis, free and clear of any
Lien, except as set forth in the financial statements included in the Allegiance Reports or to the extent such securities or commodities
are pledged in the ordinary course of business to secure obligations of Allegiance or its Subsidiaries. Such securities and commodities
are valued on the books of Allegiance in accordance with GAAP in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Real
Property</U>. Except as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on
Allegiance, Allegiance or an Allegiance Subsidiary (a)&nbsp;has good and marketable title to all the real property reflected in the latest
audited balance sheet included in the Allegiance Reports as being owned by Allegiance or an Allegiance Subsidiary or acquired after the
date thereof which are material to Allegiance on a consolidated basis (except properties sold or otherwise disposed of since the date
thereof in the ordinary course of business) (the &ldquo;<U>Allegiance Owned Properties</U>&rdquo;), free and clear of all material Liens,
except for Permitted Encumbrances and (b)&nbsp;is the lessee of all leasehold estates reflected in the latest audited financial statements
included in such Allegiance Reports or acquired after the date thereof which are material to Allegiance on a consolidated basis (except
for leases that have expired by their terms since the date thereof) (such leasehold estates, collectively with the Allegiance Owned Properties,
the &ldquo;<U>Allegiance Real Property</U>&rdquo;), free and clear of all material Liens, except for Permitted Encumbrances, and is in
possession of the properties purported to be leased thereunder, and each such lease is valid without default thereunder by the lessee
or, to the knowledge of Allegiance, the lessor. There are no pending or, to the knowledge of Allegiance, threatened condemnation proceedings
against the Allegiance Real Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. Allegiance and each of its Subsidiaries owns, or is licensed to use (in each case, free and clear of any material Liens),
all Intellectual Property necessary for the conduct of its business as currently conducted. Except as would not reasonably be expected
to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance: (a)&nbsp;(i)&nbsp;to the knowledge of Allegiance,
the use of any Intellectual Property by Allegiance and its Subsidiaries does not infringe, misappropriate or otherwise violate the rights
of any person and is in accordance with any applicable license pursuant to which Allegiance or any Allegiance Subsidiary acquired the
right to use any Intellectual Property, and (ii)&nbsp;no person has asserted in writing to Allegiance that Allegiance or any of its Subsidiaries
has infringed, misappropriated or otherwise violated the Intellectual Property rights of such person, (b)&nbsp;to the knowledge of Allegiance,
no person is challenging, infringing on or otherwise violating any right of Allegiance or any of its Subsidiaries with respect to any
Intellectual Property owned by and/or licensed to Allegiance or its Subsidiaries, and (c)&nbsp;neither Allegiance nor any Allegiance Subsidiary
has received any written notice of any pending claim with respect to any Intellectual Property owned by Allegiance or any Allegiance Subsidiary,
and Allegiance and its Subsidiaries have taken commercially reasonable actions to avoid the abandonment, cancellation or unenforceability
of all Intellectual Property owned or licensed, respectively, by Allegiance and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Related
Party Transactions</U>. As of the date hereof, there are no transactions or series of related transactions, agreements, arrangements or
understandings, nor are there any currently proposed transactions or series of related transactions, between Allegiance or any of its
Subsidiaries, on the one hand, and any current or former director or &ldquo;executive officer&rdquo; (as defined in Rule&nbsp;3b-7 under
the Exchange Act) of Allegiance or any of its Subsidiaries or any person who beneficially owns (as defined in Rules&nbsp;13d-3 and 13d-5
of the Exchange Act) five percent (5%) or more of the outstanding Allegiance Common Stock (or any of such person&rsquo;s immediate family
members or affiliates) (other than Allegiance Subsidiaries) on the other hand, of the type required to be reported in any Allegiance Report
pursuant to Item 404 of Regulation S-K promulgated under the Exchange Act that have not been disclosed therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>State
Takeover Laws</U>. The Board of Directors of Allegiance has approved this Agreement and the transactions contemplated hereby and has taken
all such other necessary actions as required to render inapplicable to such agreements and transactions the provisions of any potentially
applicable Takeover Restrictions. In accordance with Section&nbsp;10.354 of the TBOC, no appraisal or dissenters&rsquo; rights will be
available to the holders of Allegiance Common Stock in connection with the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reorganization</U>.
Allegiance has not taken any action and is not aware of any fact or circumstance that could reasonably be expected to prevent the Merger
from qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Opinions
of Financial Advisors</U>. Prior to the execution of this Agreement, the Board of Directors of Allegiance has received the opinion (which
if initially rendered orally, has been or will be confirmed by written opinion of the same date) from Raymond James, to the effect that
as of the date of such opinion and based upon and subject to the assumptions, limitations, qualifications and other matters set forth
in the written opinion, the Exchange Ratio pursuant to this Agreement is fair, from a financial point of view, to the holders of Allegiance
Common Stock. Such opinion has not been amended or rescinded as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loan
Portfolio</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, neither Allegiance nor any of its Subsidiaries is a party to any written or oral Loan in which Allegiance or any
Allegiance Subsidiary is a creditor that, as of September&nbsp;30, 2021, had an outstanding balance of $5,000,000 or more and under the
terms of which the obligor was, as of September&nbsp;30, 2021, over ninety (90) days or more delinquent in payment of principal or interest.
Set forth in <U>Section&nbsp;4.24(a)</U>&nbsp;of the Allegiance Disclosure Schedule is a true, correct and complete list of (A)&nbsp;all
the Loans of Allegiance and its Subsidiaries that, as of September&nbsp;30, 2021, had an outstanding balance of $5,000,000 and were classified
by Allegiance as &ldquo;Other Loans Specially Mentioned,&rdquo; &ldquo;Special Mention,&rdquo; &ldquo;Substandard,&rdquo; &ldquo;Doubtful,&rdquo;
&ldquo;Loss,&rdquo; &ldquo;Classified,&rdquo; &ldquo;Criticized,&rdquo; &ldquo;Credit Risk Assets,&rdquo; &ldquo;Concerned Loans,&rdquo;
&ldquo;Watch List&rdquo; or words of similar import, together with the principal amount of and accrued and unpaid interest on each such
Loan and the identity of the borrower thereunder, together with the aggregate principal amount of and accrued and unpaid interest on
such Loans, by category of Loan (<U>e</U>.g., commercial, consumer,&nbsp;etc.), together with the aggregate principal amount of such
Loans by category and (B)&nbsp;each asset of Allegiance or any of its Subsidiaries that, as of September&nbsp;30, 2021, is classified
as &ldquo;Other Real Estate Owned&rdquo; and the book value thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, each Loan
of Allegiance or any of its Subsidiaries (i)&nbsp;is evidenced by notes, agreements or other evidences of indebtedness that are true,
genuine and what they purport to be, (ii)&nbsp;to the extent carried on the books and records of Allegiance and its Subsidiaries as secured
Loans, has been secured by valid Liens, which have been perfected; and (iii)&nbsp;is the legal, valid and binding obligation of the obligor
named therein, enforceable in accordance with its terms, subject to the Enforceability Exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Allegiance, each outstanding
Loan of Allegiance or any of its Subsidiaries (including Loans held for resale to investors) was solicited and originated, and is and
has been administered and, where applicable, serviced, and the relevant Loan files are being maintained, in all material respects in
accordance with the relevant notes or other credit or security documents, the written underwriting standards of Allegiance and its Subsidiaries
(and, in the case of Loans held for resale to investors, the underwriting standards, if any, of the applicable investors) and with all
applicable federal, state and local laws, regulations and rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Except as would not reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect on Allegiance,
(a)&nbsp;Allegiance and its Subsidiaries are insured with reputable insurers against such risks and in such amounts as the management
of Allegiance reasonably has determined to be prudent and consistent with industry practice, and Allegiance and its Subsidiaries are in
compliance in all material respects with their insurance policies and are not in default under any of the terms thereof; (b)&nbsp;each
such policy is outstanding and in full force and effect and, except for policies insuring against potential liabilities of officers, directors
and employees of Allegiance and its Subsidiaries, Allegiance or the relevant Subsidiary thereof is the sole beneficiary of such policies;
(c)&nbsp;all premiums and other payments due under any such policy have been paid, and all claims thereunder have been filed in due and
timely fashion; (d)&nbsp;there is no claim for coverage by Allegiance or any of its Subsidiaries pending under any insurance policy as
to which coverage has been questioned, denied or disputed by the underwriters of such insurance policy and (e)&nbsp;neither Allegiance
nor any of its Subsidiaries has received notice of any threatened termination of, material premium increase with respect to, or material
alteration of coverage under, any insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Investment Advisor Subsidiary</U>. Neither Allegiance nor any Allegiance Subsidiary provides any investment management, investment advisory
or sub-advisory services or is required to register with the SEC as an investment advisor under the Investment Advisers Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Broker-Dealer Subsidiary</U>. Neither Allegiance nor any Allegiance Subsidiary is a broker-dealer required to be registered under the
Exchange Act with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Allegiance
Information</U>.&nbsp; The information relating to Allegiance and the Allegiance Subsidiaries to be contained in the Joint Proxy Statement
and the S-4, and the information relating to Allegiance and the Allegiance Subsidiaries that is provided by Allegiance or its representatives
for inclusion in any other document filed with any other Regulatory Agency in connection herewith, will not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances in which they
are made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Other Representations or Warranties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
for the representations and warranties made by Allegiance in this <U>ARTICLE&nbsp;IV</U>, neither Allegiance nor any other person makes
any express or implied representation or warranty with respect to Allegiance, its Subsidiaries, or their respective businesses, operations,
assets, liabilities, conditions (financial or otherwise) or prospects, and Allegiance hereby disclaims any such other representations
or warranties. In particular, without limiting the foregoing disclaimer, neither Allegiance nor any other person makes or has made any
representation or warranty to CBTX or any of its affiliates or representatives with respect to (i)&nbsp;any financial projection, forecast,
estimate, budget or prospective information relating to Allegiance, any of its Subsidiaries or their respective businesses or (ii)&nbsp;except
for the representations and warranties made by Allegiance in this <U>ARTICLE&nbsp;IV</U>, any oral or written information presented to
CBTX or any of its affiliates or representatives in the course of their due diligence investigation of Allegiance, the negotiation of
this Agreement or in the course of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
acknowledges and agrees that neither CBTX nor any other person has made or is making any express or implied representation or warranty
other than those contained in <U>ARTICLE&nbsp;III</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;V</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
COVENANTS RELATING TO CONDUCT OF BUSINESS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conduct
of Businesses Prior to the Effective Time</U>. During the period from the date of this Agreement to the Effective Time or earlier termination
of this Agreement, except as expressly contemplated or permitted by this Agreement (including as set forth in the CBTX Disclosure Schedule
or the Allegiance Disclosure Schedule), required by law or as consented to in writing by the other party (such consent not to be unreasonably
withheld, conditioned or delayed), each of Allegiance and CBTX shall, and shall cause each of its respective Subsidiaries to (a)&nbsp;conduct
its business in the ordinary course in all material respects; <U>provided</U>, <U>however</U>, that Allegiance or CBTX, as the case may
be, shall be permitted to engage in COVID-19 Measures; (b)&nbsp;use reasonable best efforts to maintain and preserve intact its business
organization, employees and advantageous business relationships and (c)&nbsp;take no action that would reasonably be expected to adversely
affect or delay the ability of either Allegiance or CBTX to obtain any necessary approvals of any Regulatory Agency or other Governmental
Entity required for the transactions contemplated hereby or to perform its covenants and agreements under this Agreement or to consummate
the transactions contemplated hereby on a timely basis. For the avoidance of doubt, except as would not reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect on CBTX or Allegiance, respectively, either CBTX or Allegiance, as
applicable, may take all actions necessary or appropriate to modify, procure, extend, continue or otherwise maintain policies of insurance
with such coverages, terms and conditions commensurate with the risk profile of CBTX or Allegiance, as applicable, and, after the Closing,
the Surviving Entity. &ldquo;<U>COVID-19 Measures</U>&rdquo; means any quarantine, &ldquo;shelter in place,&rdquo; &ldquo;stay at home,&rdquo;
workforce reduction, social distancing, shut down, closure, sequester or any other law, directive, guidelines or recommendations by any
Governmental Entity (including the Centers for Disease Control and Prevention or the World Health Organization) in relation to, arising
out of, in connection with or in response to an epidemic, pandemic or disease outbreak (including COVID-19), or any change in such law,
directive, guideline, recommendation or interpretation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Forbearances</U>.
During the period from the date of this Agreement to the Effective Time or earlier termination of this Agreement, except as set forth
in the Allegiance Disclosure Schedule or the CBTX Disclosure Schedule, as expressly contemplated or permitted by this Agreement or as
required by law, neither Allegiance nor CBTX shall, and neither Allegiance nor CBTX shall permit any of their respective Subsidiaries
to, without the prior written consent of the other party to this Agreement (such consent not to be unreasonably withheld, conditioned
or delayed):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">other
than (i)&nbsp;federal funds borrowings and Federal Home Loan Bank borrowings, in each case with a maturity not in excess of six (6)&nbsp;months;
(ii)&nbsp;the creation of deposit liabilities; (iii)&nbsp;issuances of letters of credit; (iv)&nbsp;purchases of federal funds; (v)&nbsp;
sales of certificates of deposit; and (vi)&nbsp;entry into term repurchase agreements for fixed income securities, in each case in the
ordinary course of business, incur any indebtedness for borrowed money (other than indebtedness of CBTX or any of its wholly-owned Subsidiaries
to CBTX or any of its wholly-owned Subsidiaries, on the one hand, or of Allegiance or any of its wholly-owned Subsidiaries to Allegiance
or any of its wholly-owned Subsidiaries, on the other hand), or assume, guarantee, endorse or otherwise as an accommodation become responsible
for the obligations of any other individual, corporation or other entity&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">adjust,
split, combine or reclassify any capital stock&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make,
declare, pay or set a record date for any dividend, or any other distribution on, or directly or indirectly redeem, purchase or otherwise
acquire any shares of its capital stock or other equity or voting securities or any securities or obligations convertible (whether currently
convertible or convertible only after the passage of time or the occurrence of certain events) or exchangeable into or exercisable for
any shares of its capital stock or other equity or voting securities, including any CBTX Securities or CBTX Subsidiary Securities, in
the case of CBTX, or Allegiance Securities or Allegiance Subsidiary Securities, in the case of Allegiance, except, in each case, (i)&nbsp;regular
quarterly cash dividends by CBTX at a rate not in excess of $0.13 per share of CBTX Common Stock and by Allegiance at a rate not in excess
of $0.12 per share of Allegiance Common Stock; (ii)&nbsp;dividends paid by any of the Subsidiaries of each of Allegiance and CBTX to Allegiance
and CBTX or any of their wholly-owned Subsidiaries, respectively; (iii)&nbsp;dividends provided for and paid on the Allegiance Trust Preferred
Securities in accordance with the terms thereof; (iv)&nbsp;the acceptance of shares of CBTX Common Stock or Allegiance Common Stock, as
the case may be, as payment for the exercise price of stock appreciation rights or stock options or for withholding Taxes incurred in
connection with the exercise of stock appreciation rights or stock options or the vesting or settlement of equity compensation awards,
in each case, in accordance with past practice and the terms of the applicable award agreements; or (v)&nbsp;redemptions, purchases or
acquisitions of such securities pursuant to any repurchase plan or program approved by the Board of Directors of CBTX or Allegiance, as
the case may be, as of the date hereof&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">grant
any stock appreciation rights, stock options, restricted stock units, performance units, phantom stock units, restricted shares or other
equity-based awards or interests, or grant any person any right to acquire any CBTX Securities or CBTX Subsidiary Securities, in the
case of CBTX, or Allegiance Securities or Allegiance Subsidiary Securities, in the case of Allegiance, other than reasonable grants to
any employee or officer (i)&nbsp;in connection with commencement of employment, promotion or change in responsibilities, (ii)&nbsp;in
the ordinary course of business consistent with past practice or (iii)&nbsp;by the payment of incentive compensation for completed performance
periods based upon corporate performance, the performance of such employee and, if applicable, such employee&rsquo;s business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">issue,
sell, transfer, encumber or otherwise permit to become outstanding any shares of capital stock or voting securities or equity interests
or securities convertible (whether currently convertible or convertible only after the passage of time of the occurrence of certain events)
or exchangeable into, or exercisable for, any shares of its capital stock or other equity or voting securities, including any CBTX Securities
or CBTX Subsidiary Securities, in the case of CBTX, or Allegiance Securities or Allegiance Subsidiary Securities, in the case of Allegiance,
or any options, warrants, or other rights of any kind to acquire any shares of capital stock or other equity or voting securities, including
any CBTX Securities or CBTX Subsidiary Securities, in the case of CBTX, or Allegiance Securities or Allegiance Subsidiary Securities,
in the case of Allegiance, except pursuant to the exercise of stock appreciation rights or stock options or the settlement of equity compensation
awards in accordance with their terms&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">sell,
transfer, mortgage, encumber or otherwise dispose of any of its material properties or assets to any individual, corporation or other
entity other than a wholly-owned Subsidiary, or cancel, release or assign any indebtedness to any such person or any claims held by any
such person, in each case other than in the ordinary course of business or pursuant to contracts or agreements in force at the date of
this Agreement&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
for foreclosure or acquisitions of control in a fiduciary or similar capacity or in satisfaction of debts previously contracted in good
faith in the ordinary course of business, make any material investment in or acquisition of (whether by purchase of stock or securities,
contributions to capital, property transfers, merger or consolidation, or formation of a joint venture or otherwise) any other person
or the property or assets of any other person, in each case other than a wholly-owned Subsidiary of CBTX or Allegiance, as applicable&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">in
each case except for transactions in the ordinary course of business, terminate, materially amend, or waive any material provision of,
any CBTX Contract or Allegiance Contract, as the case may be, or make any change in any instrument or agreement governing the terms of
any of its securities, other than normal renewals of contracts without material adverse changes of terms with respect to CBTX or Allegiance,
as the case may be, or enter into any contract that would constitute a CBTX Contract or an Allegiance Contract, as the case may be, if
it were in effect on the date of this Agreement&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as required under applicable law or the terms of any CBTX Benefit Plan or Allegiance Benefit Plan existing as of the date hereof, as applicable,
(i)&nbsp;enter into, establish, adopt, commence participation in, materially amend, cease participation in or terminate any CBTX Benefit
Plan or Allegiance Benefit Plan, or any plan, program, agreement, contract, policy or arrangement that would be a CBTX Benefit Plan or
an Allegiance Benefit Plan if in effect on the date hereof, other than (x)&nbsp;in the ordinary course of business consistent with past
practice and (y)&nbsp;as would not reasonably be expected to materially increase the cost of benefits under any CBTX Benefit Plan, Allegiance
Benefit Plan, CBTX Contract or Allegiance Contract, as the case may be; (ii)&nbsp;increase the compensation or benefits payable to any
current or former employee, officer, director or individual consultant, other than as set forth in <U>Section&nbsp;5.2(i)</U>&nbsp;of
the CBTX Disclosure Schedule or other than increases to current employees and officers (x)&nbsp;in connection with a promotion or change
in responsibilities and to a level consistent with similarly situated peer employees, (y)&nbsp;in the ordinary course of business consistent
with past practice or (z)&nbsp;by the payment of incentive compensation for completed performance periods based upon corporate performance,
the performance of such employee and, if applicable, such employee&rsquo;s business; (iii)&nbsp;accelerate the vesting or payment of any
equity-based awards or other compensation; (iv)&nbsp;enter into any new, or amend any existing, employment, severance, change in control,
retention, collective bargaining agreement or similar agreement or arrangement; or (v)&nbsp;fund any rabbi trust or similar arrangement
or in any other way secure the payment of compensation or benefits under any CBTX Benefit Plan, Allegiance Benefit Plan, CBTX Contract
or Allegiance Contract, as the case may be;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as set forth in <U>Section&nbsp;5.2(j)</U>&nbsp;of the CBTX Disclosure Schedule or except as set forth in <U>Section&nbsp;5.2(j)</U>&nbsp;of
the Allegiance Disclosure Schedule, as the case may be, settle any material claim, suit, action or proceeding, except involving solely
monetary remedies in an amount, individually and in the aggregate, that is not material to CBTX or Allegiance, as applicable, and that
would not impose any material restriction on, or create any adverse precedent that would be material to, the business of it or its Subsidiaries
or the Surviving Entity or to the receipt of regulatory approvals for the Merger or the Bank Merger on a timely basis&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">take
any action or knowingly fail to take any action where such action or failure to act could reasonably be expected to prevent the Merger
from qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">amend
its certificate of formation, its bylaws or comparable governing documents of its Subsidiaries that are &ldquo;significant subsidiaries&rdquo;
within the meaning of Rule&nbsp;1-02 of Regulation S-X of the SEC&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">other
than in prior consultation with the other party to this Agreement, materially restructure or materially change its investment securities
or derivatives portfolio or its interest rate exposure, through purchases, sales or otherwise, or the manner in which the portfolio is
classified or reported&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">implement
or adopt any change in its accounting principles, practices or methods, other than as may be required by GAAP&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any new line of business or, other than in the ordinary course of business consistent with past practice, change in any material
respect its lending, investment, underwriting, risk and asset liability management and other banking and operating, securitization and
servicing policies (including any change in the maximum ratio or similar limits as a percentage of its capital exposure applicable with
respect to its loan portfolio or any segment thereof), except as required by applicable law, regulation or policies imposed by any Governmental
Entity&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">change
or revoke any material Tax election, change an annual Tax accounting period, change any material Tax accounting method, file any material
amended Tax Return, enter into any closing or similar agreement with respect to a material amount of Taxes, or settle or compromise any
material Tax claim, audit, assessment or dispute or surrender any material right to claim a refund of Taxes&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">merge
or consolidate itself or any of its Subsidiaries that are &ldquo;significant subsidiaries&rdquo; within the meaning of Rule&nbsp;1-02
of Regulation S-X of the SEC with any other person, or restructure, reorganize or completely or partially liquidate or dissolve it or
any of its Subsidiaries that are &ldquo;significant subsidiaries&rdquo; within the meaning of Rule&nbsp;1-02 of Regulation S-X of the
SEC&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">take
any action that is intended or expected to result in any of the conditions to the Merger set forth in <U>ARTICLE&nbsp;VII</U> not being
satisfied, except as may be required by applicable law&#894; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">agree
to take, make any commitment to take, or adopt any resolutions of its Board of Directors or similar governing body in support of, any
of the actions prohibited by this <U>Section&nbsp;5.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;VI</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
ADDITIONAL AGREEMENTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulatory
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Promptly
after the date of this Agreement, Allegiance and CBTX shall prepare and file with the SEC the Joint Proxy Statement, and CBTX shall prepare
and file with the SEC the S-4, in which the Joint Proxy Statement will be included as a prospectus. Allegiance and CBTX, as applicable,
shall use reasonable best efforts to make such filings within forty-five (45) days of the date of this Agreement. Each of Allegiance and
CBTX shall use its reasonable best efforts to have the S-4 declared effective under the Securities Act as promptly as practicable after
such filings, and to keep the S-4 effective for so long as necessary to consummate the transactions contemplated by this Agreement, and
Allegiance and CBTX shall thereafter mail or deliver the Joint Proxy Statement to their respective shareholders. CBTX shall also use its
reasonable best efforts to obtain all necessary state securities law or &ldquo;Blue Sky&rdquo; permits and approvals required to carry
out the transactions contemplated by this Agreement, and Allegiance shall furnish all information concerning Allegiance and the holders
of Allegiance Common Stock as may be reasonably requested in connection with any such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
parties hereto shall cooperate with each other and use their reasonable best efforts to promptly prepare and file all necessary documentation,
to effect all applications, notices, petitions and filings and in the case of the applications, notices, petitions and filings in respect
of the Requisite Regulatory Approvals, use their reasonable best efforts to make them within forty-five (45) days of the date of this
Agreement, to obtain as promptly as practicable all permits, consents, approvals and authorizations of all third parties and Governmental
Entities which are necessary or advisable to consummate the transactions contemplated by this Agreement (including the Merger and the
Bank Merger), and to comply with the terms and conditions of all such permits, consents, approvals and authorizations of all such Governmental
Entities. Allegiance and CBTX shall have the right to review in advance, and, to the extent practicable, each will consult the other
on, in each case subject to applicable laws relating to the exchange of information, all the information relating to Allegiance or CBTX,
as the case may be, and any of their respective Subsidiaries, which appears in any filing made with, or written materials submitted to,
any third party or any Governmental Entity, including the Joint Proxy Statement, the S-4 and any other filing made in connection with
the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto shall act reasonably and
as promptly as practicable. The parties hereto agree that they will consult with each other with respect to the obtaining of all permits,
consents, approvals and authorizations of all third parties and Governmental Entities necessary or advisable to consummate the transactions
contemplated by this Agreement and each party will keep the other apprised of the status of matters relating to completion of the transactions
contemplated herein, and each party shall consult with the other in advance of any meeting or conference with any Governmental Entity
in connection with the transactions contemplated by this Agreement and, to the extent permitted by such Governmental Entity, give the
other party and/or its counsel the opportunity to attend and participate in such meetings and conferences, in each case subject to applicable
law. As used in this Agreement, the term &ldquo;<U>Requisite Regulatory Approvals</U>&rdquo; shall mean all regulatory authorizations,
consents, orders and approvals (and the expiration or termination of all statutory waiting periods in respect thereof) (i)&nbsp;from
the Federal Reserve Board, the FDIC, the Texas Department of Banking, the OCC and (ii)&nbsp;set forth in <U>Section&nbsp;3.4</U> or <U>Section&nbsp;4.4
</U>that are necessary to consummate the transactions contemplated by this Agreement (including the Merger and the Bank Merger) or those
the failure of which to be obtained would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect
on the Surviving Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
party shall use its reasonable best efforts to respond to any request for information and resolve any objection that may be asserted
by any Governmental Entity with respect to this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, nothing
contained herein shall be deemed to require Allegiance or CBTX or any of their respective Subsidiaries, and neither Allegiance nor CBTX
nor any of their respective Subsidiaries shall be permitted (without the written consent of the other party), to take any action, or
commit to take any action, or agree to any condition or restriction, in connection with (i)&nbsp;the settlement of the FinCEN Matter
with FinCEN or the OCC, or (ii)&nbsp;obtaining the foregoing permits, consents, approvals and authorizations of Governmental Entities
that in the case of either (i)&nbsp;or (ii)&nbsp;would reasonably be expected to have a Material Adverse Effect on the Surviving Entity
and its Subsidiaries, taken as a whole, after giving effect to the Merger (a &ldquo;<U>Materially Burdensome Regulatory Condition</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
and CBTX shall, upon request, furnish each other with all information concerning themselves, their Subsidiaries, directors, officers
and shareholders and such other matters as may be reasonably necessary or advisable in connection with the Joint Proxy Statement, the
S-4 or any other statement, filing, notice or application made by or on behalf of Allegiance, CBTX or any of their respective Subsidiaries
to any Governmental Entity in connection with the Merger, the Bank Merger and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX agrees, as to itself and its Subsidiaries, as applicable, that the information relating to it and its Subsidiaries
or that is provided by it or its Subsidiaries or their respective representatives for inclusion in the Joint Proxy Statement and the
S-4, or in any other document filed with any Regulatory Agency or Governmental Entity in connection herewith, will not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances
in which they are made, not misleading. The Joint Proxy Statement and the S-4 (except for such portions thereof that relate only to the
other party or any of its Subsidiaries) will comply in all material respects with the provisions of the Exchange Act and the Securities
Act, as applicable, and the rules&nbsp;and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Allegiance
and CBTX shall promptly advise each other upon receiving any communication from any Governmental Entity whose consent or approval is required
for consummation of the transactions contemplated by this Agreement that causes such party to believe that there is a reasonable likelihood
that any Requisite Regulatory Approval will not be obtained, or that the receipt of any such approval will be materially delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Access
to Information&#894; Confidentiality</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;9.14</U>, upon reasonable notice and subject to applicable laws, each of Allegiance and CBTX, for the purposes of
verifying the representations and warranties of the other and preparing for the Merger and the other matters contemplated by this Agreement,
shall, and shall cause each of their respective Subsidiaries to, afford to the officers, employees, accountants, counsel, advisors and
other representatives of the other party, access, during normal business hours during the period prior to the Effective Time, to all
its properties, books, contracts, commitments, personnel, information technology systems, and records, and each shall cooperate with
the other party in preparing to execute after the Effective Time the conversion or consolidation of systems and business operations generally,
and, during such period, each of Allegiance and CBTX shall, and shall cause its respective Subsidiaries to, make available to the other
party (i)&nbsp;a copy of each report, schedule, registration statement and other document filed or received by it during such period
pursuant to the requirements of federal securities laws or federal or state banking laws (other than reports or documents that Allegiance
or CBTX, as the case may be, is not permitted to disclose under applicable law), and (ii)&nbsp;all other information concerning its business,
properties and personnel as such party may reasonably request. Neither Allegiance nor CBTX nor any of their respective Subsidiaries shall
be required to provide access to or to disclose information where such access or disclosure would violate or prejudice the rights of
Allegiance&rsquo;s or CBTX&rsquo;s, as the case may be, customers, jeopardize the attorney-client privilege of the institution in possession
or control of such information (after giving due consideration to the existence of any common interest, joint defense or similar agreement
between the parties) or contravene any law, rule, regulation, order, judgment, decree, fiduciary duty or binding agreement entered into
prior to the date of this Agreement. The parties hereto will make appropriate substitute disclosure arrangements under circumstances
in which the restrictions of the preceding sentence apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX shall hold all information furnished by or on behalf of the other party or any of such party&rsquo;s Subsidiaries
or representatives pursuant to Section&nbsp;6.2(a)&nbsp;in confidence to the extent required by, and in accordance with, the provisions
of the confidentiality agreement dated January&nbsp;12, 2021 between Allegiance and CBTX, as amended (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
investigation by either of the parties or their respective representatives shall affect or be deemed to modify or waive the representations
and warranties of the other set forth herein. Nothing contained in this Agreement shall give either party, directly or indirectly, the
right to control or direct the operations of the other party prior to the Effective Time. Prior to the Effective Time, each party shall
exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over its and its Subsidiaries&rsquo;
respective operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shareholders&rsquo;
Approvals</U>. Each of Allegiance and CBTX shall call a meeting of its shareholders (the &ldquo;<U>Allegiance Meeting</U>&rdquo; and the
&ldquo;<U>CBTX Meeting</U>,&rdquo; respectively) to be held as soon as reasonably practicable after the S-4 is declared effective, for
the purpose of obtaining (a)&nbsp;the Requisite Allegiance Vote and the Requisite CBTX Vote required in connection with this Agreement
and the Merger and (b)&nbsp;if so desired and mutually agreed, a vote upon other matters of the type customarily brought before a meeting
of shareholders in connection with the approval of a merger agreement or the transactions contemplated thereby, and each of Allegiance
and CBTX shall use its reasonable best efforts to cause such meetings to occur as soon as reasonably practicable and on the same date.
Each of Allegiance and CBTX and their respective Boards of Directors shall use its reasonable best efforts to obtain from the shareholders
of Allegiance and CBTX, as applicable, the Requisite Allegiance Vote and the Requisite CBTX Vote, as applicable, including by communicating
to the respective shareholders of Allegiance and CBTX its recommendation (and including such recommendation in the Joint Proxy Statement)
that, in the case of Allegiance, the shareholders of Allegiance approve this Agreement (the &ldquo;<U>Allegiance Board Recommendation</U>&rdquo;),
and in the case of CBTX, that the shareholders of CBTX approve this Agreement (the &ldquo;<U>CBTX Board Recommendation</U>&rdquo;), and
each of Allegiance and CBTX and their respective Boards of Directors shall not (i)&nbsp;withhold, withdraw, modify or qualify in a manner
adverse to the other party the Allegiance Board Recommendation, in the case of Allegiance, or the CBTX Board Recommendation, in the case
of CBTX; (ii)&nbsp;fail to make the Allegiance Board Recommendation, in the case of Allegiance, or the CBTX Board Recommendation, in the
case of CBTX, in the Joint Proxy Statement; (iii)&nbsp;adopt, approve, recommend or endorse an Acquisition Proposal or publicly announce
an intention to adopt, approve, recommend or endorse an Acquisition Proposal; (iv)&nbsp;fail to publicly and without qualification (A)&nbsp;recommend
against any Acquisition Proposal or (B)&nbsp;reaffirm the Allegiance Board Recommendation, in the case of Allegiance, or the CBTX Board
Recommendation, in the case of CBTX, in each case within ten (10)&nbsp;business days (or such fewer number of days as remains prior to
the Allegiance Meeting or the CBTX Meeting, as applicable) after an Acquisition Proposal is made public or any request by the other party
to do so; or (v)&nbsp;publicly propose to do any of the foregoing (any of the foregoing a &ldquo;<U>Recommendation Change</U>&rdquo;).
However, subject to <U>Section&nbsp;8.1</U> and <U>Section&nbsp;8.2</U>, if the Board of Directors of Allegiance or CBTX, after receiving
the advice of its outside counsel and, with respect to financial matters, its financial advisors, determines in good faith that it would
more likely than not result in a violation of its fiduciary duties under applicable law to make or continue to make the Allegiance Board
Recommendation or the CBTX Board Recommendation, as applicable, such Board of Directors may, in the case of Allegiance, prior to the receipt
of the Requisite Allegiance Vote, and in the case of CBTX, prior to the receipt of the Requisite CBTX Vote, submit this Agreement to its
shareholders without recommendation (although the resolutions approving this Agreement as of the date hereof may not be rescinded or amended),
in which event such Board of Directors may communicate the basis for its lack of a recommendation to its shareholders in the Joint Proxy
Statement or an appropriate amendment or supplement thereto to the extent required by law&#894; <U>provided</U>, that such Board of Directors
may not take any actions under this sentence unless it (A)&nbsp;gives the other party at least four (4)&nbsp;business days&rsquo; prior
written notice of its intention to take such action and a reasonable description of the event or circumstances giving rise to its determination
to take such action (including, in the event such action is taken in response to an Acquisition Proposal, the latest material terms and
conditions and the identity of the third party in any such Acquisition Proposal, or any amendment or modification thereof, or describe
in reasonable detail such other event or circumstances) and (B)&nbsp;at the end of such notice period, takes into account any amendment
or modification to this Agreement proposed by the other party and, after receiving the advice of its outside counsel and, with respect
to financial matters, its financial advisors, determines in good faith that it would nevertheless more likely than not result in a violation
of its fiduciary duties under applicable law to make or continue to make the Allegiance Board Recommendation or CBTX Board Recommendation,
as the case may be. Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of
this <U>Section&nbsp;6.3</U> and will require a new notice period as referred to in this <U>Section&nbsp;6.3</U>. Allegiance or CBTX shall
adjourn or postpone the Allegiance Meeting or the CBTX Meeting, as the case may be, if, as of the time for which such meeting is originally
scheduled there are insufficient shares of Allegiance Common Stock or CBTX Common Stock, as the case may be, represented (either in person
or by proxy) to constitute a quorum necessary to conduct the business of such meeting, or if on the date of such meeting CBTX or Allegiance,
as applicable, has not received proxies representing a sufficient number of shares necessary to obtain the Requisite CBTX Vote or the
Requisite Allegiance Vote, and subject to the terms and conditions of this Agreement (including the immediately preceding sentence), CBTX
or Allegiance, as applicable, shall continue to use reasonable best efforts to solicit proxies from its shareholders in order to obtain
the Requisite CBTX Vote or the Requisite Allegiance Vote, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary herein, but subject to the obligation to adjourn or postpone such meeting as set forth in the immediately preceding sentence,
unless this Agreement has been terminated in accordance with its terms, (x)&nbsp;the Allegiance Meeting shall be convened and this Agreement
shall be submitted to the shareholders of Allegiance at the Allegiance Meeting and (y)&nbsp;the CBTX Meeting shall be convened and this
Agreement shall be submitted to the shareholders of CBTX at the CBTX Meeting, and nothing contained herein shall be deemed to relieve
either Allegiance or CBTX of such obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legal
Conditions to Merger</U>. Subject in all respects to <U>Section&nbsp;6.1</U> of this Agreement, each of Allegiance and CBTX shall, and
shall cause its Subsidiaries to, use their reasonable best efforts (a)&nbsp;to take, or cause to be taken, all actions necessary, proper
or advisable to comply promptly with all legal requirements that may be imposed on such party or its Subsidiaries with respect to the
Merger and the Bank Merger and, subject to the conditions set forth in <U>ARTICLE&nbsp;VII</U> hereof, to consummate the transactions
contemplated by this Agreement, (b)&nbsp;to obtain (and to cooperate with the other party to obtain) any material consent, authorization,
order or approval of, or any exemption by, any Governmental Entity and any other third party that is required to be obtained by CBTX or
Allegiance or any of their respective Subsidiaries in connection with the Merger, the Bank Merger and the other transactions contemplated
by this Agreement, and (c)&nbsp;to obtain the tax opinions referenced in <U>Section&nbsp;7.2(c)</U>&nbsp;and <U>Section&nbsp;7.3(c)</U>,
including by executing and delivering representations contained in the Allegiance Tax Certificate and the CBTX Tax Certificate, reasonably
satisfactory in form and substance to Allegiance&rsquo;s and CBTX&rsquo;s counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Exchange Listing</U>. CBTX shall cause the shares of CBTX Common Stock to be issued in the Merger to be approved for listing on the NASDAQ,
subject to official notice of issuance, prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Employee
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Commencing
on the Effective Time and ending on December&nbsp;31, 2022 (or the date of termination of the applicable Continuing Allegiance Employee,
if earlier), unless otherwise mutually determined by Allegiance and CBTX prior to the Closing, the Surviving Entity shall provide the
employees of Allegiance and its Subsidiaries who, at the Effective Time, are employed by the Surviving Entity or any of its Subsidiaries
(the &ldquo;<U>Continuing Allegiance Employees</U>&rdquo;) (i)&nbsp;base salary or base wage rate and bonus opportunity, in each case,
no less than in effect immediately prior to the Effective Time and (ii)&nbsp;benefits that are substantially comparable, in the aggregate,
to the benefits provided to such Continuing Allegiance Employees by Allegiance and its Subsidiaries immediately prior to the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Commencing
on the Effective Time and ending on December&nbsp;31, 2022 (or the date of termination of the applicable Continuing CBTX Employee, if
earlier), unless otherwise mutually determined by Allegiance and CBTX prior to the Closing, the Surviving Entity shall provide the employees
of CBTX and its Subsidiaries who, at the Effective Time, are employed by the Surviving Entity or any of its Subsidiaries (the &ldquo;<U>Continuing
CBTX Employees</U>&rdquo;, and together with the Continuing Allegiance Employees, the &ldquo;<U>Continuing Employees</U>&rdquo;) (i)&nbsp;base
salary or base wage rate and bonus opportunity, in each case, no less than in effect immediately prior to the Effective Time and (ii)&nbsp;benefits
that are substantially comparable, in the aggregate, to the benefits provided to such Continuing CBTX Employees by CBTX and its Subsidiaries
immediately prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Closing Date, Allegiance and CBTX shall cooperate in reviewing, evaluating and analyzing the Allegiance Benefit Plans and the CBTX
Benefit Plans with a view towards developing appropriate new benefit plans with respect to employees of the Surviving Entity and its Subsidiaries
(&ldquo;<U>New Benefit Plans</U>&rdquo;), which New Benefit Plans will, to the extent permitted by applicable law, and among other things,
(i)&nbsp;treat similarly situated employees on a substantially equivalent basis, taking into account all relevant factors, including duties,
geographic location, tenure, qualifications and abilities, and (ii)&nbsp;not discriminate between Continuing Allegiance Employees, on
the one hand, and Continuing CBTX Employees, on the other hand. Notwithstanding the foregoing, Allegiance and CBTX agree that any Continuing
Employee who, during the period commencing on the Closing Date and ending on December&nbsp;31, 2022, is involuntarily terminated other
than for cause by the Surviving Entity or any of its respective Subsidiaries will be provided with severance pay and benefits pursuant
to a severance program to be mutually agreed between Allegiance and CBTX prior to the Effective Time. Notwithstanding the foregoing, except
as otherwise provided expressly in this Agreement, nothing herein shall require the Surviving Entity to continue, suspend or terminate
any Allegiance Benefit Plan or CBTX Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any CBTX Benefit Plan or New Benefit Plan in which a Continuing Allegiance Employee becomes eligible to participate on or after
the Effective Time, the Surviving Entity shall and shall cause its Subsidiaries to: (i)&nbsp;use reasonable best efforts to (A)&nbsp;waive
all pre-existing conditions, exclusions and waiting periods with respect to participation and coverage requirements applicable to such
Continuing Allegiance Employee and his or her eligible dependents under such plan, except to the extent such pre-existing conditions,
exclusions or waiting periods would apply under the analogous Allegiance Benefit Plan, and (B)&nbsp;provide such Continuing Allegiance
Employee and his or her eligible dependents with credit for any co-payments or deductibles paid during the plan year in which participation
under the plan commences in satisfying any applicable deductible or out-of-pocket requirements, if and to the same extent that such credit
was given under the analogous Allegiance Benefit Plan prior to the Effective Time; and (ii)&nbsp;recognize all service of such Continuing
Allegiance Employee with Allegiance and its Subsidiaries (and their respective predecessors, if applicable) for purposes of eligibility
to participate, vesting (other than vesting with respect to equity-based and incentive compensation), and benefit accrual to the same
extent such service was recognized under the analogous Allegiance Benefit Plan prior to the Effective Time; <I>provided that</I> the foregoing
service recognition shall not apply (x)&nbsp;to the extent it would result in duplication of benefits for the same period of services,
(y)&nbsp;for purposes of any defined benefit pension or similar plan or any plan that provides retiree welfare benefits, or (z)&nbsp;to
any plan that is a frozen plan or provides grandfathered benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Allegiance Benefit Plan or New Benefit Plan which a Continuing CBTX Employee becomes eligible to participate on or after
the Effective Time, the Surviving Entity shall and shall cause its Subsidiaries to: (i)&nbsp;use reasonable best efforts to (A)&nbsp;waive
all pre-existing conditions, exclusions and waiting periods with respect to participation and coverage requirements applicable to such
Continuing CBTX Employee and his or her eligible dependents under such plan, except to the extent such pre-existing conditions, exclusions
or waiting periods would apply under the analogous CBTX Benefit Plan, and (B)&nbsp;provide such Continuing CBTX Employee and his or her
eligible dependents with credit for any co-payments or deductibles paid during the plan year in which participation under the plan commences
in satisfying any applicable deductible or out-of-pocket requirements, if and to the same extent that such credit was given under the
analogous CBTX Benefit Plan prior to the Effective Time; and (ii)&nbsp;recognize all service of such Continuing CBTX Employee with CBTX
and its Subsidiaries (and their respective predecessors, if applicable) for purposes of eligibility to participate, vesting (other than
vesting with respect to equity-based and incentive compensation), and benefit accrual to the same extent such service was recognized
under the analogous CBTX Benefit Plan prior to the Effective Time; <I>provided that</I> the foregoing service recognition shall not apply
(x)&nbsp;to the extent it would result in duplication of benefits for the same period of services, (y)&nbsp;for purposes of any defined
benefit pension or similar plan or any plan that provides retiree welfare benefits, or (z)&nbsp;to any plan that is a frozen plan or
provides grandfathered benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Surviving Entity agrees to honor (i)&nbsp;all Allegiance Benefit Plans in accordance with their terms, (ii)&nbsp;all CBTX Benefit Plans
in accordance with their terms, and (iii)&nbsp;all accrued but unused vacation and other paid time off of the Continuing Employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to service provided by applicable employees for the portion of calendar year 2022 following the Closing, the Surviving Entity
shall continue to permit benefit accruals and deferrals for purposes of that certain Executive Nonqualified Excess Plan (with respect
to applicable Continuing Employees) (the &ldquo;<U>Excess Plan</U>&rdquo;) and of those certain Executive Deferred Compensation Agreements
(with respect to applicable employees of pre-Merger CBTX Bank) (the &ldquo;<U>Deferred Compensation Arrangements</U>&rdquo;), but only
with respect to Deferred Compensation Arrangements that have not been frozen as to active participation. Effective with respect to years
beginning on and after January&nbsp;1, 2023, the Surviving Entity shall cause (i)&nbsp;benefit accruals and deferrals under the Deferred
Compensation Agreements to cease, to the extent not previously ceased, with respect to any service provided on or after January&nbsp;1,
2023 (but contributions and deferrals during calendar year 2023 with respect to amounts earned in calendar year 2022 shall be permitted),
with amounts deferred thereunder payable in accordance with the terms of the Deferred Compensation Arrangements, and (ii)&nbsp;unless
determined otherwise by the Surviving Entity in accordance with the immediately following sentence, benefit accruals and deferrals under
the Excess Plan to cease with respect to any service provided on or after January&nbsp;1, 2023 (but contributions and deferrals during
calendar year 2023 with respect to amounts earned in calendar year 2022 shall be permitted), with amounts deferred thereunder payable
in accordance with the terms of the Excess Plan. Effective for calendar years beginning on or after January&nbsp;1, 2023, the Surviving
Company shall implement a deferred compensation plan for select employees thereof (which shall include both then-current executives who
are Continuing Employees and then-current executives who were executives of pre-Merger CBTX Bank), which plan may take the form of the
Excess Plan, as it may be amended with respect to prospective accruals and deferrals, or such other plan or arrangement as the Surviving
Company determines to implement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Closing Date, Allegiance and CBTX shall cooperate in reviewing, evaluating and analyzing the Allegiance Bank 401(k)&nbsp;&amp;
Profit Sharing Plan (the &ldquo;<U>Allegiance 401(k)&nbsp;Plan</U>&rdquo;) and the CommunityBank of Texas, N.A. 401(k)&nbsp;Plan (the
&ldquo;<U>CBTX 401(k)&nbsp;Plan</U>&rdquo;) and make a mutual determination as to whether one or both of the Allegiance 401(k)&nbsp;Plan
and the CBTX 401(k)&nbsp;Plan will continue to be maintained by the Surviving Entity immediately following the Effective Time (the &ldquo;<U>Continuing
401(k)&nbsp;Plan(s)</U>&rdquo;) and, if either the Allegiance 401(k)&nbsp;Plan or the CBTX 401(k)&nbsp;Plan is to be terminated prior
to the Closing, which one will be terminated (such plan, the &ldquo;<U>Terminated 401(k)&nbsp;Plan</U>&rdquo;). If it is determined that
either the Allegiance 401(k)&nbsp;Plan or the CBTX 401(k)&nbsp;Plan shall be the Terminated 401(k)&nbsp;Plan, the Board of Directors (or
an appropriate committee thereof) of Allegiance or CBTX, as applicable, shall adopt resolutions and take such corporate action as is necessary
or appropriate to terminate the Terminated 401(k)&nbsp;Plan, effective as of the day prior to the Closing Date and contingent upon the
occurrence of the Effective Time. In such case, Allegiance or CBTX, as applicable, shall provide the other party with evidence that the
Terminated 401(k)&nbsp;Plan has been terminated (the form and substance of which shall be subject to reasonable review and comment by
the other party) not later than two (2)&nbsp;days immediately preceding the Closing Date and (ii)&nbsp;the employees who participated
in the Terminated 401(k)&nbsp;Plan immediately prior to the Closing and who continue in employment immediately after the Closing shall
be eligible to participate, effective as immediately after the Closing, in the Continuing 401(k)&nbsp;Plan. Allegiance and CBTX shall
take any and all actions as may be required, including amendments to the Allegiance 401(k)&nbsp;Plan and/or the CBTX 401(k)&nbsp;Plan,
to permit the employees participating in the Terminated 401(k)&nbsp;Plan to make rollover contributions from the Terminated 401(k)&nbsp;Plan
to the Continuing 401(k)&nbsp;Plan of &ldquo;eligible rollover distributions&rdquo; (within the meaning of Section&nbsp;401(a)(31) of
the Code) in the form of cash, notes (in the case of loans) or a combination thereof in an amount equal to the full account balance distributed
to such employee from the Terminated 401(k)&nbsp;Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
in this Agreement shall confer upon any employee, officer, director or consultant of Allegiance or CBTX or any of their Subsidiaries or
affiliates any right to continue in the employ or service of the Surviving Entity, Allegiance, CBTX or any Subsidiary or affiliate thereof,
or shall interfere with or restrict in any way the rights of the Surviving Entity, Allegiance, CBTX or any Subsidiary or affiliate thereof
to discharge or terminate the services of any employee, officer, director or consultant of Allegiance or CBTX or any of their Subsidiaries
or affiliates at any time for any reason whatsoever, with or without cause, or for no reason. Nothing in this Agreement shall be deemed
to (i)&nbsp;establish, amend, or modify any Allegiance Benefit Plan, CBTX Benefit Plan, New Benefit Plan or any other benefit or employment
plan, program, agreement or arrangement, or (ii)&nbsp;alter or limit the ability of the Surviving Entity or any of its Subsidiaries or
affiliates to amend, modify or terminate any particular Allegiance Benefit Plan, CBTX Benefit Plan, New Benefit Plan or any other benefit
or employment plan, program, agreement or arrangement after the Effective Time. Without limiting the generality of Section&nbsp;9.11,
nothing in this Agreement, express or implied, is intended to or shall confer upon any person, including any current or former employee,
officer, director or consultant of Allegiance or CBTX or any of their Subsidiaries or affiliates, any right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification&#894;
Directors&rsquo; and Officers&rsquo; Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Time, the Surviving Entity shall indemnify and hold harmless and shall advance expenses as incurred, in each
case to the extent (subject to applicable law) such persons are indemnified as of the date of this Agreement by Allegiance pursuant to
the Allegiance Certificate of Formation, the Allegiance Bylaws, the governing or organizational documents of any Allegiance Subsidiary
and any indemnification agreements in existence as of the date hereof and disclosed in <U>Section&nbsp;6.7(a)</U>&nbsp;of the Allegiance
Disclosure Schedule, each present and former director, officer or employee of Allegiance and its Subsidiaries (collectively, the &ldquo;<U>Allegiance
Indemnified Parties</U>&rdquo;) against any costs or expenses (including reasonable attorneys&rsquo; fees), judgments, fines, losses,
damages or liabilities incurred in connection with any threatened or actual claim, action, suit, proceeding or investigation, whether
civil, criminal, administrative or investigative, whether arising before or after the Effective Time, arising out of the fact that such
person is or was a director, officer or employee of Allegiance or any of its Subsidiaries and pertaining to matters existing or occurring
at or prior to the Effective Time, including the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CBTX
and Allegiance shall cooperate to obtain at or prior to the Effective Time a six (6)-year &ldquo;tail&rdquo; policy under Allegiance&rsquo;s
existing directors&rsquo; and officers&rsquo; insurance policy with a substantially comparable insurer providing equivalent coverage
and amounts containing terms and conditions that are no less advantageous to the insured as the current policies of directors&rsquo;
and officers&rsquo; liability insurance maintained by Allegiance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
obligations of the Surviving Entity, Allegiance or CBTX under this <U>Section&nbsp;6.7</U> shall not be terminated or modified after the
Effective Time in a manner so as to adversely affect any Allegiance Indemnified Party without the prior written consent of the affected
Allegiance Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
provisions of this <U>Section&nbsp;6.7</U> shall survive the Effective Time and are intended to be for the benefit of, and shall be enforceable
by, each Allegiance Indemnified Party and his or her heirs and representatives. If the Surviving Entity or any of its successors or assigns
(i)&nbsp;consolidates with or merges into any other person and is not the continuing or surviving entity of such consolidation or merger,
or (ii)&nbsp;transfers all or substantially all of its assets or deposits to any other person or engages in any similar transaction,
then in each such case, the Surviving Entity will cause proper provision to be made so that the successors and assigns of the Surviving
Entity will expressly assume the obligations set forth in this <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Additional
Agreements</U>. In case at any time after the Effective Time any further action is necessary or desirable to carry out the purposes of
this Agreement (including any merger between an Allegiance Subsidiary, on the one hand, and a CBTX Subsidiary, on the other hand) or
to vest the Surviving Entity with full title to all properties, assets, rights, approvals, immunities and franchises of any of the parties
to the Merger or the Bank Merger, the proper officers and directors of each party to this Agreement and their respective Subsidiaries
shall take all such necessary action as may be reasonably requested by CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Advice
of Changes</U>. Allegiance and CBTX shall each promptly advise the other party of any effect, change, event, circumstance, condition,
occurrence or development (i)&nbsp;that has had or would reasonably be expected to have, either individually or in the aggregate, a Material
Adverse Effect on it or (ii)&nbsp;that it believes would or would reasonably be expected to cause or constitute a material breach of any
of its representations, warranties, obligations, covenants or agreements contained herein that reasonably could be expected to give rise,
individually or in the aggregate, to the failure of a condition in <U>ARTICLE&nbsp;VII</U>&#894; <U>provided</U>, that any failure to
give notice in accordance with the foregoing with respect to any breach shall not be deemed to constitute a violation of this <U>Section&nbsp;6.9</U>
or the failure of any condition set forth in <U>Section&nbsp;7.2</U> or <U>Section&nbsp;7.3</U> to be satisfied, or otherwise constitute
a breach of this Agreement by the party failing to give such notice, in each case unless the underlying breach would independently result
in a failure of the conditions set forth in <U>Section&nbsp;7.2</U> or <U>Section&nbsp;7.3</U> to be satisfied&#894; and <U>provided</U>,
further, that the delivery of any notice pursuant to this <U>Section&nbsp;6.9</U> shall not cure any breach of, or noncompliance with,
any other provision of this Agreement or limit the remedies available to the party receiving such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shareholder
Litigation</U>. Each party shall give the other party prompt notice of any shareholder litigation against such party or its directors
or officers relating to the transactions contemplated by this Agreement, and shall give the other party the opportunity to participate
(at such other&rsquo;s party&rsquo;s expense) in the defense or settlement of any such litigation. Each party shall give the other the
right to review and comment on all filings or responses to be made by such party in connection with any such litigation, and will in good
faith take such comments into account. No party shall agree to settle any such litigation without the other party&rsquo;s prior written
consent, which consent shall not be unreasonably withheld, conditioned or delayed&#894; <U>provided</U>, that the other party shall not
be obligated to consent to any settlement which does not include a full release of such other party and its affiliates or which imposes
an injunction or other equitable relief after the Effective Time upon the Surviving Entity or any of its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Corporate
Governance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Effective Time, the Board of Directors of CBTX shall take all actions necessary to adopt the CBTX Bylaw Amendment and to effect
the requirements referenced therein that are to be effected as of the Effective Time. CBTX shall take all action necessary to cause, effective
as of the Effective Time and in accordance with the CBTX Bylaw Amendment, the Board of Directors of the Surviving Entity to consist, as
of the Effective Time, of fourteen (14) directors (i)&nbsp;seven (7)&nbsp;of whom shall be persons designated by CBTX and (ii)&nbsp;seven
(7)&nbsp;of whom shall be persons designated by Allegiance. The directors designated by CBTX shall be selected from among the current
directors of CBTX as of the date hereof (each a &ldquo;<U>CBTX Director</U>&rdquo;), which shall include CBTX&rsquo;s current Chairman,
President and Chief Executive Officer, and the directors designated by Allegiance shall be selected from among the current directors of
Allegiance as of the date hereof (each an &ldquo;<U>Allegiance Director</U>&rdquo;), which shall include Allegiance&rsquo;s current Chief
Executive Officer. Effective as of the Effective Time, the CBTX Directors, on the one hand, and the Allegiance Directors, on the other
hand, shall be, as nearly evenly as is practicably possible, evenly apportioned among the different classes of the Board of Directors
of the Surviving Entity such that one class of the Board of Directors shall consist of two CBTX Directors and two Allegiance Directors,
one class of the Board of Directors shall consist of three (3)&nbsp;CBTX Directors and two Allegiance Directors, and one class of the
Board of Directors shall consist of two CBTX Directors and three (3)&nbsp;Allegiance Directors&#894; <U>provided</U> that CBTX&rsquo;s
current Chairman, President and Chief Executive Officer and Allegiance&rsquo;s current Chief Executive Officer shall each be in the same
class of the Board of Directors of the Surviving Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
accordance with the CBTX Bylaw Amendment, CBTX shall take all actions necessary to cause the Board of Directors of the Surviving Entity
to have the following four standing committees as of the Effective Time and shall maintain: (i)&nbsp;Audit Committee; (ii)&nbsp;Compensation
Committee; (iii)&nbsp;Corporate Governance and Nominating Committee; and (iv)&nbsp;Risk Committee (collectively, the &ldquo;<U>Committees</U>&rdquo;).
For a period of three (3)&nbsp;years beginning on the Effective Time (i)&nbsp;the Committees shall be maintained, (ii)&nbsp;two Committees
shall be chaired by a CBTX Director (or successor thereof) and two Committees shall be chaired by an Allegiance Director (or successor
thereof), and (iii)&nbsp;the membership of each Committee shall be apportioned as evenly as possible between CBTX Directors and Allegiance
Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Within
one hundred eighty (180) days following the Effective Time, the Board of Directors of the Surviving Entity shall elect a Lead Director
in accordance with the CBTX Bylaws, as amended by the CBTX Bylaw Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
accordance with the CBTX Bylaw Amendment, effective as of the Effective Time, (i)&nbsp;CBTX&rsquo;s current Chairman, President and Chief
Executive Officer shall continue to serve as Chief Executive Officer of the Surviving Entity, and (ii)&nbsp;Allegiance&rsquo;s current
Chief Executive Officer shall serve as Executive Chairman of the Surviving Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Surviving Entity, and CBTX and Allegiance prior to the Effective Time, as applicable, shall take all action necessary to cause Ramon
A. Vitulli,&nbsp;III to be appointed as the Chief Executive Officer of Allegiance Subsidiary Bank effective as of the effective time
of the Bank Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Following
the date hereof and in preparation for the Closing, Allegiance and CBTX shall cooperate in good faith to (i)&nbsp;develop, and make recommendations
for approval by the Board of Directors of the Surviving Entity effective from and after the Effective Time with respect to, any advisable
changes to the corporate governance guidelines for the Surviving Entity to reflect best practices of Allegiance, CBTX and otherwise, (ii)&nbsp;determine
the name of the Surviving Entity to be effective as of the Effective Time, (iii)&nbsp;determine the name of Allegiance Subsidiary Bank
to be effective as of the effective time of the Bank Merger, and (iv)&nbsp;determine the size and composition of the initial board of
directors of Allegiance Subsidiary Bank to be effective as of the effective time of the Bank Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
certificate of formation and bylaws of Allegiance Subsidiary Bank will be amended effective as of the effective time of the Bank Merger
as necessary to be consistent in all respects with the foregoing provisions of this <U>Section&nbsp;6.11</U>.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acquisition
Proposals</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
party agrees that it will not, and will cause each of its Subsidiaries and its and their respective officers, directors, employees, agents,
advisors and representatives (collectively, &ldquo;<U>Representatives</U>&rdquo;) not to, directly or indirectly (i)&nbsp;initiate, solicit,
knowingly encourage or knowingly facilitate any inquiries or proposals with respect to any Acquisition Proposal; (ii)&nbsp;engage or
participate in any negotiations with any person concerning any Acquisition Proposal; (iii)&nbsp;provide any confidential or nonpublic
information or data to, have or participate in any discussions with any person relating to any Acquisition Proposal; or (iv)&nbsp;unless
this Agreement has been terminated in accordance with its terms, approve or enter into any term sheet, letter of intent, commitment,
memorandum of understanding, agreement in principle, acquisition agreement, merger agreement or other agreement (whether written or oral,
binding or nonbinding) (other than a confidentiality agreement referred to and entered into in accordance with this <U>Section&nbsp;6.11(a)</U>)
in connection with or relating to any Acquisition Proposal. Notwithstanding the foregoing, in the event that after the date of this Agreement
and prior to the receipt of the Requisite Allegiance Vote, in the case of Allegiance, or the Requisite CBTX Vote, in the case of CBTX,
a party receives an unsolicited <I>bona fide </I>written Acquisition Proposal, such party may, and may permit its Subsidiaries and its
and its Subsidiaries&rsquo; Representatives to, furnish or cause to be furnished confidential or nonpublic information or data and participate
in such negotiations or discussions with the person making the Acquisition Proposal if the Board of Directors of such party concludes
in good faith (after receiving the advice of its outside counsel, and with respect to financial matters, its financial advisors) that
failure to take such actions would be more likely than not to result in a violation of its fiduciary duties under applicable law&#894;
<U>provided</U>, that, prior to furnishing any confidential or nonpublic information permitted to be provided pursuant to this sentence,
such party shall have entered into a confidentiality agreement with the person making such Acquisition Proposal on terms no less favorable
to it than the Confidentiality Agreement, which confidentiality agreement shall not provide such person with any exclusive right to negotiate
with such party. Each party will, and will cause its Representatives to, immediately cease and cause to be terminated any activities,
discussions or negotiations conducted before the date of this Agreement with any person other than CBTX or Allegiance, as applicable,
with respect to any Acquisition Proposal. Each party will promptly (within twenty-four (24) hours) advise the other party following receipt
of any Acquisition Proposal or any inquiry which could reasonably be expected to lead to an Acquisition Proposal, and the substance thereof
(including the terms and conditions of and the identity of the person making such inquiry or Acquisition Proposal), will provide the
other party with an unredacted copy of any such Acquisition Proposal and any draft agreements, proposals or other materials received
in connection with any such inquiry or Acquisition Proposal, and will keep the other party apprised of any related developments, discussions
and negotiations on a current basis, including any amendments to or revisions of the terms of such inquiry or Acquisition Proposal. Each
party shall use its reasonable best efforts to enforce any existing confidentiality or standstill agreements to which it or any of its
Subsidiaries is a party in accordance with the terms thereof. As used in this Agreement, &ldquo;<U>Acquisition Proposal</U>&rdquo; shall
mean, with respect to Allegiance or CBTX, as applicable, other than the transactions contemplated by this Agreement, any offer, proposal
or inquiry relating to, or any third-party indication of interest in, (i)&nbsp;any acquisition or purchase, direct or indirect, of twenty-five
percent (25%) or more of the consolidated assets of a party and its Subsidiaries or twenty-five percent (25%) or more of any class of
equity or voting securities of a party or its Subsidiaries whose assets, individually or in the aggregate, constitute twenty-five percent
(25%) or more of the consolidated assets of the party; (ii)&nbsp;any tender offer (including a self-tender offer) or exchange offer that,
if consummated, would result in such third party beneficially owning twenty-five percent (25%) or more of any class of equity or voting
securities of a party or its Subsidiaries whose assets, individually or in the aggregate, constitute twenty-five percent (25%) or more
of the consolidated assets of the party; or (iii)&nbsp;a merger, consolidation, share exchange, business combination, reorganization,
recapitalization, liquidation, dissolution or other similar transaction involving a party or its Subsidiaries whose assets, individually
or in the aggregate, constitute twenty-five percent (25%) or more of the consolidated assets of the party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
contained in this Agreement shall prevent a party or its Board of Directors from complying with Rule&nbsp;14d-9 and Rule&nbsp;14e-2 under
the Exchange Act with respect to an Acquisition Proposal&#894; <U>provided</U>, that such rules&nbsp;will in no way eliminate or modify
the effect that any action pursuant to such rules&nbsp;would otherwise have under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Public
Announcements</U>. CBTX and Allegiance agree that the initial press release with respect to the execution and delivery of this Agreement
shall be a release mutually agreed to by the parties. Thereafter, each of the parties agrees that no public release or announcement or
statement concerning this Agreement or the transactions contemplated hereby shall be issued by any party without the prior written consent
of the other party (which consent shall not be unreasonably withheld, conditioned or delayed), except (i)&nbsp;as required by applicable
law or the rules&nbsp;or regulations of any applicable Governmental Entity or stock exchange to which the relevant party is subject,
in which case the party required to make the release or announcement shall consult with the other party about, and allow the other party
reasonable time to comment on, such release or announcement in advance of such issuance or (ii)&nbsp;for such releases, announcements
or statements that are consistent with other such releases, announcement or statements made after the date of this Agreement in compliance
with this <U>Section&nbsp;6.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Change
of Method</U>. CBTX and Allegiance shall be empowered, upon their mutual agreement, at any time prior to the Effective Time, to change
the method or structure of effecting the transactions contemplated by this Agreement (including the provisions of <U>ARTICLE&nbsp;I</U>),
if and to the extent they both deem such change to be necessary, appropriate or desirable&#894; <U>provided</U>, <U>however</U>, that
no such change shall (i)&nbsp;alter or change the Exchange Ratio or the number of shares of CBTX Common Stock received by holders of
Allegiance Common Stock in exchange for each share of Allegiance Common Stock; (ii)&nbsp;have a material adverse effect on the Tax treatment
of Allegiance&rsquo;s shareholders or CBTX&rsquo;s shareholders pursuant to this Agreement; (iii)&nbsp;have a material adverse effect
on the Tax treatment of Allegiance or CBTX pursuant to this Agreement; or (iv)&nbsp;materially impede or delay the consummation of the
transactions contemplated by this Agreement in a timely manner. The parties agree to reflect any such change in an appropriate amendment
to this Agreement executed by both parties in accordance with <U>Section&nbsp;9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restructuring
Efforts</U>. If either CBTX or Allegiance shall have failed to obtain the Requisite CBTX Vote or the Requisite Allegiance Vote at the
duly convened CBTX Meeting or Allegiance Meeting, as applicable, or any adjournment or postponement thereof, each of the parties shall
in good faith use its reasonable best efforts to negotiate a restructuring of the transactions provided for herein (it being understood
that neither party shall have any obligation to alter or change any material terms, including the Exchange Ratio or the amount or kind
of the consideration to be issued to holders of the capital stock of Allegiance as provided for in this Agreement, or any term that would
have a material adverse effect on the Tax treatment of the transactions contemplated hereby, in a manner adverse to such party or its
shareholders) and/or resubmit this Agreement and the transactions contemplated hereby (or as restructured pursuant to this <U>Section&nbsp;6.15</U>)
to its respective shareholders for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Takeover
Restrictions</U>. None of CBTX, Allegiance or their respective Boards of Directors shall take any action that would cause any Takeover
Restriction to become applicable to this Agreement, the Merger, or any of the other transactions contemplated hereby, and each shall take
all necessary steps to exempt (or ensure the continued exemption of) the Merger and the other transactions contemplated hereby from any
applicable Takeover Restriction now or hereafter in effect. If any Takeover Restriction may become, or may purport to be, applicable to
the transactions contemplated hereby, each party and the members of its Board of Directors will grant such approvals and take such actions
as are necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms contemplated
hereby and otherwise act to eliminate or minimize the effects of any Takeover Restriction on any of the transactions contemplated by this
Agreement, including, if necessary, challenging the validity or applicability of any such Takeover Restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of Certain Indebtedness</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the Effective Time, CBTX shall assume the due and punctual performance and observance of the covenants to be performed by Allegiance
in connection with the (i)&nbsp;Allegiance Trust Preferred Securities, which consist of junior subordinated debentures with an aggregate
original principal amount of $11.3 million and a current carrying value of $9.7 million at September&nbsp;30, 2021 and (ii)&nbsp;$60.0
million aggregate principal amount of Fixed-to-Floating Rate Subordinated Notes due October&nbsp;1, 2029. In connection therewith, Allegiance
and CBTX shall cooperate and use reasonable best efforts to execute and deliver any supplemental indentures, officer&rsquo;s certificates
or other documents, and the parties hereto shall cooperate and use reasonable best efforts to provide any opinion of counsel to the trustee
thereof, required to make such assumption effective as of the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Effective Time, CBTX and Allegiance shall cooperate with each other and use their reasonable best efforts to terminate at the
Effective Time either the Second Amended and Restated Loan Agreement between CBTX, as borrower, and Frost Bank, as lender, dated as of
December&nbsp;13, 2019 (the &ldquo;<U>CBTX Credit Agreement</U>&rdquo;) or the Credit Agreement by and among Allegiance, as borrower,
and Prosperity Bank, as lender, dated as of December&nbsp;22, 2014 (the &ldquo;<U>Allegiance Credit Agreement</U>&rdquo;). Promptly after
the date of this Agreement, Allegiance and CBTX shall agree whether to terminate the CBTX Credit Agreement or the Allegiance Credit Agreement
(such credit facility to be terminated, the &ldquo;<U>Terminated Credit Agreement</U>&rdquo;). Thereafter, CBTX or Allegiance, as applicable
(the &ldquo;<U>Terminated Credit Agreement Party</U>&rdquo;) shall deliver all notices and take all other actions to facilitate the termination
at the Effective Time of all commitments in respect of the Terminated Credit Agreement and the repayment in full on the Closing Date
of all obligations, and releases of all Liens securing obligations, in respect of the indebtedness thereunder&#894; <U>provided</U>,
that the Terminated Credit Agreement Party shall provide any funds required to effect all such repayments at or prior to the Closing.
In furtherance and not in limitation of the foregoing, the Terminated Credit Agreement Party shall use commercially reasonable efforts
to deliver to the other party to this Agreement at least two business days prior to the Closing Date an executed payoff letter with respect
to the Terminated Credit Agreement in form and substance customary for transactions of this type, which payoff letter shall, among other
things, include the payoff amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exemption
from Liability Under Section&nbsp;16(b)</U>. Allegiance and CBTX agree that, in order to most effectively compensate and retain Allegiance
Insiders, both prior to and after the Effective Time, it is desirable that Allegiance Insiders not be subject to a risk of liability
under Section&nbsp;16(b)&nbsp;of the Exchange Act to the fullest extent permitted by applicable law in connection with the conversion
of shares of Allegiance Common Stock into shares of CBTX Common Stock in the Merger and the conversion of Allegiance Equity Awards into
corresponding CBTX Equity Awards in the Merger consistent with <U>Section&nbsp;1.7</U> of this Agreement, and for that compensatory and
retentive purpose agree to the provisions of this <U>Section&nbsp;6.18</U>. Allegiance shall deliver to CBTX in a reasonably timely fashion
prior to the Effective Time accurate information regarding those officers and directors of Allegiance subject to the reporting requirements
of Section&nbsp;16(a)&nbsp;of the Exchange Act (the &ldquo;<U>Allegiance Insiders</U>&rdquo;), and the Board of Directors of CBTX and
of Allegiance, or a committee of non-employee directors thereof (as such term is defined for purposes of Rule&nbsp;16b-3(d)&nbsp;under
the Exchange Act), shall reasonably promptly thereafter, and in any event prior to the Effective Time, take all such steps as may be
required to cause (in the case of Allegiance) any dispositions of Allegiance Common Stock or Allegiance Equity Awards by the Allegiance
Insiders, and (in the case of CBTX) any acquisitions of CBTX Common Stock or CBTX Equity Awards by any Allegiance Insiders who, immediately
following the Merger, will be officers or directors of the Surviving Entity subject to the reporting requirements of Section&nbsp;16(a)&nbsp;of
the Exchange Act, in each case pursuant to the transactions contemplated by this Agreement, to be exempt from liability pursuant to Rule&nbsp;16b-3
under the Exchange Act to the fullest extent permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Tax Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX shall, and shall cause their respective Subsidiaries to, take all actions reasonably necessary to cause the Merger
to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code, including by reporting consistently
for all U.S. federal, state, and local income Tax or other purposes. Without limiting the generality of the foregoing, neither Allegiance,
CBTX, nor any of their respective Subsidiaries shall take any action, or fail to take any action, that would reasonably be expected to
cause the Merger to fail to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX will cooperate with one another to facilitate the issuance of the opinions of counsel referred to in Section&nbsp;7.2(c)&nbsp;and
Section&nbsp;7.3(c). In connection therewith, (i)&nbsp;Allegiance shall deliver to each such counsel a duly executed certificate containing
such representations, warranties and covenants as shall be reasonably necessary or appropriate to enable such counsel to render the opinion
described in Section&nbsp;7.2(c)&nbsp;and Section&nbsp;7.3(c), as applicable (the &ldquo;<U>Allegiance Tax Certificate</U>&rdquo;) and
(ii)&nbsp;the CBTX shall deliver to each such counsel a duly executed certificate containing such representations, warranties and covenants
as shall be reasonably necessary or appropriate to enable such counsel to render the opinion described in Section&nbsp;7.2(c)&nbsp;and
Section&nbsp;7.3(c), as applicable (the &ldquo;<U>CBTX Tax Certificate</U>&rdquo;). Each of Allegiance and CBTX will comply, to the extent
reasonably expected to be necessary to cause the Merger to qualify as a reorganization under the provisions of Section&nbsp;368(a)&nbsp;of
the Code, and with all covenants contained in the Allegiance Tax Certificate and CBTX Tax Certificate, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX further agrees, upon request, to use their commercially reasonable efforts to obtain any certificate or other
document from any Governmental Entity or any other person that it is legally entitled to obtain as may be necessary to mitigate, reduce
or eliminate any Tax that could be imposed with respect to the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX shall promptly notify the other of the receipt of any written notice of any pending or threatened Tax proceeding
or claim against or with respect to Allegiance or CBTX, as the case may be, or any of their respective Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limiting the provisions of this <U>Section&nbsp;6.19</U>, Allegiance and CBTX shall comply with the recordkeeping and information reporting
requirements set forth in Treasury Regulation Section&nbsp;1.368-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;VII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
CONDITIONS PRECEDENT</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to Each Party&rsquo;s Obligation to Effect the Merger</U>. The respective obligations of the parties to effect the Merger shall be subject
to the satisfaction at or prior to the Effective Time of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shareholder
Approvals</U>. This Agreement shall have been approved by the shareholders of Allegiance by the Requisite Allegiance Vote. This Agreement,
the issuance of CBTX Common Stock in the Merger and the CBTX Certificate Amendment shall have been approved by the shareholders of CBTX
by the Requisite CBTX Vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>NASDAQ
Listing</U>. The shares of CBTX Common Stock that shall be issuable pursuant to this Agreement shall have been authorized for listing
on the NASDAQ, subject to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulatory
Approvals</U>. (i)&nbsp;All Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all
statutory waiting periods in respect thereof shall have expired or been terminated and (ii)&nbsp;no such Requisite Regulatory Approval
shall have resulted in the imposition of any Materially Burdensome Regulatory Condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>S-4</U>.
The S-4 shall have become effective under the Securities Act and no stop order suspending the effectiveness of the S-4 shall have been
issued, and no proceedings for such purpose shall have been initiated or threatened by the SEC and not withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Injunctions or Restraints&#894; Illegality</U>. No order, injunction or decree issued by any court or Governmental Entity of competent
jurisdiction or other legal restraint or prohibition preventing the consummation of the Merger, the Bank Merger or any of the other transactions
contemplated by this Agreement shall be in effect. No law, statute, rule, regulation, order, injunction or decree shall have been enacted,
entered, promulgated or enforced by any Governmental Entity which prohibits or makes illegal consummation of the Merger, the Bank Merger
or any of the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to Obligations of Allegiance</U>. The obligation of Allegiance to effect the Merger is also subject to the satisfaction, or waiver by
Allegiance, at or prior to the Effective Time, of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The representations and warranties of CBTX set forth in <U>Section&nbsp;3.2(a)</U>&nbsp;and <U>Section&nbsp;3.8(a)</U>&nbsp;(in
each case after giving effect to the lead-in to <U>ARTICLE&nbsp;III</U>) shall be true and correct (other than, in the case of <U>Section&nbsp;3.2(a)</U>,
such failures to be true and correct as are <I>de minimis</I>) in each case as of the date of this Agreement and as of the Closing Date
as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in
which case as of such earlier date), and the representations and warranties of CBTX set forth in <U>Section&nbsp;3.1(a)</U>, <U>Section&nbsp;3.1(b)</U>&nbsp;(but
only with respect to CBTX Subsidiary Bank), <U>Section&nbsp;3.2(b)</U>&nbsp;(but only with respect to CBTX Subsidiary Bank), <U>Section&nbsp;3.3(a)</U>&nbsp;and
<U>Section&nbsp;3.7</U> (read without giving effect to any qualification as to materiality or Material Adverse Effect set forth in such
representations or warranties but, in each case, after giving effect to the lead-in to <U>ARTICLE&nbsp;III</U>) shall be true and correct
in all material respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date (except
to the extent such representations and warranties speak as of an earlier date, in which case as of such earlier date). All other representations
and warranties of CBTX set forth in this Agreement (read without giving effect to any qualification as to materiality or Material Adverse
Effect set forth in such representations or warranties but, in each case, after giving effect to the lead-in to <U>ARTICLE&nbsp;III</U>)
shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made on and as of the
Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case as of such earlier
date)&#894; <U>provided</U>, <U>however</U>, that for purposes of this sentence, such representations and warranties shall be deemed
to be true and correct unless the failure or failures of such representations and warranties to be so true and correct, either individually
or in the aggregate, and without giving effect to any qualification as to materiality or Material Adverse Effect set forth in such representations
or warranties, has had or would reasonably be expected to have a Material Adverse Effect on CBTX or the Surviving Entity. Allegiance
shall have received a certificate dated as of the Closing Date and signed on behalf of CBTX by the Chief Executive Officer or the Chief
Financial Officer of CBTX to the foregoing effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Performance
of Obligations of CBTX</U>. CBTX shall have performed in all material respects the obligations, covenants and agreements required to
be performed by it under this Agreement at or prior to the Closing Date, including, but not limited to, the covenant to take all actions
necessary to adopt the CBTX Bylaw Amendment and the resolutions referenced therein and to effect the requirements referenced therein
that are to be effected as of the Effective Time, and Allegiance shall have received a certificate dated as of the Closing Date and signed
on behalf of CBTX by the Chief Executive Officer or the Chief Financial Officer of CBTX to such effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Federal
Tax Opinion</U>. Allegiance shall have received the opinion of Bracewell LLP, in form and substance reasonably satisfactory to Allegiance,
dated as of the Closing Date, to the effect that, on the basis of facts, representations and assumptions set forth or referred to in
such opinion, the Merger will qualify as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code. In
rendering such opinion, counsel may require and rely upon representations contained in the Allegiance Tax Certificate and the CBTX Tax
Certificate, reasonably satisfactory in form and substance to such counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investigation</U>.
With respect to the investigation of the BSA/AML Program of CBTX Bank by the Financial Crimes Enforcement Network of the U.S. Department
of Treasury (&ldquo;<U>FinCEN</U>&rdquo;) pending as of the date hereof (the &ldquo;<U>FinCEN Matter</U>&rdquo;), the FinCEN Matter has
been settled with FinCEN and all monetary penalties assessed or issued by FinCEN or the OCC shall have been paid or accrued by CBTX Bank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to Obligations of CBTX</U>. The obligation of CBTX to effect the Merger is also subject to the satisfaction, or waiver by CBTX, at or
prior to the Effective Time of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The representations and warranties of Allegiance set forth in <U>Section&nbsp;4.2(a)</U>&nbsp;and <U>Section&nbsp;4.8(a)</U>&nbsp;(in
each case, after giving effect to the lead-in to <U>ARTICLE&nbsp;IV</U>) shall be true and correct (other than, in the case of <U>Section&nbsp;4.2(a)</U>,
such failures to be true and correct as are <I>de minimis</I>) in each case as of the date of this Agreement and as of the Closing Date
as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in
which case as of such earlier date), and the representations and warranties of Allegiance set forth in <U>Section&nbsp;4.1(a)</U>, <U>Section&nbsp;4.1(b)</U>&nbsp;(but
only with respect to Allegiance Subsidiary Bank), <U>Section&nbsp;4.2(b)</U>&nbsp;(but only with respect to Allegiance Subsidiary Bank),
<U>Section&nbsp;4.3(a)</U>&nbsp;and <U>Section&nbsp;4.7</U> (read without giving effect to any qualification as to materiality or Material
Adverse Effect set forth in such representations or warranties but, in each case, after giving effect to the lead-in to <U>ARTICLE&nbsp;IV</U>)
shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as though made on and
as of the Closing Date (except to the extent such representations and warranties speak as of an earlier date, in which case as of such
earlier date). All other representations and warranties of Allegiance set forth in this Agreement (read without giving effect to any
qualification as to materiality or Material Adverse Effect set forth in such representations or warranties but, in each case, after giving
effect to the lead-in to <U>ARTICLE&nbsp;IV</U>) shall be true and correct in all respects as of the date of this Agreement and as of
the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of an
earlier date, in which case as of such earlier date), <U>provided</U>, <U>however</U>, that for purposes of this sentence, such representations
and warranties shall be deemed to be true and correct unless the failure or failures of such representations and warranties to be so
true and correct, either individually or in the aggregate, and without giving effect to any qualification as to materiality or Material
Adverse Effect set forth in such representations or warranties, has had or would reasonably be expected to have a Material Adverse Effect
on Allegiance. CBTX shall have received a certificate dated as of the Closing Date and signed on behalf of Allegiance by the Chief Executive
Officer or the Chief Financial Officer of Allegiance to the foregoing effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Performance
of Obligations of Allegiance</U>. Allegiance shall have performed in all material respects the obligations, covenants and agreements
required to be performed by it under this Agreement at or prior to the Closing Date, and CBTX shall have received a certificate dated
as of the Closing Date and signed on behalf of Allegiance by the Chief Executive Officer or the Chief Financial Officer of Allegiance
to such effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Federal
Tax Opinion</U>. CBTX shall have received the opinion of Norton Rose Fulbright US LLP, in form and substance reasonably satisfactory
to CBTX, dated as of the Closing Date, to the effect that, on the basis of facts, representations and assumptions set forth or referred
to in such opinion, the Merger will qualify as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code.
In rendering such opinion, counsel may require and rely upon and may incorporate by reference representations and covenants, including
those contained in the Allegiance Tax Certificate and CBTX Tax Certificate, and such other information reasonably requested by and provided
to it by Allegiance and/or CBTX for purposes of rendering such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;VIII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
TERMINATION AND AMENDMENT</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.
This Agreement may be terminated at any time prior to the Effective Time, whether before or after receipt of the Requisite CBTX Vote
or the Requisite Allegiance Vote:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
mutual written consent of Allegiance and CBTX&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
either Allegiance or CBTX if any Governmental Entity that must grant a Requisite Regulatory Approval has denied approval of the Merger
or the Bank Merger and such denial has become final and nonappealable or any Governmental Entity of competent jurisdiction shall have
issued a final and nonappealable order, injunction, decree or other legal restraint or prohibition permanently enjoining or otherwise
prohibiting or making illegal the consummation of the Merger or the Bank Merger, unless the failure to obtain a Requisite Regulatory
Approval shall be due to the failure of the party seeking to terminate this Agreement to perform or observe the obligations, covenants
and agreements of such party set forth herein&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
either Allegiance or CBTX if the Merger shall not have been consummated on or before August&nbsp;2, 2022 (the &ldquo;<U>Termination Date</U>&rdquo;),
unless the failure of the Closing to occur by such date shall be due to the failure of the party seeking to terminate this Agreement
to perform or observe the obligations, covenants and agreements of such party set forth herein; <U>provided</U>,&nbsp;<U>however</U>,
that if the conditions to the Closing set forth in&nbsp;<U>Section&nbsp;7.1(c)</U>&nbsp;or&nbsp;<U>Section&nbsp;7.1(e)</U>&nbsp;(to the
extent related to a Requisite Regulatory Approval) have not been satisfied or waived on or prior to such date but all other conditions
to Closing set forth in&nbsp;<U>Article&nbsp;VII</U>&nbsp;have been satisfied or waived (other than those conditions that by their nature
can only be satisfied or waived at the Closing (so long as such conditions are reasonably capable of being satisfied)), the Termination
Date will be automatically extended to October&nbsp;31, 2022, and such date, as so extended, shall be the &ldquo;<U>Termination Date</U>&rdquo;&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
either Allegiance or CBTX (<U>provided</U>, that the terminating party is not then in material breach of any representation, warranty,
obligation, covenant or other agreement contained herein) if there shall have been a breach of any of the obligations, covenants or agreements
or any of the representations or warranties (or any such representation or warranty shall cease to be true) set forth in this Agreement
on the part of CBTX, in the case of a termination by Allegiance, or Allegiance, in the case of a termination by CBTX, which breach or
failure to be true, either individually or in the aggregate with all other breaches by such party (or failures of such representations
or warranties to be true), would constitute, if occurring or continuing on the Closing Date, the failure of a condition set forth in
<U>Section&nbsp;7.2</U>, in the case of a termination by Allegiance, or <U>Section&nbsp;7.3</U>, in the case of a termination by CBTX,
and which is not cured within forty-five (45) days following written notice to CBTX, in the case of a termination by Allegiance, or Allegiance,
in the case of a termination by CBTX, or by its nature or timing cannot be cured during such period (or such fewer days as remain prior
to the Termination Date)&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
CBTX prior to such time as the Requisite Allegiance Vote is obtained, if (i)&nbsp;Allegiance or the Board of Directors of Allegiance
shall have made a Recommendation Change or (ii)&nbsp;Allegiance or the Board of Directors of Allegiance shall have breached its obligations
under <U>Section&nbsp;6.3</U> or <U>Section&nbsp;6.11(a)</U>&nbsp;in any material respect&#894; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
Allegiance prior to such time as the Requisite CBTX Vote is obtained, if (i)&nbsp;CBTX or the Board of Directors of CBTX shall have made
a Recommendation Change or (ii)&nbsp;CBTX or the Board of Directors of CBTX shall have breached its obligations under <U>Section&nbsp;6.3
</U>or <U>Section&nbsp;6.11(a)</U>&nbsp;in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
Allegiance, if (i)&nbsp;the civil money penalties assessed against CBTX Bank by FinCEN and the OCC in the FinCEN Matter exceed, in the
aggregate, the top end of the range disclosed in CBTX&rsquo;s September&nbsp;30, 2021 10-Q filed with the SEC by 0.67% of the combined
market capitalization of Allegiance and CBTX as of market close on November&nbsp;3, 2021, as reported by NASDAQ, or (ii)&nbsp;if the
condition set forth in <U>Section&nbsp;7.2(d)</U>&nbsp;is not satisfied (or waived by Allegiance in its sole discretion) by May&nbsp;31,
2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Effect
of Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event of termination of this Agreement by either Allegiance or CBTX as provided in <U>Section&nbsp;8.1</U>, this Agreement shall
forthwith become void and have no effect, and none of Allegiance, CBTX, any of their respective Subsidiaries or any of the officers or
directors of any of them shall have any liability of any nature whatsoever hereunder, or in connection with the transactions contemplated
hereby, except that (i)&nbsp;<U>Section&nbsp;6.2(b)</U>&nbsp;(Access to Information&#894; Confidentiality), <U>Section&nbsp;6.13</U>
(Public Announcements), this <U>Section&nbsp;8.2</U> and <U>ARTICLE&nbsp;IX</U> shall survive any termination of this Agreement, and
(ii)&nbsp;notwithstanding anything to the contrary contained in this Agreement, neither Allegiance nor CBTX shall be relieved or released
from any liabilities or damages arising out of its willful and material breach of any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that after the date of this Agreement and prior to the termination of this Agreement, a <I>bona fide </I>Acquisition Proposal
(i)&nbsp;shall have been communicated to or otherwise made known to the Board of Directors or senior management of CBTX or shall have
been made directly to the shareholders of CBTX or (ii)&nbsp;any person shall have publicly announced (and not withdrawn at least two
(2)&nbsp;business days prior to the CBTX Meeting) an Acquisition Proposal, in each case with respect to CBTX and (A)&nbsp;(x)&nbsp;thereafter
this Agreement is terminated by either Allegiance or CBTX pursuant to <U>Section&nbsp;8.1(c)</U>&nbsp;without the Requisite CBTX Vote
having been obtained (and all other conditions set forth in <U>Section&nbsp;7.1</U> and <U>Section&nbsp;7.3</U> were satisfied or were
capable of being satisfied prior to such termination) or (y)&nbsp;thereafter this Agreement is terminated by Allegiance pursuant to <U>Section&nbsp;8.1(d)</U>&nbsp;as
a result of a willful breach, and (B)&nbsp;prior to the date that is twelve (12) months after the date of such termination, CBTX enters
into a definitive agreement or consummates a transaction with respect to an Acquisition Proposal (whether or not the same Acquisition
Proposal as that referred to above), then CBTX shall, on the earlier of the date it enters into such definitive agreement and the date
of consummation of such transaction, pay Allegiance, by wire transfer of same-day funds, a fee equal to $32,500,000 (the &ldquo;<U>Termination
Fee</U>&rdquo;)&#894; <U>provided</U>, that for purposes of this <U>Section&nbsp;8.2(c)</U>, all references in the definition of Acquisition
Proposal to &ldquo;twenty-five percent (25%)&rdquo; shall instead refer to &ldquo;fifty percent (50%).&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that this Agreement is terminated by Allegiance pursuant to <U>Section&nbsp;8.1(f)</U>, then CBTX shall pay Allegiance, by
wire transfer of same-day funds, the Termination Fee within two (2)&nbsp;business days of the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that after the date of this Agreement and prior to the termination of this Agreement, a <I>bona fide </I>Acquisition Proposal
shall (i)&nbsp;have been communicated to or otherwise made known to the Board of Directors or senior management of Allegiance or shall
have been made directly to the shareholders of Allegiance or (ii)&nbsp;any person shall have publicly announced (and not withdrawn at
least two (2)&nbsp;business days prior to the Allegiance Meeting) an Acquisition Proposal, in each case with respect to Allegiance and
(A)&nbsp;(x)&nbsp;thereafter this Agreement is terminated by either Allegiance or CBTX pursuant to <U>Section&nbsp;8.1(c)</U>&nbsp;without
the Requisite Allegiance Vote having been obtained (and all other conditions set forth in <U>Section&nbsp;7.1</U> and <U>Section&nbsp;7.2</U>
were satisfied or were capable of being satisfied prior to such termination) or (y)&nbsp;thereafter this Agreement is terminated by CBTX
pursuant to <U>Section&nbsp;8.1(d)</U>&nbsp;as a result of a willful breach, and (B)&nbsp;prior to the date that is twelve (12) months
after the date of such termination, Allegiance enters into a definitive agreement or consummates a transaction with respect to an Acquisition
Proposal (whether or not the same Acquisition Proposal as that referred to above), then Allegiance shall, on the earlier of the date it
enters into such definitive agreement and the date of consummation of such transaction, pay CBTX the Termination Fee by wire transfer
of same-day funds&#894; <U>provided</U>, that for purposes of this <U>Section&nbsp;8.2(d)</U>, all references in the definition of Acquisition
Proposal to &ldquo;twenty-five percent (25%)&rdquo; shall instead refer to &ldquo;fifty percent (50%).&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that this Agreement is terminated by CBTX pursuant to <U>Section&nbsp;8.1(e)</U>, then Allegiance shall pay CBTX, by wire transfer
of same-day funds, the Termination Fee within two (2)&nbsp;business days of the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that this Agreement is terminated by Allegiance pursuant to <U>Section&nbsp;8.1(g)</U>, then CBTX shall pay to Allegiance,
by wire transfer of same-day funds, an amount equal to all of Allegiance&rsquo;s documented expenses incident to the negotiation, preparation,
execution, delivery and performance of this Agreement, including in respect of Allegiance&rsquo;s legal and financial advisors (the &ldquo;<U>Expense
Reimbursement</U>&rdquo;) within two (2)&nbsp;days of delivery to CBTX of such documented expenses; provided, however, that the Expense
Reimbursement shall not exceed $1,000,000 in the aggregate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary herein, but without limiting the right of any party to recover liabilities or damages to the extent permitted
herein, in no event shall either party be required to pay the Termination Fee more than once.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Allegiance and CBTX acknowledges that the agreements contained in this <U>Section&nbsp;8.2</U> are an integral part of the transactions
contemplated by this Agreement, and that, without these agreements, the other party would not enter into this Agreement&#894; accordingly,
if Allegiance or CBTX, as the case may be, fails promptly to pay the amount due pursuant to this <U>Section&nbsp;8.2</U>, and, in order
to obtain such payment, the other party commences a suit which results in a judgment against the non-paying party for the Termination
Fee, the Expense Reimbursement or any portion thereof, such non-paying party shall pay the costs and expenses of the other party (including
attorneys&rsquo; fees and expenses) in connection with such suit. In addition, if Allegiance or CBTX, as the case may be, fails to pay
the amounts payable pursuant to this <U>Section&nbsp;8.2</U>, then such party shall pay interest on such overdue amounts at a rate per
annum equal to the &ldquo;prime rate&rdquo; published in <I>The Wall Street Journal </I>on the date on which such payment was required
to be made for the period commencing as of the date that such overdue amount was originally required to be paid and ending on the date
that such overdue amount is actually paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>ARTICLE&nbsp;IX</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
GENERAL PROVISIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
Subject to compliance with applicable law, this Agreement may be amended by the parties hereto at any time before or after the receipt
of the Requisite Allegiance Vote or the Requisite CBTX Vote&#894; <U>provided</U>, <U>howeve</U>r, that after the receipt of the Requisite
Allegiance Vote or the Requisite CBTX Vote, there may not be, without further approval of the shareholders of Allegiance or CBTX, as
applicable, any amendment of this Agreement that requires such further approval under applicable law. This Agreement may not be amended,
modified or supplemented except by an instrument in writing signed on behalf of each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Extension&#894;
Waiver</U>. At any time prior to the Effective Time, each of the parties hereto may, to the extent legally allowed, (a)&nbsp;extend the
time for the performance of any of the obligations or other acts of the other party hereto; (b)&nbsp;waive any inaccuracies in the representations
and warranties of the other party contained herein or in any document delivered by such other party pursuant hereto and (c)&nbsp;waive
compliance with any of the agreements or satisfaction of any conditions for its benefit contained herein&#894; <U>provided</U>, <U>however</U>,
that after the receipt of the Requisite Allegiance Vote or the Requisite CBTX Vote, there may not be, without further approval of the
shareholders of Allegiance or CBTX, as applicable, any extension or waiver of this Agreement or any portion thereof that requires such
further approval under applicable law. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only
if set forth in a written instrument signed on behalf of such party, but such extension or waiver or failure to insist on strict compliance
with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or
other failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonsurvival
of Representations, Warranties and Agreements</U>. None of the representations, warranties, obligations, covenants and agreements in this
Agreement (or in any certificate delivered pursuant to this Agreement) shall survive the Effective Time, except for <U>Section&nbsp;6.6(a)</U>&nbsp;and
for those other obligations, covenants and agreements contained herein which by their terms apply in whole or in part after the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Expenses</U>.
Except as otherwise expressly provided in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such expense&#894; <U>provided</U>, <U>however</U>, that the costs and expenses
of printing and mailing the Joint Proxy Statement and all filing and other fees paid to Governmental Entities in connection with the
Merger and the other transactions contemplated hereby shall be borne equally by Allegiance and CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally, by e-mail transmission
(with confirmation), mailed by registered or certified mail (return receipt requested) or delivered by an express courier (with confirmation)
to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
to CBTX, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">CBTX,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">9 Greenway Plaza, Suite&nbsp;110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Houston, Texas 77046</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Robert R. Franklin,&nbsp;Jr., Chairman, President
and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">E-mail: [REDACTED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>With a copy (which shall not constitute
notice) to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Chet A. Fenimore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Fenimore Kay Harrison LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">812 San Antonio Street, Suite&nbsp;600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Austin, Texas 78701</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: cfenimore@fkhpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Michael G. Keeley</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Norton Rose Fulbright US LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2200 Ross Avenue, Suite&nbsp;3600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Dallas, Texas 75201</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: mike.keeley@nortonrosefulbright.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
to Allegiance, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Allegiance Bancshares,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">8847 West Sam Houston Parkway, N., Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Houston, Texas 77040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Steven F. Retzloff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: [REDACTED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>With a copy (which shall not constitute
notice) to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Jason M. Jean</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Bracewell LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">711 Louisiana St., Suite&nbsp;2300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Houston, Texas 77002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: jason.jean@bracewell.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Joshua T. McNulty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Bracewell LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">1445 Ross Avenue, Suite&nbsp;3800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Dallas, Texas 75202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: josh.mcnulty@bracewell.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Interpretation</U>.
The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent
or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. When a reference is made
in this Agreement to Articles, Sections, Exhibits or Schedules, such reference shall be to an Article&nbsp;or Section&nbsp;of or Exhibit&nbsp;or
Schedule to this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &ldquo;include,&rdquo;
&ldquo;includes&rdquo; or &ldquo;including&rdquo; are used in this Agreement, they shall be deemed to be followed by the words &ldquo;without
limitation.&rdquo; The word &ldquo;or&rdquo; shall not be exclusive. References to &ldquo;the date hereof&rdquo; shall mean the date
of this Agreement. As used in this Agreement, the &ldquo;knowledge&rdquo; of CBTX means the actual knowledge of any of the officers of
CBTX listed on <U>Section&nbsp;9.6</U> of the CBTX Disclosure Schedule, and the &ldquo;knowledge&rdquo; of Allegiance means the actual
knowledge of any of the officers of Allegiance listed on <U>Section&nbsp;9.6</U> of the Allegiance Disclosure Schedule. As used herein,
(i)&nbsp;the term &ldquo;person&rdquo; means any individual, corporation (including not-for-profit), general or limited partnership,
limited liability company, joint venture, estate, trust, association, organization, Governmental Entity or other entity of any kind or
nature; (ii)&nbsp;an &ldquo;affiliate&rdquo; of a specified person is any person that directly or indirectly controls, is controlled
by, or is under common control with, such specified person; and (iii)&nbsp;the term &ldquo;made available&rdquo; means any document or
other information that was (a)&nbsp;provided by one party or its representatives to the other party and its representatives at least
one (1)&nbsp;day prior to the date hereof, (b)&nbsp;included in the virtual data room of a party at least one (1)&nbsp;day prior to the
date hereof or (c)&nbsp;filed by a party with the SEC and publicly available on EDGAR at least one (1)&nbsp;day prior to the date hereof.
The CBTX Disclosure Schedule and the Allegiance Disclosure Schedule, as well as all other schedules and all exhibits hereto, shall be
deemed part of this Agreement and included in any reference to this Agreement. Nothing contained herein shall require any party or person
to take any action in violation of applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need
not sign the same counterpart.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement (including the documents and instruments referred to herein) together with the Confidentiality Agreement
constitutes the entire agreement among the parties and supersedes all prior agreements and understandings, both written and oral, among
the parties with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law&#894; Jurisdiction</U>. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF EACH OF THE PARTIES SUBJECT TO THIS AGREEMENT SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF TEXAS WITHOUT REGARD TO THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE
PRINCIPLES OF CONFLICTS OF LAWS. IN ADDITION, EACH PARTY: (A)&nbsp;SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION OF THE STATE OF TEXAS,
COUNTY OF HARRIS, OR IF IT CAN ACQUIRE JURISDICTION,&nbsp;IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF TEXAS&ndash;HOUSTON
DIVISION, AND APPELLATE COURTS THEREOF,&nbsp;IN THE EVENT THAT ANY DISPUTE (WHETHER IN CONTRACT, TORT OR OTHERWISE) ARISES OUT OF THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY; (B)&nbsp;AGREES THAT IT WILL NOT ATTEMPT TO DENY OR DEFEAT SUCH PERSONAL JURISDICTION
BY MOTION OR OTHER REQUEST FOR LEAVE FROM ANY SUCH COURT; (C)&nbsp;AGREES THAT IT WILL NOT BRING ANY PROCEEDING RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY IN ANY COURT OTHER THAN THE ABOVE-NAMED COURTS; AND (D)&nbsp;AGREES THAT IT WILL NOT SEEK TO ASSERT
BY WAY OF MOTION, AS A DEFENSE OR OTHERWISE, THAT: (I)&nbsp;ANY SUCH PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM; (II)&nbsp;ANY SUCH
PROCEEDING SHOULD BE TRANSFERRED OR REMOVED TO ANY COURT OTHER THAN ONE OF THE ABOVE-NAMED COURTS; (III)&nbsp;ANY SUCH PROCEEDING SHOULD
BE STAYED BY REASON OF THE PENDENCY OF SOME OTHER PROCEEDING IN ANY COURT OTHER THAN ONE OF THE ABOVE-NAMED COURTS; OR (IV)&nbsp;THIS
AGREEMENT OR THE SUBJECT MATTER HEREOF MAY&nbsp;NOT BE ENFORCED IN OR BY THE ABOVE-NAMED COURTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver
of Jury Trial</U>. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY&nbsp;ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE EXTENT PERMITTED
BY LAW AT THE TIME OF INSTITUTION OF THE APPLICABLE LITIGATION, ANY RIGHT SUCH PARTY MAY&nbsp;HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH
PARTY CERTIFIES AND ACKNOWLEDGES THAT: (I)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,&nbsp;IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II)&nbsp;EACH PARTY
UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (III)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY; AND (IV)&nbsp;EACH
PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&nbsp;9.10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment&#894;
Third-Party Beneficiaries</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by
any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other party. Any purported
assignment in contravention hereof shall be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure
to the benefit of and be enforceable by the parties and their respective successors and assigns. Except as otherwise provided in <U>Section&nbsp;6.7</U>,
this Agreement (including the documents and instruments referred to herein) is not intended to, and does not, confer upon any person
other than the parties hereto any rights or remedies hereunder, including the right to rely upon the representations and warranties set
forth herein. The representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for
the sole benefit of the parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto
in accordance herewith without notice or liability to any other person. In some instances, the representations and warranties in this
Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge
of any of the parties hereto. Consequently, persons other than the parties may not rely upon the representations and warranties in this
Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Specific
Performance</U>. The parties hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in
accordance with the specific terms hereof and, accordingly, that the parties shall be entitled to an injunction or injunctions to prevent
breaches or threatened breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof (including
the parties&rsquo; obligation to consummate the Merger), in addition to any other remedy to which they are entitled at law or in equity.
Each of the parties hereby further waives (a)&nbsp;any defense in any action for specific performance that a remedy at law would be adequate
and (b)&nbsp;any requirement under any law to post security or a bond as a prerequisite to obtaining equitable relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or
unenforceable in any respect under any applicable law or rule&nbsp;in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed
and enforced in such jurisdiction such that the invalid, illegal or unenforceable provision or portion thereof shall be interpreted to
be only so broad as is enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Confidential
Supervisory Information</U>. Notwithstanding any other provision of this Agreement, no disclosure, representation or warranty shall be
made (or other action taken) pursuant to this Agreement that would involve the disclosure of confidential supervisory information (including
confidential supervisory information as defined in 12 C.F.R. &sect; 261.2(c)&nbsp;and as identified in 12 C.F.R. &sect; 309.5(g)(8)) of
a Governmental Entity by any party to this Agreement to the extent prohibited by applicable law. For purposes of clarity, a representation
relating to receipt of regulatory approvals on a timely basis shall not be given, or continue to be given, to the extent the reason for
it no longer continuing to be accurate involves such confidential supervisory information. To the extent legally permissible, appropriate
substitute disclosures or actions shall be made or taken under circumstances in which the limitations of the preceding sentences apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
by Electronic Transmission</U>. This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments or waivers hereto or thereto, to the extent signed and delivered by means of e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have
the same binding legal effect as if it were the original signed version thereof delivered in person. No party hereto or to any such agreement
or instrument shall raise the use of e-mail delivery of a &ldquo;.pdf&rdquo; format data file to deliver a signature to this Agreement
or any amendment hereto or the fact that any signature or agreement or instrument was transmitted or communicated through the use e-mail
delivery of a &ldquo;.pdf&rdquo; format data file as a defense to the formation of a contract and each party hereto forever waives any
such defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CBTX,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert R. Franklin,&nbsp;Jr.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert R. Franklin,&nbsp;Jr.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>[Signature Page to Agreement and Plan of Merger]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALLEGIANCE BANCSHARES,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven F. Retzloff</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven F. Retzloff</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Voting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached as Exhibit 10.1 to Form 8-K]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Director Support Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached as Exhibit 10.2 to Form 8-K]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of CBTX Certificate Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECOND
AMENDED AND RESTATED CERTIFICATE<BR>
OF FORMATION OF CBTX,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I<BR>
Name</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the corporation
is CBTX,&nbsp;Inc. (the &ldquo;<U>Corporation</U>&rdquo;). The Corporation is a for-profit corporation. The file number issued to the
Corporation by the Secretary of State is 800765321. The date of formation of the Corporation was January&nbsp;26, 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II<BR>
Registered Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The address of the registered
office of the Corporation is c/o Capitol Corporate Services,&nbsp;Inc., 206 E 9th Street, Suite&nbsp;No.&nbsp;1300, Austin, Texas 78701,
and the name of its registered agent at such address is Capitol Services,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III<BR>
Purpose and Duration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose for which the
Corporation is organized is the transaction of any or all lawful business for which a for-profit corporation may be organized under the
Texas Business Organizations Code, as such may be amended from time to time (the &ldquo;<U>TBOC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IV<BR>
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify"><U>Authorized Shares</U>. The Corporation is authorized to issue two classes of shares designated &ldquo;Common&rdquo;
and &ldquo;Preferred.&rdquo; The aggregate number of shares of all classes which the Corporation is authorized to issue is 150,000,000,
consisting of (i)&nbsp;140,000,000 Common shares, having a par value of $0.01 per share (&ldquo;<U>Common Shares</U>&rdquo;), and (ii)&nbsp;10,000,000
Preferred shares, having a par value of $0.01 per share (&ldquo;<U>Preferred Shares</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify"><U>Preferred</U>. The Board of Directors is hereby expressly authorized, by resolution or resolutions
from time to time adopted, to provide, out of the unissued Preferred Shares, for the issuance of one or more series of Preferred Shares.
Before any shares of any such series are issued, the Board of Directors shall fix and state, and hereby is expressly empowered to fix,
by resolution or resolutions, the relative rights and preferences of the shares of each such series, and the qualifications, limitations,
or restrictions thereon, including, but not limited to, determination of any of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the designation of such series, and the number of shares to constitute such series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">whether the shares of such series shall have voting rights, in addition to any voting rights provided
by law, and, if so, the terms of such voting rights, which may be full or limited;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the dividends, if any, payable on such series, and at what rates, whether any such dividends shall be
cumulative, and if so, from what dates, the conditions and dates upon which such dividends shall be payable, the preference or relation
which such dividends shall bear to the dividends payable on any shares of stock of any other class or any other series of this class;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">whether the shares of such series shall be subject to redemption by the Corporation, and, if so, the times,
prices and other terms and conditions of such redemption;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">the amount or amounts payable upon shares of such series upon, and the rights of the holders of such series
in, the voluntary or involuntary liquidation, dissolution, or winding up of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">whether the shares of such series shall be subject to the operation of a retirement or sinking fund and,
if so, the extent to and manner in which any such retirement or sinking fund shall be applied to the purchase or redemption of the shares
of such series for retirement or other corporate purposes and the terms and provisions relative to the operation thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">whether the shares of such series shall be convertible into, or exchangeable for, shares of stock of any
other class or any other series of this class or any other class or classes of securities and, if so, the price or prices or the rate
or rates of conversion or exchange and the method, if any, of adjusting the same, and any other terms and conditions of conversion or
exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">the limitations and restrictions, if any, to be effective while any shares of such series are outstanding
upon the payment of dividends or the making of other distributions on, and upon the purchase, redemption or other acquisition by the Corporation
of, the Common Shares or shares of stock of any other class or any other series of this class;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">the conditions or restrictions, if any, upon the creation of indebtedness of the Corporation or upon the
issue of any additional stock, including additional shares of such series or of any other series of this class or of any other class;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">any other powers, preferences and relative, participating, optional and other special rights, and any
qualifications, limitations and restrictions thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The relative rights and preferences of each series
of Preferred Shares, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series
of Preferred Shares at any time outstanding; provided, that all shares of any one series of Preferred Shares shall be identical in all
respects with all other shares of such series. Any of the designations, preferences, limitations, or relative rights, including the voting
rights, of any series of shares may be dependent upon facts ascertainable outside the Certificate of Formation, provided that the manner
in which such facts operate upon the designations, preferences, and relative rights, including the voting rights, of such series of shares
is clearly set forth in the Certificate of Formation. The Board of Directors may increase the number of Preferred Shares designated for
any existing series by a resolution adding to such series authorized and unissued Preferred Shares not designated for any other series.
The Board of Directors may decrease the number of Preferred Shares designated for any existing series by a resolution subtracting from
such series unissued Preferred Shares designated for such series, and the shares so subtracted shall become authorized, unissued, and
undesignated Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify"><U>Voting and Dividends</U>. Each holder of Common Shares shall be entitled to one vote for each Common
Share held of record on all matters on which shareholders generally are entitled to vote. Subject to applicable law and the rights of
the Preferred Shares and any other class or series of stock having a preference as to dividends over the Common Shares then outstanding,
dividends may be paid on the Common Shares out of assets legally available for dividends, but only at such times and in such amounts as
the Board of Directors shall determine and declare. Subject to applicable law, upon the dissolution, liquidation or winding up of the
Corporation, after any preferential amounts to be distributed to the holders of the Preferred Shares and any other class or series of
stock having a preference over the Common Shares then outstanding have been paid or declared and set apart for payment, the holders of
the Common Shares shall be entitled to receive all the remaining assets of the Corporation available for distribution to its shareholders
ratably in proportion to the number of shares held by them, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify"><U>No Cumulative Voting</U>. The right to accumulate votes in the election of directors or cumulative
voting by any shareholder is hereby expressly denied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify"><U>No Preemptive Rights</U>. No shareholder of this Corporation shall, by reason of his holding shares
of any class of stock of this Corporation, have any preemptive or preferential right to purchase or subscribe for any shares of any class
of stock of this Corporation, now or hereafter to be authorized (or any notes, debentures, bonds or other securities convertible into
or carrying options, warrants or rights to purchase shares of any class, now or hereafter to be authorized, whether or not the issuance
of any such shares or such notes, debentures, bonds or other securities would adversely affect the dividend or voting rights of any such
shareholder), other than such rights, if any, as the Board of Directors, at its discretion, from time to time may grant, and at such price
as the Board of Directors at its discretion may fix; and the Board of Directors may issue shares of any class of stock of this Corporation
or any notes, debentures, bonds or other securities convertible into or carrying options, or warrants or rights to purchase shares of
any class without offering any such shares of any class of such notes, debentures, bonds or other securities, either in whole or in part,
to the existing shareholders of any class.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;V<BR>
Written Consent of Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any action required by the
TBOC to be taken at any annual or special meeting of shareholders, or any action which may be taken at any annual or special meeting of
shareholders, may be taken without a meeting, without prior notice, and without a vote, if a consent or consents in writing, setting forth
the action so taken, shall be signed by all of the shareholders entitled to vote with respect to the action that is the subject of the
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VI<BR>
Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify"><U>Powers</U>. The property, business and affairs of the Corporation and all corporate powers shall be
managed by the Board of Directors, subject to any limitation imposed by statute, the Certificate of Formation or the Bylaws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify"><U>Number of Directors</U>. The number of directors shall be fixed and determined from time to time by
resolution of the Board of Directors at any annual, regular, or special meeting, provided that any decrease in the number of directors
does not shorten the time of any incumbent director. Directors need not be residents of the State of Texas. The number of directors currently
constituting the Board of Directors is fourteen.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify"><U>Classes of Directors</U>. The Board of Directors shall be divided into three classes, as nearly equal
in number as possible, designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. In case of any increase or decrease, from time to
time, in the number of directors, the number of directors in each class shall be apportioned as nearly equal as possible.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify"><U>Term of Offices</U>. Each director shall serve for a term ending on the date of the third annual meeting
of shareholders following the annual meeting at which such director was elected; provided, however, that each director initially elected
to Class&nbsp;I shall serve for an initial term expiring at the Corporation&rsquo;s first annual meeting of shareholders following the
effectiveness of this provision; each director initially elected to Class&nbsp;II shall serve for an initial term expiring at the Corporation&rsquo;s
second annual meeting of shareholders following the effectiveness of this provision; and each director initially elected to Class&nbsp;III
shall serve for an initial term expiring at the Corporation&rsquo;s third annual meeting of shareholders following the effectiveness of
this provision; provided further, that the term of each director shall continue until the election and qualification of a successor and
be subject to such director&rsquo;s earlier death, resignation or removal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The initial division of the Board of
Directors following the effectiveness of this provision shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Class&nbsp;I directors shall initially
consist of the following individuals, and their term shall expire at the annual meeting of shareholders to be held in [2023]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-right: 1in; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 50%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Class&nbsp;II directors shall initially
consist of the following individuals, and their term shall expire at the annual meeting of shareholders to be held in [2024]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-right: 1in; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: black 1pt solid; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; width: 50%; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Class&nbsp;III directors shall initially
consist of the following individuals, and their term shall expire at the annual meeting of shareholders to be held in [2025]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-right: 1in; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Robert R. Franklin,&nbsp;Jr.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Steven F. Retzloff</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify"><U>Resignation</U>. A director may resign at any time on written notice to the Board of Directors or to
the Chairman of the Board. A director&rsquo;s resignation is effective when the notice is delivered unless the notice specifies a later
effective date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify"><U>Election of Directors</U>. Directors shall be elected by a plurality of the voting power of the shares
entitled to vote who are present, in person or by proxy, at any such meeting and entitled to vote on the election of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VII<BR>
Special Meetings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special meetings of the shareholders for any purpose
or purposes may be called by (A)&nbsp; the Chairman of the Board or (B)&nbsp;a majority of the entire Board of Directors. In addition,
a special meeting of the shareholders shall be called at the request in writing of shareholders owning 50% or more of the issued and outstanding
shares of the Corporation entitled to vote at such meeting by the Chairman of the Board or the Secretary. Such request for a special meeting
shall state the purpose or purposes of the proposed meeting, which purpose or purposes shall be stated in the notice of the meeting. Business
transacted at any special meeting of shareholders shall be limited to the purposes stated in the notice. Notwithstanding anything set
forth in the Certificate of Formation to the contrary, at a special meeting requested by the shareholders of the Corporation, only the
Corporation and the shareholders who participated in the written meeting request may propose any item for consideration or nominate directors
for election at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VIII<BR>
Amendment of Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of the Corporation may
alter, amend, or repeal the bylaws of the Corporation or may adopt new bylaws. The shareholders of the Corporation shall not have the
power to alter, amend, or repeal the bylaws of the Corporation or adopt new bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IX<BR>
Liabilities of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No director of the Corporation
will have any liability to the Corporation or its shareholders for monetary damages for any act or omission by the director in the director&rsquo;s
capacity as a director of the Corporation, except that this provision does not eliminate or limit the liability of a director to the extent
the director is found liable under applicable law for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">a breach of the director&rsquo;s duty of loyalty to the Corporation or its shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">an act or omission not in good faith that constitutes a breach of duty of the director to the Corporation
or that involves intentional misconduct or a knowing violation of law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">a transaction from which the director received an improper benefit, regardless of whether the benefit
resulted from an action taken within the scope of the director&rsquo;s duties; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">an act or omission for which the liability of the director is expressly provided for by an applicable
statute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the TBOC is amended to authorize action further
eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or
limited to the fullest extent permitted by the TBOC as so amended. Any repeal or modification of this Article&nbsp;shall not adversely
affect any right of protection of a director of the Corporation existing at the time of such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;X<BR>
Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify"><U>Right to Indemnification</U>. The Corporation shall indemnify and hold harmless, to the greatest extent
permitted by applicable law, any director or officer of the Corporation, any former director or officer of the Corporation, or any current
or former delegate of the Corporation who was, is, or is threatened to be made a respondent in any proceeding because the person is or
was a director, officer or delegate of the Corporation from and against all expenses actually incurred by such person in connection with
such proceeding, and such indemnification shall continue as to a person who has ceased to be a director, officer, or delegate of the Corporation
and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that the Corporation shall indemnify
any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding
(or part thereof) was authorized by the Board of Directors. The right to indemnification conferred in this Article&nbsp;shall be a contract
right. The right to indemnification conferred by this Article&nbsp;shall, to the extent permitted by the TBOC, include the right to be
paid by the Corporation the expenses incurred in defending or otherwise participating in any proceeding in advance of its final disposition.
The Corporation may, by action of the Board of Directors, provide indemnification to employees and agents of the Corporation with the
same scope and effect as the foregoing indemnification of directors, officers, and delegates. The terms &ldquo;delegate,&rdquo; &ldquo;expenses,&rdquo;
and &ldquo;enterprise&rdquo; shall have the meaning given to them in the Section&nbsp;8.001 of the TBOC, or any successor provision thereto.
Nothing in this Article&nbsp;shall be construed as a limitation on any rights of the Corporation to indemnify or insure any person that
is otherwise permitted by applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify"><U>Insurance</U>. The Corporation may, in its discretion, purchase or procure or establish and maintain
insurance or another arrangement to indemnify and hold harmless an existing or former director, delegate, officer, employee, or agent
against any liability: asserted against and incurred by the person in that capacity, or arising out of the person&rsquo;s status in that
capacity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify"><U>Non-Exclusivity</U>. The power to indemnify or obtain insurance provided in this Article&nbsp;shall
be cumulative and non-exclusive of any other power of the Board of Directors, the Corporation, or any rights to which such a person or
entity may be entitled by law, the Certificate of Formation, the bylaws of the Corporation, contract, other agreement, vote, or otherwise.
Any repeal or modification of this Article&nbsp;shall be prospective only, and shall not adversely affect any right of a person to indemnification
by the Corporation existing at the time of such repeal or modification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify"><U>Validity</U>. Notwithstanding any provision of this Article&nbsp;to the contrary, all indemnification
payments must be consistent with the requirements of Section&nbsp;18(k)&nbsp;of the Federal Deposit Insurance Act and the implementing
regulations thereunder. The invalidity of any provision of this Article&nbsp;will not affect the validity of the remaining provisions
of this Article.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of CBTX Bylaw Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit&nbsp;D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FORM&nbsp;OF AMENDMENT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDED AND RESTATED BYLAWS OF CBTX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Second Amended and Restated
Bylaws (the &ldquo;<U>Bylaws</U>&rdquo;) of CBTX,&nbsp;Inc. (the &ldquo;<U>Corporation</U>&rdquo;) shall be amended as follows, effective
as of the Effective Time (as such term is defined in the Agreement and Plan of Merger, dated as of November&nbsp;5, 2021, by and between
the Corporation and Allegiance Bancshares,&nbsp;Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Section&nbsp;3.04 of the Bylaws is amended to conform to the provisions of the Certificate of Formation
regarding classes of directors and terms of offices. Section&nbsp;3.04 of the Bylaws is hereby amended and restated, in its entirety,
to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.04</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Classes
of Directors; Term of Offices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Board of Directors shall be divided into three classes, as nearly equal in number as possible, designated as Class&nbsp;I, Class&nbsp;II
and Class&nbsp;III. In case of any increase or decrease, from time to time, in the number of directors, the number of directors in each
class shall be apportioned as nearly equal as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
director shall serve for a term ending on the date of the third annual meeting of shareholders following the annual meeting at which such
director was elected; provided, however, that each director initially elected to Class&nbsp;I shall serve for an initial term expiring
at the Corporation&rsquo;s first annual meeting of shareholders following the effectiveness of this provision; each director initially
elected to Class&nbsp;II shall serve for an initial term expiring at the Corporation&rsquo;s second annual meeting of shareholders following
the effectiveness of this provision; and each director initially elected to Class&nbsp;III shall serve for an initial term expiring at
the Corporation&rsquo;s third annual meeting of shareholders following the effectiveness of this provision; provided further, that the
term of each director shall continue until the election and qualification of a successor and be subject to such director&rsquo;s earlier
death, resignation or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Directors
shall be elected by a plurality of the voting power of the shares entitled to vote who are present, in person or by proxy, at any such
meeting and entitled to vote on the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Section&nbsp;4.01 of the Bylaws is amended to add the offices of Chairman of the Board and Chief Executive
Officer as mandatory offices of the Corporation. Section&nbsp;4.01 of the Bylaws is hereby amended and restated, in its entirety, to read
as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.01</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Election,
Number, Qualifications</U>. The officers of the Corporation shall be elected annually by the Board of Directors at the first meeting of
the Board of Directors held after each annual meeting of shareholders and shall consist of a Chairman of the Board, a Chief Executive
Officer, a President and a Secretary. In its discretion, the Board of Directors may also elect a Vice Chairman, a Treasurer, one or more
Executive Vice Presidents, Senior Vice Presidents or Vice Presidents, one or more Assistant Secretaries and Assistant Treasurers and such
other officers and assistant officers and agents as it shall deem necessary, who shall hold their offices for such terms and shall have
such authority and exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors by
resolution not inconsistent with these Bylaws. Two or more offices may be held by the same person. In its discretion, the Board of Directors
may choose not to fill any office for any period as it may deem advisable, except that the offices of Chairman of the Board, Chief Executive
Officer, President and Secretary shall be filled as expeditiously as possible. In the event of an officer&rsquo;s absence or inability
to act in his official capacity as an officer of the Corporation, the Board of Directors may delegate the duties of such officer to any
other officer or Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Section&nbsp;8.01 of the Bylaws is amended to change the exclusive forum to Harris County, Texas. Section&nbsp;8.01
of the Bylaws is hereby amended and restated, in its entirety, to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.01</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exclusive
Forum</U>. Unless the Corporation consents in writing to the selection of an alternative forum for the following purposes, any state or
federal court located in Harris County in the State of Texas shall be the sole and exclusive forum for (a)&nbsp;any actual or purported
derivative action or proceeding brought on behalf of the Corporation, (b)&nbsp;any action asserting a claim of breach of a fiduciary duty
owed by any current or former director, officer, or other employee or agent of the Corporation to the Corporation or the Corporation&rsquo;s
shareholders or creditors, including a claim alleging the aiding and abetting of such a breach of fiduciary duty, (c)&nbsp;any action
asserting a claim against the Corporation or any current or former director, officer, or other employee or agent of the Corporation arising
pursuant to any provision of the TBOC, the Certificate of Formation, or the Bylaws of the Corporation (as any of the foregoing may be
amended from time to time), or (d)&nbsp;any action asserting a claim against the Corporation or any current or former director, officer,
or other employee or agent of the Corporation as governed by the internal affairs doctrine, including any action to interpret, apply,
enforce or determine the validity of any provision of the TBOC, the Certificate of Formation, or the Bylaws of the Corporation (as any
of the foregoing may be amended from time to time).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">A new Article&nbsp;IX shall be added to the Bylaws, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IX &ndash; CERTAIN GOVERNANCE MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.02.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Interpretations;
Definitions</U>. The following definitions apply to this Article&nbsp;IX and otherwise as applicable in these Bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Effective
Time</U>&rdquo; shall have the meaning set forth in the Agreement and Plan of Merger, dated as of November&nbsp;5, 2021, by and between
Legacy CBTX and Legacy Allegiance, as it may have been amended, restated, supplemented or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Entire
Board of Directors</U>&rdquo; shall mean the total authorized number of directors on the Board of Directors of the Corporation without
giving effect to vacancies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Legacy
Allegiance</U>&rdquo; shall mean Allegiance Bancshares,&nbsp;Inc., a Texas corporation, which has merged with and into the Corporation
effective as of the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Legacy
Allegiance Directors</U>&rdquo; shall mean (i)&nbsp;the directors of the Corporation as of the Effective Time who were directors of Legacy
Allegiance as of immediately prior to the Effective Time, and (ii)&nbsp;directors of the Corporation who were subsequently appointed or
nominated and elected to fill a vacancy created by the cessation of service of a Legacy Allegiance Director pursuant to this Article&nbsp;IX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Legacy
CBTX</U>&rdquo; shall mean CBTX,&nbsp;Inc., a Texas corporation, as in existence immediately prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Legacy
CBTX Directors</U>&rdquo; shall mean (i)&nbsp;the directors of the Corporation as of the Effective Time who were directors of Legacy CBTX
as of immediately prior to the Effective Time, and (ii)&nbsp;any directors of the Corporation who were subsequently appointed or nominated
and elected to fill a vacancy created by the cessation of service of a Legacy CBTX Director pursuant to this Article&nbsp;IX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Period</U>&rdquo; shall mean the period beginning at the Effective Time and ending on the three (3)&nbsp;year anniversary of the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.03.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Chief
Executive Officer; Executive Chairman; Independent Lead Director</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Effective
as of the Effective Time, (i)&nbsp;Robert R. Franklin,&nbsp;Jr. shall serve as the Chief Executive Officer and a Director, and (ii)&nbsp;Steven
F. Retzloff shall serve as the Executive Chairman and a Director. The Corporation may enter into or amend appropriate agreements or arrangements
with Mr.&nbsp;Franklin and Mr.&nbsp;Retzloff in connection with the subject matter of this Article&nbsp;IX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, (i)&nbsp;any removal of any of the individuals serving in the capacities set forth in Section&nbsp;9.03(a)&nbsp;above
from, or failure to appoint, re-elect or re-nominate any of them to, any such positions, (ii)&nbsp;any amendment or modification to any
employment or similar agreement with any of them to the extent such amendment or modification would materially and adversely affect such
individual, or (iii)&nbsp;any termination of their employment by the Corporation or any subsidiary of the Corporation shall, in each case,
require the affirmative vote of at least seventy-five percent (75%) of the Entire Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Within
one hundred eighty (180) days following the Effective Time, the Board of Directors shall, by the affirmative vote of at least seventy-five
percent (75%) of the Entire Board of Directors, select an independent director from among the Legacy CBTX Directors and the Legacy Allegiance
Directors as the lead independent director (the &ldquo;lead director&rdquo;) of the Board of Directors of the Corporation. During the
Specified Period, any removal of the individual serving in the capacity of the lead director from, or failure to appoint, re-elect or
re-nominate such individual to, the position of lead director, shall, in each case, require the affirmative vote of at least seventy-five
percent (75%) of the Entire Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.04.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Composition
of the Board of Directors; Vacancies and Removal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, the Entire Board of Directors shall be comprised of fourteen (14) directors, of which seven (7)&nbsp;shall be the
Legacy CBTX Directors (one of whom, as of the Effective Time, shall be Robert R. Franklin,&nbsp;Jr.) and seven (7)&nbsp;shall be the Legacy
Allegiance Directors (one of whom, as of the Effective Time, shall be Steven F. Retzloff).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Legacy CBTX Directors and the Legacy Allegiance Directors shall be, as nearly evenly as is practicably possible, evenly apportioned among
the different classes of the Board of Directors of the Corporation such that one class of the Board of Directors shall consist of two
(2)&nbsp;Legacy CBTX Directors and two Legacy Allegiance Directors, one class of the Board of Directors shall consist of three (3)&nbsp;Legacy
CBTX Directors and two (2)&nbsp;Legacy Allegiance Directors, and one class of the Board of Directors shall consist of two (2)&nbsp;Legacy
CBTX Directors and three (3)&nbsp;Legacy Allegiance Directors; <U>provided</U> that Robert R. Franklin,&nbsp;Jr. and Steven F. Retzloff
shall each be in the same class of the Board of Directors of the Corporation with a term expiring at the third succeeding annual meeting
of shareholders following the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Time through the second (2nd) anniversary of the Effective Time, no vacancy on the Board of Directors of the Corporation
created by the cessation of service of a director shall be filled by the Board of Directors and the Board of Directors shall not nominate
any individual to fill such vacancy, unless (i)&nbsp;such individual would be an independent director of the Corporation (unless such
predecessor director was not an independent director), (ii)&nbsp;in the case of a vacancy created by the cessation of service of a Legacy
CBTX Director, not less than a majority of the Legacy CBTX Directors have approved the appointment or nomination (as applicable) of the
individual appointed or nominated (as applicable) to fill such vacancy, in which case the Legacy Allegiance Directors shall vote to approve
the appointment or nomination (as applicable) of such individual, and (iii)&nbsp;in the case of a vacancy created by the cessation of
service of a Legacy Allegiance Director, not less than a majority of the Legacy Allegiance Directors have approved the appointment or
nomination (as applicable) of the individual appointed or nominated (as applicable) to fill such vacancy, in which case the Legacy CBTX
Directors shall vote to approve the appointment or nomination (as applicable) of such individual; <U>provided</U> that any such appointment
or nomination pursuant to clause (ii)&nbsp;or (iii)&nbsp;shall be made in accordance with applicable law and the rules&nbsp;of the Nasdaq
Stock Market, LLC (or other national securities exchange on which the Corporation&rsquo;s securities are listed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Time through the second (2nd) anniversary of the Effective Time, subject to applicable law, newly created directorships
resulting from any increase in the authorized number of directors may be filled only by the affirmative vote of at least seventy-five
percent (75%) of the remaining directors, even though less than a quorum of the Board of Directors, and in the event that there is only
one director remaining in office, by such sole remaining director, and directors so chosen shall hold office until such director&rsquo;s
successor shall have been duly elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.05.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Committees</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, (i)&nbsp;the Board of Directors shall have and maintain as standing committees an Audit Committee, a Compensation
Committee, a Corporate Governance and Nominating Committee, and a Risk Committee, (ii)&nbsp;the membership of each such committee shall
be, as practicably as possible, evenly divided between Legacy CBTX Directors and Legacy Allegiance Directors, and (iii)&nbsp;the chairpersons
of two such committees shall be designated from among the Legacy CBTX Directors and the chairpersons of two such committees shall be designated
from among the Legacy Allegiance Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period,&nbsp;any removal of a director from a committee of the Corporation or as chairperson of a committee, or failure
to appoint, re-elect or re-nominate any of them to, any such positions, shall require the affirmative vote of at least seventy-five percent
(75%) of the Entire Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, the Board of Directors may by resolution (which, during the Specified Period, shall require the affirmative vote
of at least seventy-five percent (75%) of the Entire Board of Directors) establish any committees not expressly contemplated by these
Bylaws composed of directors as they may determine to be necessary or appropriate for the conduct of business of the Corporation and may
prescribe the composition, duties and procedures thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
any time during the Specified Period in which an Executive Committee is in existence, each of Robert R. Franklin,&nbsp;Jr. and Steven
F. Retzloff shall serve as a member of the Executive Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary in these Bylaws, during the Specified Period, no committee (including, for the avoidance of doubt, any Executive
Committee, to the extent such a committee is in existence) shall be permitted to take any action, and the Board of Directors shall not
delegate to any committee the power to take any action, that, if taken by the Board of Directors, would require the affirmative vote of
at least seventy-five percent (75%) of the Entire Board of Directors pursuant to this Article&nbsp;IX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.06.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Actions</U>. During the Specified Period, each of the following shall require the affirmative vote of at least seventy-five percent (75%)
of the Entire Board of Directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Corporation entering into a &ldquo;fundamental business transaction&rdquo; (as defined in Section&nbsp;1.002 of the TBOC);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">an
amendment to the Certificate of Formation or the Bylaws of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
change in the authorized number of directors of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">issuances
of securities of the Corporation, other than (i)&nbsp;upon the conversion of options, warrants or other securities of the Corporation
convertible into common stock, (ii)&nbsp;as dividends or distributions on outstanding securities of the Corporation, (iii)&nbsp;upon a
stock split or other subdivision of securities of the Corporation, (iv)&nbsp;to directors, officers, employees or consultants of the Corporation
or its affiliates as part of an equity compensation plan or as fees, commissions or compensation for services rendered or otherwise, or
(v)&nbsp;to an employee stock ownership plan or other qualified defined contribution or benefit plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
disposition of material assets of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Corporation entering into an affiliate transaction (as contemplated by Sections 23A and 23B of the Federal Reserve Act and the implementing
regulations thereunder);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">incurrence
of indebtedness of the Corporation; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">approval
of a stock repurchase program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.07.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headquarters</U>.
Effective as of and from the Effective Time, the corporate headquarters of the Corporation shall be located in Houston, Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.08.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conflicts;
Amendments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, in the event of any inconsistency between any provision of this Article&nbsp;IX and any other provision of these
Bylaws or the Corporation&rsquo;s other constituent documents, the provisions of this Article&nbsp;IX shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Specified Period, the provisions of this Article&nbsp;IX and any other provision of these Bylaws that sets forth the authority and
responsibility of the Chief Executive Officer or the Executive Chairman, may be modified, amended or repealed, and any Bylaw provision
or other resolution inconsistent with this Article&nbsp;IX may be adopted, by the Board of Directors only by (and any of the foregoing,
or any corresponding modification, amendment, repeal or inconsistent provision of the Corporation&rsquo;s other constituent documents,
may be proposed or recommended by the Board of Directors for approval by the shareholders of the Corporation) an affirmative vote of at
least seventy-five percent (75%) of the Entire Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm2131964d8_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM&nbsp;OF
VOTING AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS VOTING AGREEMENT (the
&ldquo;<U>Voting Agreement</U>&rdquo;), dated as of [&#9679;], 2021, is executed by and among Allegiance Bancshares,&nbsp;Inc., a Texas
corporation (&ldquo;<U>Allegiance</U>&rdquo;), CBTX,&nbsp;Inc., a Texas corporation (&ldquo;<U>CBTX</U>&rdquo;), and the other persons
who are signatories hereto (referred to herein individually as a &ldquo;<U>Shareholder</U>&rdquo; and collectively as the &ldquo;<U>Shareholders</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently herewith,
Allegiance and CBTX (individually, a &ldquo;<U>Party</U>&rdquo; and collectively, the &ldquo;<U>Parties</U>&rdquo;) are entering into
that certain Agreement and Plan of Merger dated as of the date hereof, by and between CBTX and Allegiance (as such agreement may be amended
or supplemented from time to time, the &ldquo;<U>Merger Agreement</U>&rdquo;), pursuant to which Allegiance will merge with and into CBTX,
with CBTX as the surviving entity (the &ldquo;<U>Merger</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Merger Agreement
provides that all of the issued and outstanding shares of common stock, par value $1.00 per share, of Allegiance (subject to certain exceptions
as described in the Merger Agreement) (&ldquo;<U>Allegiance Stock</U>&rdquo;) will be exchanged for the right to receive shares of common
stock, par value $0.01 per share, of CBTX (&ldquo;<U>CBTX Stock</U>&rdquo;) and other such consideration as set forth in the Merger Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as a condition and
inducement to the Parties&rsquo; willingness to enter into the Merger Agreement, each member of the board of directors of Allegiance and
CBTX and certain officers of each of Allegiance, CBTX, Allegiance Bank, a Texas-chartered state bank and wholly owned subsidiary of Allegiance,
and CommunityBank of Texas, National Association, a federally-chartered national association and wholly owned subsidiary of CBTX, in each
case as set forth following their name on the Shareholder signature page&nbsp;hereto, has agreed to vote his or her shares of Allegiance
Stock or CBTX Stock, as applicable, in favor of approval of the Merger Agreement and the transactions contemplated thereby; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, CBTX and Allegiance
are relying on this Voting Agreement in incurring expenses in reviewing each other&rsquo;s business, in preparing a proxy statement/prospectus,
in proceeding with the filing of applications for regulatory approvals and in undertaking other actions necessary for the consummation
of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the substantial expenses that the Parties will incur in connection with the transactions contemplated by the Merger Agreement and to
induce each Party to execute the Merger Agreement and to proceed to incur such expenses, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereby, severally and not jointly, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of this Voting Agreement, the following terms are defined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company</U>&rdquo;
means, with respect to a Shareholder of Allegiance Stock, Allegiance, and, with respect to a Shareholder of CBTX Stock, CBTX;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Shareholder
Meeting</U>&rdquo; means, with respect to a Shareholder of Allegiance Stock, the Allegiance special meeting of shareholders referred to
in Section&nbsp;6.3 of the Merger Agreement, and, with respect to a Shareholder of CBTX Stock, the CBTX special meeting of shareholders
referred to in Section&nbsp;6.3 of the Merger Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Stock</U>&rdquo; means, with respect to a Shareholder of Allegiance Stock, Allegiance Stock, and, with respect to a Shareholder of CBTX
Stock, CBTX Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the Shareholders hereby severally, but not jointly, represents and warrants to each of Allegiance and CBTX that such Shareholder is
the registered owner or beneficial owner of, or has full voting power with respect to, the number of shares of Company Stock set forth
below such Shareholder&rsquo;s name on the Shareholder signature page&nbsp;to this Voting Agreement (the &ldquo;<U>Shares</U>&rdquo;).
While this Voting Agreement is in effect, each Shareholder shall not, directly or indirectly, (a)&nbsp;sell or otherwise dispose of or
encumber (except for pledges and similar encumbrances in effect on the date hereof, which may be maintained, renewed, extended or otherwise
modified on terms and conditions substantially the same as in effect as of the date hereof) prior to the record date of the Shareholder
Meeting any or all of his or her Shares or (b)&nbsp;deposit any shares of Company Stock into a voting trust or enter into a voting agreement
or arrangement with respect to any shares of Allegiance Stock or CBTX Stock, as applicable, or grant any proxy with respect thereto, other
than to other members of the board of directors of Allegiance or CBTX, as applicable, for the purpose of voting to approve the Merger
Agreement and the transactions contemplated thereby; <I>provided</I>, <I>however</I>, that the following transfers shall be permitted:
(v)&nbsp;the sale, disposition or use of shares of Allegiance Stock or CBTX Stock, as applicable, for the payment or other satisfaction
of withholding Taxes (as defined in the Merger Agreement) incurred in the connection with the exercise, vesting, or settlement of Allegiance
Equity Awards or CBTX Equity Awards, in each case, in accordance with past practice and the terms of applicable equity compensation plans
and associated award agreements, (w)&nbsp;transfers to any member of the Shareholder&rsquo;s family, subject to the transferee agreeing
in writing to be bound by the terms of this Voting Agreement, (x)&nbsp;transfers for estate and tax planning purposes, including transfers
to relatives, trusts and charitable organizations, subject to the transferee agreeing in writing to be bound by the terms of this Voting
Agreement, (y)&nbsp;transfers to any other shareholder of Allegiance or CBTX, as applicable, who has executed a copy of this Voting Agreement
on the date hereof, and (z)&nbsp;such transfers as the Company may otherwise permit in its sole discretion. Any transfer or other disposition
in violation of the terms of this <U>Section&nbsp;2</U> shall be null and void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Shareholder hereby agrees during the term of this Voting Agreement to vote the Shares, and any additional shares of Company Stock or other
voting securities of the Company acquired by such Shareholder after the date hereof, (a)&nbsp;in favor of the approval and adoption of
the Merger Agreement and the transactions contemplated thereby at the Shareholder Meeting and (b)&nbsp;against approval of any Acquisition
Proposal (as defined in the Merger Agreement) made in opposition to or competition with such proposals (an &ldquo;<U>Opposing Proposal</U>&rdquo;)
presented at the Shareholder Meeting or any other meeting of shareholders held prior or subsequent to the Shareholder Meeting. If there
has been a modification or amendment to the Merger Agreement that reduces the Merger Consideration (as defined in the Merger Agreement),
other than any adjustment to the Merger Consideration provided for in the Merger Agreement, then this <U>Section&nbsp;3</U> shall be inapplicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Shareholder shall not invite or seek any Opposing Proposal, support (or publicly suggest that anyone else should support) any Opposing
Proposal that may be made, or ask the board of directors of the Company to consider, support or seek any Opposing Proposal or otherwise
take any action designed to make any Opposing Proposal more likely. None of the Shareholders shall meet or otherwise communicate with
any Person (as defined in the Merger Agreement) that makes or is considering making an Opposing Proposal or any representative of such
Person after becoming aware that the Person has made or is considering making an Opposing Proposal. Each Shareholder shall promptly advise
the Company of each contact the Shareholder or any of the Shareholder&rsquo;s representatives may receive from any Person relating to
any Opposing Proposal or otherwise indicating that any Person may wish to participate or engage in any transaction arising out of any
Opposing Proposal and will provide the Company with all information Allegiance or CBTX, as applicable, reasonably requests that is available
to the Shareholder regarding any such Opposing Proposal or possible Opposing Proposal. Each Shareholder will not make any claim or join
in any litigation alleging that the board of directors of the Company is required to consider, endorse or support any Opposing Proposal
or to invite or seek any Opposing Proposal. Each Shareholder shall not take any other action that is reasonably likely to make consummation
of the Merger less likely or to impair either Party&rsquo;s ability to exercise any of the rights granted by the Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Shareholder acknowledges that Allegiance and CBTX are relying on this Voting Agreement in preparing a joint proxy statement/prospectus,
in proceeding with the filing of applications for regulatory approvals and in undertaking other actions necessary for the consummation
of the Merger. Each Shareholder and the Company acknowledge that the performance of this Voting Agreement is intended to benefit each
of Allegiance and CBTX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Voting Agreement shall continue in effect until the earlier to occur of (a)&nbsp;the termination of the Merger Agreement in accordance
with its terms or (b)&nbsp;the consummation of the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
in this Voting Agreement shall be deemed to restrict any of the Shareholders from taking any action in the capacity of a director or officer
(if applicable) of the Company that such Shareholder shall believe is necessary to fulfill the Shareholder&rsquo;s duties and obligations
as a director or officer (if applicable). Each Shareholder is executing this Voting Agreement solely in the Shareholder&rsquo;s capacity
as a shareholder of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Shareholder has the legal capacity, power and authority to enter into and perform all of the Shareholder&rsquo;s obligations under this
Voting Agreement. This Voting Agreement has been duly and validly executed and delivered by the Shareholder and constitutes the legal,
valid and binding obligation of the Shareholder, enforceable against the Shareholder in accordance with its terms except as the enforceability
may be limited by bankruptcy, insolvency or other laws affecting creditors rights. If the Shareholder is married and his or her Shares
constitute community property, this Voting Agreement has been duly authorized, executed and delivered by, and constitutes a valid and
binding agreement of, such Shareholder&rsquo;s spouse, enforceable against such spouse in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Voting Agreement may not be modified, amended, altered or supplemented with respect to a particular Shareholder, except upon the execution
and delivery of a written agreement executed by Allegiance, CBTX, and the Shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Voting Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original but all of which
shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Voting Agreement, together with the Merger Agreement and the agreements contemplated thereby, embody the entire agreement and understanding
of the parties hereto in respect to the subject matter contained herein. This Voting Agreement supersedes all prior agreements and understandings
among the parties with respect to such subject matter contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
notices, requests, demands and other communications required or permitted hereby shall be in writing and shall be deemed to have been
duly given if delivered by hand or mail, certified or registered mail (return receipt requested) with postage prepaid to the addresses
of the parties hereto set forth below their signature on the signature pages&nbsp;hereof or to such other address as any party may have
furnished to the others in writing in accordance herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Shareholder recognizes and acknowledges that a breach by the Shareholder of any covenants or agreements contained in this Voting Agreement
will cause each of Allegiance and CBTX to sustain damages for which they would not have an adequate remedy at law for money damages, and
therefore the parties hereto agree that, in the event of any such breach, either Allegiance or CBTX, as the case may be, shall be entitled
to seek the remedy of specific performance of such covenants and agreements and injunctive and other equitable relief, without the necessity
of posting bond or proving actual damages, in addition to any other remedy to which it may be entitled, at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
time to time, at a Party&rsquo;s request and without further consideration, each Shareholder shall execute and deliver such additional
documents reasonably requested by&nbsp;such Party as may be necessary or desirable to consummate and make effective, in the most expeditious
manner practicable, the transactions contemplated by this Voting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Voting Agreement and the relations among the parties hereto arising from this Voting Agreement shall be governed by and construed in accordance
with the laws of the State of Texas, without giving effect to any principles of conflicts of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page&nbsp;Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Voting Agreement as of the date above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ALLEGIANCE</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ALLEGIANCE BANCSHARES,&nbsp;INC.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Address: [&#9679;]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Attention: [&#9679;]</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Voting Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CBTX</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CBTX,&nbsp;INC.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&#9679;]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[&#9679;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Address: [&#9679;]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Attention: [&#9679;]</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Voting Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Allegiance
ShareHolders:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 30%">Address for Shareholder: </TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>Name of Shareholder: [&#9679;]<BR>
Number of Shares: [&#9679;]</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp; &nbsp; Spouse</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Shareholder Signature Page&nbsp;to Voting
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CBTX
ShareHolders:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 30%">Address for Shareholder: </TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>Name of Shareholder: [&#9679;]<BR>
Number of Shares: [&#9679;]</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp; &nbsp; Spouse</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Shareholder Signature Page&nbsp;to Voting
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>tm2131964d8_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>director
Support Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">THIS
Director Support AGREEMENT</FONT> (this &ldquo;<U>Agreement</U>&rdquo;), dated as of November&nbsp;5, 2021 (the &ldquo;<U>Execution
Date</U>&rdquo;), is made and entered into by and among, Allegiance Bancshares,&nbsp;Inc., a Texas corporation
(&ldquo;<U>Allegiance</U>&rdquo;), CBTX,&nbsp;Inc., a Texas corporation (&ldquo;<U>CBTX</U>&rdquo;), and _____________________, an
individual residing in the State of _____________ (the &ldquo;<U>Undersigned</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently herewith,
Allegiance and CBTX are entering into that certain Agreement and Plan of Merger, dated as of the date hereof, by and between CBTX and
Allegiance (as such agreement may be amended or supplemented from time to time, the &ldquo;<U>Merger Agreement</U>&rdquo;), pursuant
to which, among other things, Allegiance will merge with and into CBTX, with CBTX continuing as the legal surviving entity (the &ldquo;<U>Merger</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, in connection with
the transactions contemplated by the Merger Agreement, CommunityBank of Texas, National Association, a federally-chartered national association
and wholly-owned subsidiary of CBTX (&ldquo;<U>CBTX Bank</U>&rdquo;), will merge with Allegiance Bank, a Texas-chartered state bank and
wholly-owned subsidiary of Allegiance (&ldquo;<U>Allegiance Bank</U>&rdquo; and together with Allegiance, CBTX and CBTX Bank, the &ldquo;<U>Transaction
Parties</U>&rdquo; and each a &ldquo;<U>Transaction Party</U>&rdquo;), with Allegiance Bank continuing as the legal surviving entity
(the &ldquo;<U>Surviving Bank</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the term &ldquo;<U>Surviving
Entity</U>&rdquo; as used in this Agreement with respect to time periods after the day and time the Merger is completed pursuant to the
terms of the Merger Agreement (the &ldquo;<U>Effective Time</U>&rdquo;) shall mean the Surviving Entity of the Merger as such term is
defined in the Merger Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Undersigned
is a director of Allegiance or a director of CBTX, and, as a director of Allegiance or CBTX, as applicable, has had access to (i)&nbsp;certain
Confidential Information (as defined below), including, without limitation, information concerning business, relationships between such
Transaction Party and their respective subsidiaries, vendors and customers and competitors and competition; and (ii)&nbsp;trade secrets,
customer goodwill and proprietary information of a Transaction Party and their respective businesses that constitute a substantial asset
to be acquired by the Surviving Entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Undersigned
recognizes that Allegiance&rsquo;s and CBTX&rsquo;s willingness to enter into the Merger Agreement is dependent on the Undersigned entering
into this Agreement (including the anti-piracy/non-solicitation/non-competition covenants below) and therefore this Agreement is incident
thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, any capitalized
term not defined herein shall have the meaning set forth in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for the new
Confidential Information the Undersigned will be provided and for other good and valuable consideration contained herein and in the Merger
Agreement, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Director
Support</U>. The Undersigned agrees to use his or her best efforts to refrain from harming the goodwill of any of the Transaction Parties,
the Surviving Entity and the Surviving Bank and their respective subsidiaries, and their respective customer and client relationships
during the term of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Disclosure
Obligations</U>. The Undersigned agrees that he or she will not make any unauthorized disclosure, directly or indirectly, of any Confidential
Information of the Transaction Parties, the Surviving Entity or the Surviving Bank to third parties, or make any use thereof, directly
or indirectly. The Undersigned also agrees that he or she shall deliver promptly to the applicable Transaction Party, the Surviving Entity
or the Surviving Bank at any time at the reasonable request of such Transaction Party, the Surviving Entity or the Surviving Bank, without
retaining any copies, all documents and other material in the Undersigned&rsquo;s possession at that time relating, directly or indirectly,
to any Confidential Information or other information of such Transaction Party, the Surviving Entity or the Surviving Bank, as applicable,
or Confidential Information or other information regarding third parties, learned in such person&rsquo;s position as a director, officer
or shareholder of any of the Transaction Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
&ldquo;<U>Confidential Information</U>&rdquo; means and includes the Transaction Parties,&rsquo; the Surviving Entity&rsquo;s or the
Surviving Bank&rsquo;s confidential and/or proprietary information and/or trade secrets, including those of their respective subsidiaries,
that have been and/or will be developed or used and that cannot be obtained readily by third parties from outside sources. Confidential
Information includes, but is not limited to, the: information regarding past, current and prospective customers and investors and business
affiliates, employees, contractors, and the industry not generally known to the public; strategies, methods, books, records, and documents;
technical information concerning products, equipment, services, and processes; procurement procedures, pricing, and pricing techniques,
including contact names, services provided, pricing, type and amount of services used; financial data; pricing strategies and price curves;
positions; plans or strategies for expansion or acquisitions; budgets; research; financial and sales data; trading methodologies and
terms; communications information; evaluations, opinions and interpretations of information and data; marketing and merchandising techniques;
electronic databases; models and the output from same; specifications; computer programs; contracts; bids or proposals; technologies
and methods; training methods and processes; organizational structure; personnel information, including compensation and bonuses; payments
or rates paid to consultants or other service providers; other such confidential or proprietary information; and notes, analysis, compilations,
studies, summaries, and other material prepared by or for any of the Transaction Parties, the Surviving Entity or the Surviving Bank
or any of their respective subsidiaries containing or based, in whole or in part, on any information included in any of the foregoing.
The term &ldquo;<U>Confidential Information</U>&rdquo; does not include any information that (i)&nbsp;at the time of disclosure or thereafter
is generally available to and known to the public, other than by a breach of this Agreement by the disclosing party; (ii)&nbsp;was available
to the disclosing party, prior to disclosure by the Transaction Parties, the Surviving Entity or the Surviving Bank, on a non-confidential
basis from a source other than the Undersigned and is not known by the Undersigned, after reasonable investigation, to be subject to
any fiduciary, contractual or legal obligations of confidentiality; or (iii)&nbsp;was independently acquired or developed by the Undersigned
without violating any obligations of this Agreement. The Undersigned acknowledges that each of the Transaction Parties&rsquo; respective
businesses are highly competitive, that this Confidential Information constitutes valuable, special and unique assets to be acquired
by the Surviving Entity in the Merger and constitutes existing valuable, special, and unique assets held by the each of the Transaction
Parties pre-Merger, and that protection of such Confidential Information against unauthorized disclosure and use is of critical importance
to each of the Transaction Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Competition
Obligations</U>. The Undersigned agrees that, for the period beginning on the Execution Date and continuing until the date that is two&nbsp;(2)&nbsp;years
after the Effective Time of the Merger (the &ldquo;<U>Non-Competition Period</U>&rdquo;), the Undersigned will not, except as a director
of Allegiance or CBTX or as an officer of a Transaction Party (as the case may be) prior to the Effective Time of the Merger, in any
capacity, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compete
    or engage, anywhere in the geographic area comprised of the fifty&nbsp;(50) mile radius surrounding the locations of CBTX Bank or
    Allegiance Bank (including Surviving Bank banking centers that were formerly locations of CBTX Bank at the Effective Time) (the &ldquo;<U>Market&nbsp;Area</U>&rdquo;),
    in a business as a federally insured depository institution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">take any
    action to invest in, own, manage, operate, control, participate in, be employed or engaged by, be a director of, or otherwise be
    connected in any manner with any individual, corporation (including any non-profit corporation), general or limited partnership,
    limited liability company, joint venture, estate, trust, association, organization, or governmental body (each a &ldquo;<U>Person</U>&rdquo;)
    engaging in a business similar to that of the Transaction Parties, the Surviving Entity or the Surviving Bank anywhere within the
    Market Area. Notwithstanding the foregoing, the Undersigned is permitted hereunder to own, directly or indirectly, up to one percent
    (1%) of the issued and outstanding securities of any publicly traded financial institution conducting business in the Market Area;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;call
    on, service or solicit competing business from customers of the Transaction Parties, the Surviving Entity or the Surviving Bank,
    as applicable, or any of their respective affiliates if, within the twelve (12) months before the date of this Agreement, the Undersigned
    had or made contact with the customer, or had access to information and files about the customer or (ii)&nbsp;interfere with or damage
    (or attempt to interfere with or damage) any relationship between any of the Transaction Parties, the Surviving Entity or the Surviving
    Bank, as applicable, or any of its or their respective affiliates and any such customer; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">call on,
    solicit or induce any employee of </FONT>the Transaction Parties, the Surviving Entity or the Surviving Bank, as applicable, or any
    of their respective affiliates whom the Undersigned had contact with, knowledge of, or association with in the course of service
    with Allegiance and/or Allegiance Bank or of CBTX and/or CBTX Bank, as the case may be (whether as an employee or a contractor),
    to terminate his or her employment from or contract with such Transaction Party, the Surviving Entity or the Surviving Bank, as applicable,
    or any of its or their respective affiliates, and will not assist any other Person in such activities.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Competition
Covenant Reasonable</U>. </FONT>The Undersigned acknowledges that the restrictions imposed by this Agreement are legitimate, reasonable
and necessary to protect Allegiance and CBTX&rsquo;s combination into the Surviving Entity and the goodwill thereof. The Undersigned
acknowledges that the scope and duration of the restrictions contained herein are reasonable in light of the time that the Undersigned
has been engaged in the business of Allegiance and/or Allegiance Bank or of CBTX and/or CBTX Bank, as applicable, and the Undersigned&rsquo;s
relationship with the customers of Allegiance and/or Allegiance Bank or of CBTX and/or CBTX Bank, as the case may be. The Undersigned
further acknowledges that the restrictions contained herein are not burdensome to the Undersigned in light of the other opportunities
that remain open to the Undersigned. Moreover, the Undersigned acknowledges that he or she has and will have other means available to
him or her for the pursuit of his or her livelihood after the Effective Time of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration</U>.
In consideration for the above obligations of the Undersigned, in addition to those matters set forth in the Recitals to this Agreement,
the Transaction Parties, as applicable, agree to provide the Undersigned with access to new Confidential Information relating to such
Transaction Party&rsquo;s business, which will become the Surviving Entity&rsquo;s business after the Effective Time of the Merger, in
a greater quantity and/or expanded nature than that already provided to the Undersigned. The Undersigned also will have access to, or
knowledge of, new Confidential Information of third parties, such as actual and potential customers, suppliers, partners, joint venturers,
investors, financing sources,&nbsp;etc., of certain of the Transaction Parties prior to the Merger and certain of the Transaction Parties
after the Effective Time of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Injunctive
Relief and Additional Remedies</U>. The Undersigned acknowledges that the injury that would be suffered by Allegiance, CBTX or the Surviving
Entity as a result of a breach of the provisions of this Agreement (including any provision of <U>Section&nbsp;3</U>) would be irreparable
and that an award of monetary damages to Allegiance, CBTX or the Surviving Entity, as the case may be, for such a breach would be an
inadequate remedy. Consequently, each of Allegiance, CBTX and the Surviving Entity will have the right, in addition to any other rights
it may have, to seek specific performance, to obtain injunctive relief to restrain any proposed or actual breach or threatened breach
or otherwise to specifically enforce any provision of this Agreement without the obligation to post bond or other security in seeking
such relief. Such equitable remedies are in addition to the right to obtain compensatory and punitive damages, and attorney&rsquo;s fees,
and, notwithstanding Allegiance&rsquo;s, CBTX&rsquo;s or the Surviving Entity&rsquo;s, as applicable, right to so seek damages, the Undersigned
waives any defense that an adequate remedy for Allegiance, CBTX or the Surviving Entity, as applicable, exists under law. If the Undersigned,
on the one hand, or Allegiance, CBTX or the Surviving Entity, on the other hand, must bring suit to enforce this Agreement, the prevailing
party shall be entitled to recover its attorneys&rsquo; fees and costs related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Extension
of Restrictive Covenant Period</U>. In the event that Allegiance, CBTX or the Surviving Entity shall file a lawsuit in any court of competent
jurisdiction alleging a breach of <U>Section&nbsp;3</U> of this Agreement by the Undersigned and Allegiance, CBTX or the Surviving Entity,
as applicable, is successful on the merits of such lawsuit, then any time period set forth in this Agreement including the time periods
set forth in <U>Section&nbsp;3</U>, will be extended one month for each month the Undersigned was in breach of this Agreement, so that
the Surviving Entity, Allegiance or CBTX is provided the benefit of the full Non-Competition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
of this Agreement</U>. This Agreement shall become effective on the Execution Date. This Agreement shall automatically terminate and
be of no further force or effect if (a)&nbsp;the Merger Agreement is not executed on or prior to the Execution Date, or (b)&nbsp;the
Merger Agreement (once executed) is terminated in accordance with its terms and the Merger does not occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>.
The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither the failure nor any delay by either
party in exercising any right, power, or privilege under this Agreement will operate as a waiver of such right power, or privilege, and
no single or partial exercise of any such right, power, or privilege will preclude any other or further exercise of such right, power,
or privilege or the exercise of any other right, power, or privilege. To the maximum extent permitted by applicable law, (a)&nbsp;no
claim or right arising out of this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the
claim or right unless in writing signed by the other party; (b)&nbsp;no waiver that may be given by a party will be applicable except
in the specific instance for which it is given; and (c)&nbsp;no notice to or demand on one party will be deemed to be a waiver of any
obligation of such party or of the right of the party giving such notice or demand to take further action without notice or demand as
provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and shall inure to the benefit of Allegiance, CBTX and their respective successors
and assigns, including, without limitation, any successor by merger, consolidation or stock purchase of Allegiance, CBTX and any Person
that acquires all or substantially all of the assets of Allegiance or CBTX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, consents, waiver, and other communications under this Agreement must be in writing and will be deemed to have been duly
given when (a)&nbsp;delivered by hand (with written confirmation of receipt), (b)&nbsp;sent by electronic mail, provided, that a copy
is mailed by registered mail, return receipt requested, or (c)&nbsp;when received by the addressee, if sent by a nationally recognized
overnight delivery service (receipt requested), in each case to the appropriate addresses and electronic mail addresses set forth below
(or to such other address or to such other Person as any party hereto has last designated by notice to the other parties in accordance
herewith):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to Allegiance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Allegiance Bancshares,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">8847 West Sam Houston Parkway, N., Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Houston, Texas 77040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Steven F. Retzloff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: [REDACTED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy to</I></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Bracewell LLP<BR>
1445 Ross Avenue, Suite&nbsp;3800<BR>
Dallas, Texas 75202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mr.&nbsp;Joshua T. McNulty<BR>
Email: josh.mcnulty@bracewell.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to CBTX:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">CBTX,&nbsp;Inc.<BR>
9 Greenway Plaza, Suite&nbsp;110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Houston, Texas 77046<BR>
Attention: Robert R. Franklin,&nbsp;Jr., Chairman, President and Chief Executive Officer<BR>
E-mail: [REDACTED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
copies to</I></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fenimore Kay Harrison&nbsp;&amp; Ford, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">812 San Antonio Street, Suite&nbsp;600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Austin, Texas 78701</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mr.&nbsp;Chet A. Fenimore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: cfenimore@fkhpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Undersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the address set forth
under the Undersigned&rsquo;s signature page&nbsp;hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendment</U>. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof
and supersedes all prior agreements and understandings, oral or written, between the parties hereto with respect to the subject matter
hereof. This Agreement may not be amended orally, but only by an agreement in writing signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement and any claim, controversy or dispute arising under or related in any way to this Agreement and/or the interpretation
and enforcement of the rights and duties of the parties hereunder or related in any way to the foregoing, shall be governed by and construed
in accordance with the internal, substantive laws of the State of Texas applicable to agreements entered into and to be performed solely
within such state without giving effect to the principles of conflict of laws thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
Any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement may be brought against
either of the parties in the courts of the State of Texas, County of Harris, or, if it has or can acquire jurisdiction, in a United States
District Court of the Southern District of Texas located in Houston, Texas, and each of the parties consents to the jurisdiction of such
courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein. Process
in any action or proceeding referred to in the preceding sentence may be served on either party anywhere in the world. Notwithstanding
the foregoing a party may commence any action or proceeding in a court other than the above-named courts solely for the purpose of enforcing
an order or judgment issued by one of the above-named courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section&nbsp;Headings,
Construction</U>. The headings of Sections in this Agreement are provided for convenience only and will not affect its construction or
interpretation. All references to &ldquo;Section&rdquo; or &ldquo;Sections&rdquo; refer to the corresponding Section&nbsp;or Sections
of this Agreement unless otherwise specified. All words used in this Agreement will be construed to be of such gender or number, as the
circumstances require. Unless otherwise expressly provided, the word &ldquo;including&rdquo; does not limit the preceding words or terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree
will remain in full force and effect to the extent not held invalid or unenforceable. If any restriction in this Agreement is held invalid
or unenforceable by any court of competent jurisdiction, it is the intention of the parties that the restrictions be reformed by such
court in such a manner that protects the business and Confidential Information of each the Transaction Parties and the Surviving Entity
to the maximum extent permissible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representation
by Counsel; Interpretation</U>. Each party to this Agreement acknowledges that it has had the opportunity to be represented by counsel
in the negotiation, preparation, and execution of this Agreement and the transactions contemplated by this Agreement. Accordingly, any
rule&nbsp;of law, including, but not limited to, the doctrine of contra proferentem, or any legal decision which would require interpretation
of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived. The provisions of
this Agreement shall be interpreted in a reasonable manner to effect the intent of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in multiple counterparts (including by means of telecopied signature pages&nbsp;or electronic transmission
in portable document format (pdf)), any one of which need not contain the signatures of more than one party, but all such counterparts
taken together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CBTX</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">CBTX,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 49%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Director Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALLEGIANCE</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ALLEGIANCE
    BANCSHARES,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Director Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERSIGNED</B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice address:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: _______________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Director Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cbtx-20211105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaKA2bOdzZR+uYkxtmB9bdnqDysiM6XLUyv2lKV2gcMN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:CBTX="http://cbtx.com/20211105" elementFormDefault="qualified" targetNamespace="http://cbtx.com/20211105">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://cbtx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cbtx-20211105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cbtx-20211105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cbtx-20211105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cbtx-20211105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cbtx.com/role/Cover" xlink:href="cbtx-20211105.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cbtx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2131964d8_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbtx-20211105.xsd" xlink:type="simple"/>
    <context id="From2021-11-05to2021-11-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001473844</identifier>
        </entity>
        <period>
            <startDate>2021-11-05</startDate>
            <endDate>2021-11-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-11-05to2021-11-05">0001473844</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-11-05to2021-11-05">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-11-05to2021-11-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-11-05to2021-11-05">2021-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-11-05to2021-11-05">CBTX, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-11-05to2021-11-05">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-11-05to2021-11-05">001-38280</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-11-05to2021-11-05">20-8339782</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-05to2021-11-05">9 Greenway Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-05to2021-11-05">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-05to2021-11-05">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-11-05to2021-11-05">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-05to2021-11-05">77046</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-11-05to2021-11-05">(713)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-11-05to2021-11-05">210-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-11-05to2021-11-05">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-11-05to2021-11-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-11-05to2021-11-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-11-05to2021-11-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-11-05to2021-11-05">Common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-11-05to2021-11-05">CBTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-11-05to2021-11-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-11-05to2021-11-05">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-11-05to2021-11-05">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140052255319576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CBTX,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001473844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8339782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Greenway Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">210-7600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !>(;%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  7B&Q3)W.'LNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:@,A$(9?I7C?'=>$'F3CI:6G! H-M/0F.DFDJRLZ93=O7W>;;"CM Q2\.//[
MS3=@:Z(T?<+GU$=,Y##?C;X+69JX82>B* &R.:'7N2Z)4)J'/GE-Y9J.$+7Y
MT$<$P?D]>"1M-6F8@%5<B$RUUDB34%.?+GAK%GS\3-T,LP:P0X^!,C1U TQ-
M$^-Y[%JX 2888?+YNX!V(<[5/[%S!]@E.6:WI(9AJ(?5G"L[-/"VV[[,ZU8N
M9-+!8'F5G:1SQ V[3GY=/3SNGY@27#154X[8"R$YE^OU^^3ZP^\F['OK#NX?
M&U\%50N__H7Z E!+ P04    "  7B&Q3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M !>(;%-C<6.^;P0  &X1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=;]LV%(:OVU]!&+MH 2>2Z,\4C@''2=J@;>K%[EILV 4MT181B=1(*H[W
MZW<H.Y*7R4?&;FQ)UGGU\!SJY:%'&Z4?3<RY)<]I(LUE*[8V^^!Y)HQYRLRY
MRKB$7U9*I\S"J5Y[)M.<1450FGC4]_M>RH1LC4?%M9D>CU1N$R'Y3!.3IRG3
MVRN>J,UE*VB]7'@0Z]BZ"]YXE+$UGW/[/9MI./-*E4BD7!JA)-%\==F:!!^N
M:-\%%'?\)OC&'!P3-Y2E4H_NY"ZZ;/F.B"<\M$Z"P=<3G_(D<4K \==>M%4^
MTP4>'K^HWQ:#A\$LF>%3E?P0D8TO6\,6B?B*Y8E]4)M/?#^@GM,+56**3[+9
MW=OS6R3,C57I/A@(4B%WW^QYGXB#@.ZQ +H/H 7W[D$%Y36S;#S2:D.TNQO4
MW$$QU"(:X(1T59E;#;\*B+/CJ7KB>N19D'(7O' ?=K4+HT?"[M73.?%[;4)]
M&OP[W ."$H.6&+30ZV 8Y(_)TE@-A?H3D>R4DIU"LGM$\EJ%.4P?2Q;;C->-
M$ \?GGU&(+HE1!=5F0!!5%#<)FQ=1X''KUAB.,+1*SEZIR5CQK50$;F1$8'Y
M4IL77*FH?*_]]LV;AM+W2[0^*G@CK;!;<BL23N[S=%D_'7$-WP_..D,Z]!&>
M0<DS.(7G@:^%FXR0LWN6UB8*UYE>+7ZVW][)\!R!&I90PU.@IE!"S1)R)R/^
M3#[S;1T6KN1#KKJ#SK#;1; N2JR+4[ 6[)G<1< F5B)DA=L>KR2N2/VS8:=S
M,1A2!"_P*W?S3P&$*BB=*5VPM<G<PM0G2I.IRB&AD%<5U5:X07WQ$X,\L.#@
M%,A)%&EN3/OE@'R!^\@W64^&2UZ0CYISN6%;,DO8WPSCK#PZH/^?<[%1M9RX
MY#P74(D@P%[<H'+\ /?LUX!3=P9E7JB-K(7#Y3XIM_Y*#*U:!P+<R%^CE5-P
MIM63D&%]D7%-?/I52T. ._IKM)DR%CSF=Y$=?R]PQ<' [_8QMFIM"'!C+RHX
M@7;S. HN\&X0=-YC*-6R$.!^_D6%D)59K"2V3C6(T, _&_1]=+I7:T* 6_D/
M+:SE$E*3IKG<.Z^II<*%K,ZQ)B.HEH, =^^Y2D0HK)!K\A7FMQ8LJ<7!59J:
M'EK9/\4->J;Y60C9X?""[7I!:,>@T?RV6M67KT&OD:SR?(H;]'_([HS)@:P1
M$)=M!#QHR'%G7@@+#9E:D8"^6[XG<Q[F,-UJ&XX&)3<]H2, *PT?VR1CFCRQ
M).?D%__<#T@&HS4QTRAUM0)0W+(7FD5N]LVWZ5+5SKT& =>U8225X5/<G%\2
M1FZ>PYC)-3_:1C8(W4_FUY-?,:;*Z>E)3G^3<KUV6?H("C9V_I$Q65]:7+#!
M.&CE\[1A$^!VZ3PB]PK>446^&TYLS"%WUKT/$8&Z2B.*SG*W@ZF%Q9]Q#-8[
MV#V[?R*^,I<=0Q*^ AW_?  YT+O-_>[$JJS84"^5A>UY<1AS!J^MNP%^7REE
M7T[<'KW\BV7\#U!+ P04    "  7B&Q3GZ ;\+$"  #B#   #0   'AL+W-T
M>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/Z
MZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N
M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2
MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(
M&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=
MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-
M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]
MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU
MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>
MDO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A
M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[
M7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..V
MBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/
M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>
MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%'
M, ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  7B&Q3EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( !>(;%.J
MQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A
M#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B
M;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"
M$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;
M%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z
M0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&)
M)@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>
M9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  7B&Q3)!Z;HJT   #X
M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !>(;%,G<X>R[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !>(
M;%.97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ %XAL4V-Q8[YO!   ;A$  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !>(
M;%.?H!OPL0(  .(,   -              "  ;(,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ %XAL4Y>*NQS     $P(   L              ( !C@\
M %]R96QS+RYR96QS4$L! A0#%     @ %XAL4ZK$(A8S 0  (@(   \
M         ( !=Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !>(;%,D
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !>(;%-ED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2131964d8_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cbtx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2131964d8_8k.htm">tm2131964d8_8k.htm</File>
    <File>cbtx-20211105.xsd</File>
    <File>cbtx-20211105_lab.xml</File>
    <File>cbtx-20211105_pre.xml</File>
    <File>tm2131964d8_ex10-1.htm</File>
    <File>tm2131964d8_ex10-2.htm</File>
    <File>tm2131964d8_ex2-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2131964d8_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2131964d8_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbtx-20211105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbtx-20211105_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbtx-20211105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "CBTX",
   "nsuri": "http://cbtx.com/20211105",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2131964d8_8k.htm",
      "contextRef": "From2021-11-05to2021-11-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://cbtx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2131964d8_8k.htm",
      "contextRef": "From2021-11-05to2021-11-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cbtx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-21-138192-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-138192-xbrl.zip
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M?B%[L'0MG5LR )M-- Q10&S8G0%PE&*4JY&4>\3C3B0;+/:+).KI/-I"MX!
M1IN$F*J $ &L 8R4:K28S_SW+4N\F\<2VN0A*=Y#[V$%U+M%IL=VDQQ '!!
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MV!_8?E0AZ!#C9^W.? $W]8$"L<E=7,D-2UD!G;/5.[ML5LMWVD1!D-+EK+6
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MMW]=I;DW0_NA&K['%(H=9TMH2!X.\"QAAB:%8T,FB(AM.K;;P>?)[^M+0<.
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MU9'6GH98,\>S)X]'.(\=/K0#C)V%Z$SGG\Y-Y5UG;/[5-R\&&SJ(REJHH;D
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MB_Z*,,7*Y%#/PUH#_GGI][RIFX^SKG_5B]R]TZO>4Z,L67GCY*T7!:'GKDP
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M!98@"^QQY(2&RT%;.#,6@ T7#&;TJGS!Z\/*TE05<VKAI0CF\9GASM2S@>?
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MB32H!5EF!)+692;W0P.0(MM1C<!, >$STT&!>4CK"9;M$V(Q@*YT#OE[&%?
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M/A]Z./,\1,0$$XJ3H.-&&6 3+PAL<.(*U/P12YC!K0MA<#CE5.>Y &_K:_E
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M+L,"&!X #<2UP7UP2@9V?'H( ((7>H64=1>OC!N=(=EHEI%CC^W8]!5!"V)
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M_H[1,3#[!<]3%!';T<HX\$ BU9%(3:!1^>O(QUK^D;B;"8P!3&SX?<]//@
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M-WIU>+-]?G79Z2%$[0N$7&RH_OKRNL?J9V>PR_I%HR69'R'(F?KET50[;@U
M!:Q"S,^8XC3JF"#"+0-JIFAZDZ058,"3QJL%YE&-$I:0&;YT/@JY+5IS_)+<
M[V7"4]^+AF*4<DS&:%^2?4U?V8P=FWQ_A37O637=<SWVC'"S%!RBF#?E55.T
M7V]>F30BU9PF7-Q4+>BP5;8W"._P%ZVI(;;XQHGDA:8Z O#K1 @E2*XV"WK_
M7:RI!4A$62$%-N.T+_@9$.-0&#@$ 3P9X;<QY">:4Q_'/F1O8&_N% [VRC'^
M-H!:(H!=^IJ5<B'32)SM[Y=K>P56#T.@FWE8"VQS'T.05?!3]_?*Y8)RHU8^
M[8=A/\?'SZ#?B$<@_A'W&)/^^<AG6=S?EVH/+M[!06V??<))NL9881[<$/\;
M'!!^53IU/-5R_O&4L8WN066+'1S6BCLPZN7)(3#7K_#"#>/W<;(44(MF9[Y(
MXURDX&2B$&:JU4&JG!<X)ZX:IL#L?*<!>1MBX3V,3 <3EY49W&5M=&H^H-]H
MKV!34?QW!=.MQ%3"V^+&-2J,K&F/%-BB"\E\"SC;EUQ'T@T\-?HCF8[X,J6Y
M*)*=CH/$1K-JR".1=*]AF]Z#VG9\$3D=<>PNAQG6'A)++,1*3 MUVKF>Z+TG
MK9^)0 1^,S[^+$Q:":4<!3OSQ>Y41#*S6\H!M.D *%*I=;-/=]C.D>28]#7Q
M;4>JCQJ(-*Q$>J+-9]@F!P4YVB!SY99!1,X+3XN.<\,W1RIR&Z.CES:65.1:
MF%;T_:"4QDM8U(M\3+A0_<TLQ.#MS_S&QI)HV/[O:-@+BX:)!B&D7;OM-Q?U
MWG6GU7V!>E3^:-/W*V%@:1?KW*^TH@:11$$1;N*PV.N_MZPAU((@U)$2ORGB
MS-2U/T7P?:XU<,#@-WVC67R(A(\,9Z!NQ,G.E -0^?#(Q90OFC#Y]-'O>O(E
M-5@P&=8:_;E1?7P9=?]$]WLN&K)EP8^416>JQW?+]Y2/RW$[JPVK[?_Q#Q7(
M-4'M'67JB2M545"<7SGWR(5>SX[8TKK\Y7KDT<2P'6RK[POW2NS*'L+\R7<I
M?U6M_&.A?[F0=[F+WPA+/M[[$=,@\K[:G*01R>_[OKAJP]4ZA!T<LTO15NB(
MG1G@\S\;<^K7M>':[GO6#,]P>Q2.G9,TPKH<=G-AC %7=];=,6LWZ1]?R@>O
MOU B4$ ), 0<O<??W9U^_5A^/_U:_S!J;7^XG-WM.I/O9?OB]5N[-OFK\]?W
MMG]X&KVS1N/9K/^?MZ;3?^/<MFX^G=[<^+6;]O6-W?UPVVN?7]Q]'!G3N_T;
M/VR97G!]\X8?](>STX'?/&^'!Y_>FS?5RN'V]G[=K;]O#F_<5G>RURB?WM[>
MC=]\''Y\]_6R4W8;XZXQZ5S]U;_NE2N?+V>AX7[@W\_[Y3.C\?;CU=O7_LZX
MLMN85LK_F57.]O>^#R]GY]5.\W-C^O8_'ZKO/M:=8,^H#>Y.S;>=FS=GQD7G
MZMV[F_/P/[M]<^>2?YH,=ZKMOZ*+O>;VUU[M8[OLG IT_']02P,$%     @
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MD4>"#75(( XM[9ETJ.M3-2I"=))G)?TSXRV( G !\GU)SY)RMD2/P"AD&0J
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MK,W9#@K*+M/)1P@4V3/C$YZ-0(HY&!N4<WF(GUV[1NS&(;HX>J&SHX3+8LM
M,E=L<K"R%J3>OU?)?QF;&AR838@B+!D]TS%$!88B'\>I=5R=7@OXSMAL]XQS
M$W<XK,I>!O'9HEG8$OU&_BNSY4%A3O& WZ(#>%W5)N'# (1JJM+*>9[W05"_
MYSJ'!YQ-@Q]%L_%I?<U'LBN(&_:%T0MLVU=4Z;7%D/D%&TKRE>4Q[4(&^>5T
M%"!T.R9M$^J)-J$ 'FY-BR3W9UB3!GF<\GDH6_<,Y17('9E0!-\')&B*QSBJ
ML*6'><$'QD^UP=Y"?P[>S6'Q93,K.;6Y -ESNEUA"6(Q]_S%?4LMQ/(6J"-%
M29-NQQ*ENB4!RV.M76A9$A?8$]%$)'J(!]Q(H+6:ZOVX<DXCB@6&\IC1-+UN
MGKTI UZ$ICER[L:,Q5Y<3A<5V)=7EVH6RB(Q?0S&+&*$XW"L\0BP5R/' EX)
MGGL5SN(Y=AL#.2NNF:RWL_VP7'9OOAJHBGZ9GA1A+B,%:L*X/5=4BZ;DM!\7
M: 21B3*O[.?EKLUY-Q1OBP$-K+&+ +N$C9VDP=U.&019)8OI;LLGU)J).BLM
MOHZ\SW)5T5?KJNC35D5?K:NBJR(QCZ]='_5,]WUT+3B-\4B1RUJF*UL;EJH^
MT\9V)5"^DT$<S(P+G4/TZUACG(1B#7O-4IFF=.\'X).2CG>0\V4,U*PYD3E&
M.U0:HZHAW_W6%J6 UP&K*;SXB<MNV!SD[&$!(HS;Z;H\%ZIY=X4]UEL@6GGC
M\/BL?J=S0P_+ZN#L=3O@F&H?(;35/0^< ( \R)Q[JJKZ-,7"96DL3JN^^/*
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M<<<?.S[%7_M:N^ KZ(*OH#_\:*GB.8%Y>73^[C=2;!_Z'T][_P]02P,$%
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M2YM6B$C8%D(%SP!2+:K\ L@6O@9P;#EO$R5#',*Y//*Y$_0(= 2X24%FH@!
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MO<.RXE$=(/Z?QX_5:VN2^ 6@^-SLP/6_5<!5&#O=4>^FM.,7^-Q3]O9WU#^
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MNT3H.W0/U+ B_QU7HJ"9P00 ,>F+!8PTU05X3)(P=$&HCFWKCO4"Y*.+=KE
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M]/.WHY.RIB&>[8.3^%Q16_L=1OL46,$>@OF *[;S*I&H,L<I&K6V0RZP;K_
M$5]R"$S#IAQ/^4-.(*4/R_NYH?Q:I]A$+*-DO@G- A#%V E%2?< !<"P^W,R
MM.>5K5V?)@KD)3\$4JY'I7_3%AU*FKD8D!_;:HM \9+5+Z-+&A(9;>K^JF</
MK@2ZPAE63BYD7DQZ =22/O>$3Y?:NT8^*^ 6,%3X#J ^1]FW@0'^)U528L"-
MV,K='<[+H%)P+6H6*TTQRQNWDBJ%MR>#6E1B*Q*L&<VL4/1B*#QG]X9/Q3)=
MK4WCT?HZ%Z&+>\.4GAK#K4>29.#8O%NZX.$;;M).T(N"7(?T)J\PK'<&=*D_
MT5"M<Q[9R719OY.+GN($ [XADOI \NJ;ZGS@P-VCO7_M'NV=^H-Z[[-?K[,D
MR68%YNGO<+G"]6*I/SS$4BF6^L-#+/6KY]J/U8>CL^/#TU/UX<WAR>&[UX-0
M1W'6T#5'1)H<Y99:9 L'>R9JJ:Q]5)+FLH]L#@K:-4E0R.>;$T1+K#9Z245G
MNT]>?H5ZR]N?@NX%3P0B64\+V*?[WQ<.2.]@S.TIG$[>/SG]U3O<Y_%?'VT_
M6OBT99VDT G9"&@%O%#5%%\=HG'C85GA\:N-_NGW=PPQP8W_53!Z<G[ZTU^N
M-9%_ZXK+%CT?[UN>''F)+\6[9&[_Y?9 #SDOP,*=I87EH9(LD6^"1Y>WYS,<
MT;5@TW=XLOT"[7RT]Z^FFX!VR8%[#]AI12&9VFKY-Q?XWE43Y'I^PX]?QUNX
MCG'\8(__N0;E_MNWAS\?[1^_.GPP*]N2^<LD\-<Q$^MSDQ<PP7]/W^R?')XV
M&EO_B&+ZPNW_(0/@SUBS9:,MRY:[DZ;;TBRU/YDWEF)Y_>E[>+"DOG5+ZJ<'
M2^K!DF)+ZM?C@\.3TZ.?CP\/'DRI:XG:/K_U*IY8IJ9_MKE434]*]>XKN%LV
MUFY+W?-\'6F >\"+P\M_^O_<-GX>-G!_-B"]P=>"_VM8I7VIXYLN<E62^;_1
M5MT"*^C=E"J]7JBW.,+LSMBN7\^0?/+RW<$_D7Z?O#G[Y>W>_P-02P,$%
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M<!@EMWMQ.((>'.P?__ J2MYYTKNW_]6HM:EQWYS5&Y1?OCE<^J>'!\T_=38
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MMIIO_&=ST;U>[J*S BYKB2M\ZY)]XYPL=9/U!G"%Y7C/6Q:+@/1 ,1A%0Y#
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M_XGVVDXT4ONF>:?L@CT:P8.R5^T%]YL\5[[ER8_!=)*K,BCS4$RL412'0W1
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MW*4/R%DDA%$LQD:6B= T('*[\W'C8L!")-!<[[4PK?T6A@SE)!DS:_S:W;#
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MU)GA2$M4)4G0'$MT#6??3M#V&Y?";W(P.CY+<0;K[1='"C$35+>:ES;7^:D
M191/5 P,4X@'YOLV!;5Z%-"F2Y'WH03+=8":342EF^QIL](X@S[,1DKS2BYN
M'%B8#^["@$8C[N;M+:1 V7PUI6N)>[N)7AGE:C/GI$IB:)O5%1N!ZQQH"F7<
MKN2%GP4 ;_K-]A81_2T(/6N49?JW"\#2:D*B!:)$,29S9/E@V9Q4K0TZLXDM
MS(=?IEFKW\$7N:<Z@&1>Q/"BXR'-\]H8D!ZS?:L,+G5?Z*+$Q"NC9)5&.=+S
M2'\!?8E3-(_@"1"*>\26@P$33/GV;BKLE8B[4YU&OWO*?1,[F991W !5G[/
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MM?*[,,9)26[!"MR#0P"JC5*P0*D9A0\6,4<F5<]-N6TI8XZ5)BAU/>+51:W
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M[*8HW&DPB0H8Z@M@\%D !F]0@1,M'XVD 2^?BN/*U56Y?^MIS\2;E?-E]_;
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M45H&# &&MQ.A+ 9#Q",C:98M$KIO%V#<M8"H6(J&7TX_Z$<2Z]=%.$U*7)C
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M."MT#.'H*8V.2\+;KK+ \BR-HEA7*K/H%$6O$L'-#S%*.E(@$WR67)C8YD.
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MN+M-TR&RC(!AW)_:>$=BUM=L#PK]SO.I(OM6%Q#YHW(26[(&86K.A:)H]B'
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MLU+1-3)[[,D5@IQP<)>D<7I+I'?W98RYC)3"U 1@9>8<R\I2OY[*19]SZ+K
MI 8I:HJ!YWG3,(^P9<')>!&BFTL=*:FSVULF$=CE29F73MSN6,=?J;1E*Y/9
M)#<'3H$2L?R1&XRO:.0AO@OBT2*0;@+L\<O49E9_614?J20D129 :5P$*@Z&
MBBUG':X[WWQ^&XT*^V_RT^*5,G8&*,2+KB& !A5YD DK> ]2P!;YC.-*IN@!
MD<8E\Q9_JVP>S+A*QYC+/G#9L&C2(\S/L%*1<EFVIE^;WE -;GYV$(PG 3PI
M8?^%9\_)O& WF<R_@2,Z[#,J;Q,WE'&K*3-,NGN:9EF)'D3'>2&EJ'ZP(5XF
M2TU0D#"#=MZ';1_A#6Q7!IN:U<3ALBF61':J6R"6]4(3<5]94 P5E0B10V)2
MV%53ES>/\^<=VKQ9S1,E\'UUTY@A])%BV-J@6=@G 6]O*M@KU@=PG<0<(- T
M!OJ[+]'@"Y;;-%.AOL+2[7IW"GMACA*%U"8&G!+09D#>S_^?O6]M;AN[MOS.
M*OX'U%3FEE0%:22_NIVN2I7LMA-G.FU?RTFFYAM(@A)B$N %0,F<7S]G/\\^
M>)"0VRW2N?QP<]LBB<=Y[+,?:Z^5E+,%H,"@NHD:E*;W'L,[+W0:F2X5['.C
M<J=A=?>"]%!EI2/5;3$5DC(_@H,SHY!W2MT8U :ST]YQ<1.^VW5CI++C^]&A
MCK"=TOZNZ][)PEUBMN''<^MOT,. E:N$/F*QL4IJ\)L@PP,M3)(""23O=N2-
MHJUI(TT4^?R1%K)!,QU*Y0@;E&0_2HH^8K;_\%V/8?73IQ?'^NF^ZZ=/C_73
M@]DU^W;8]\_]?%4I 44 ^C:Q<3,WYE%A;'TAP0'P?*R(% AIIKI<QN;37L(=
M-1RRWZ>+Q1FK@T,J(B N),89D"[- A;# -?M<^]RKI@[:^.Z\QE0^ M+"OR3
MHOP.6E#VO3KW2!.\]^J^QGI#D)")8@!!4L:Z15C"F4Z!(8I<0X+H9S5$:171
M+ G-[B8HKG?]"-S1\B[EWR&IE<:_L?/@JKIPSY3'OOBM) L)Z=O>K)VOC%^!
M&I"[6,)<8":]S3I&<9>,,7),@4B?6@V*$^&159./BE>^PH*US3B:<_T+/I68
MT;G[;CV\?";"<]J!;QE6M[FNQ%3,'\)[-+[#5L K-6@&(8QE8TP!4@.X1)>3
M4J8<AQH;"&2N@/(XE(-7AE$T7?Z+/).>EX#_  TI#3*"UH\PNV?4',LRY=J]
M-%YYRG2Z-L>25/Z".+A2_J[6U0_? NX+)O],#!^^SN^'DJ?L#A?5P2(<@?$'
M#HSO\Y?R@>0.4<CMT"8>HH40B&3'AIB"ZC6&N<*Y2Y+MD+(56G20;X96+1=&
MRY'2Q9)X^L=_L]5V^3V1K6Y?:WCL,QN(B'.)WR(+14K-VWSF=P#1>'%Q>3(Y
M/;F\\()<!DYT??:_34_:*9W)QY6Q?67\/DMCT)K@QM6*J&!L#EQ6"#H&0*LV
MI1Y2V^Y"A*WD86F><0#A$M@>* 9;-EXUAW\#[M:2.#\['H+<$V9/E*6V+N^<
M)^]L$R-1PWLG0MZ.U7,B2O!\L^'C2],'?':30E5^Y48*VRI<*'A<SD.6\S=>
MSSL6LCLO):>=,.D=4L;%/0QX7/L2'KS@8P,M[J?O4Q*EHWD;M![N'G,Y8&V2
MS8*J^! 7<3%9J/H.X;<I'D9+DZ <#@*ME% ;JW!*T>V+$RP2FT]3,4#=/.3\
M(&$O,])0K[3Y_B,@"JNL9AS@/PHJ2J&1RW/GTDU5B;#)71Y(W_31->,C9\ZL
MF4<0UX_?/U&*[2CL-"L#ZA@S3!UDSTI*(9SC]O',1(Q'9M GP.*PF*[I4:7@
MF%196]IGQ_O9$298);/R,36ZG4@:/E 4D:<*UD8\:#ABIBG-Z2B1UQ >=QD$
MO<>CMQE^)[9I8+WI\EAOVG>]Z=FQWG0PNV:_)_JC'NBJ_ Q1"9"?+,21ISJ-
M/8KAA2?.2@Z,0X(\.21<$V:(@@:0%!$E]N")(U-D&H_P2]S6CT9=4#V^E\3D
M7D*I0>GZ$1YX G.4@)/AUOS*Y[D)WK1:E^ZXJ5 3<':G"O;N.:#W@O0K;'<(
M=F#]XC[SQ;;*,]14T+'/36S*9<ILRGRC.(1,\$AK\:PAB8B^CL: X*I Z4*(
M1I&S3MIIB,#JY)69UPX&_W7BQ@[+$M5Z12Q>,+W+7*EH %KE'**54EOGLX)I
M_MWA'LY^LWK(#HL%8YG<V( 0M@%YI0:<P(LP<\M'O%F<XMX8H&&+V$J*!@Q>
MCG0G8(GCU2G^P++AK$HW2=D*2B,L 3./_O \OKBX@/_#(L?2F=#OQ#/8LXW[
M5D'L=NM&1NVF3*C<M?&^YSPK*ZA,S]<5I& ;?R_F<R)KD-5+GW?Q&FFJCVHZ
MRBR"';7"-Q)9?9T.G%GR&35*H:?AME@<E]"P)92=?NVJH761+)",!B.#^@Q#
M)L/KB4W<2GO&^8SCI.R<E*_?V4,R4?#@H($ ,R3)]8**Q!C +VK<ZW3@L="]
M8%II,FOT/^KH#T^>D^'F=&1]GRY<Y'=R^>3T;.FN?"M:W'AD)K7R 7"8.H$&
MSB'9V%Q88*'"FWT!7MD7S"M+[; 5G7<@:64S N:X.RZ['4FP+X_I,Y/UP'H/
MK[D@;XD(>R980,POL#E6Q;R^AQ7$O6A+:8;6CG-9S8#Q*!9WHFLF"&MJ#D[)
MP=6UNTH16I&OEX$#K/@&N:@H52-00=?OH&)"WKMH>5G?2T\)=?LSHZ8^MZ2$
MH;"1L?-F'E5J'IDD=^BJQ^3OD'7_C9?]0U=_I3P(#%2B^6ZK[W W.]?"K-<$
M?\WR->X&DT#>W05!ZP-<_^,:V;Y&'K5>U)E&2*:4A>=($N2BBBJSB7:)T33$
M91XY6CHVG=[G15/>%OMZ-IS#A6YA7F9^;9'1Y0KGX6-X.E?,__C3F\08]X>@
M4"3COUD!XR_0=4PDZ>"V=%,5%C!6".,!95C!KT!O:0&$\]@!0YPU2NUJN&BN
MF14\!IR#B[32DIF6B2F912T;G-H"L4*$E: FM/=W*\\Y /#B 'UGF<XI"C,Z
M@'(GI&0FFNINJ:+SPUT= ]/[3X[I_7VG]Y\?T_L'LVOVC8O\?>CX=B#U$Y4%
M>*V!1@65U(S8@B89*T_F>L0RN+N=KPHTT @Q+>)?R$]%O2=H4K5!$#JV19!E
M*!7!;BW.(=P, 0-@=]LW7JJ7Z:A-#>A9-^ 7UG%M* J$/R6^._XE0TGIO%FZ
M[X]'>.B0L],^IQJ<P<106^2&J@D/YISO0/RS@ULQ=,#!>?O=V##HM9RK4<[.
M"%R+"/>T5*2MOK='6^/)__M/3OA3-SNHV1Y,"H[Y]SHI0W7M<+CMU&$I!_[(
M$N_4UDL)+6KZ")KWM1ZD\Q>L="G*,-\ *RD(5F@  \E#S,B082E(!ITSB)R'
M2+]DE29-+($E--R0,CV- =:>T&W!]W.6G\#B]6U,(!S_X]BJE$C32NFY145_
MJJR_EHQ#R0EB6_ZBK47C'#-8RW.7#EO3K<?=LHJ1\N9W,N;?9[SV"*TPSW^K
M]_#W/RG&JV(QB(_2A+F)KH#?T"T[DJ"Z]M0#S8CQ)7;E0+CXD%:+D,L I 22
M*CUS%OD,V DKDT4D#1XL1Z.K0>FE*7.IHR )*)$064*@SKG1QHO$@]DD:V63
MM^/1,ET6+J">K9$R,8B@\:SHN;X)O!?()V>387B5.F%99;E"@\1!WLZ=.M@(
MA]#8C1I@U%_%[]"F$>;]J=N!"V9(7*5YLG#/U/S9-F6I&/&&T\P%R;D@S\>C
M:KT"!HZ*J#SQ?50&9OO5D)9O5JR4_P581-%HK3Q=*IK)I,0&N&*Q9K**FEN'
M77Q4U6A<J_7-#;#5X.E"AJVY, V35A=Q,C&<*7&&Q]MSY:?I5,#5F+^BWV I
M8+[O(@TP/RQ[F]UB7:?PMVZSYVD9F?09:K$S,,:-J1L7I*-#W#VC]'DAH!E.
M\UE%GTZ):!B89;+J,UPYH021F0WXGOF LVKZE"=@\V. E'YMXJ>5W@EFCK=<
M*+Z6\Z(-SS]WV#?-!JYJ;(*E!!;L;BJJQ*V#T3N@1A.=UO!?DWR=E!M:PKJ"
MV67QCPL(WX$K+</("C$Z3%4*A@FK0"B,E]3XW[B/^;]DP2M42@_E\ EXQ(['
M8-\Q^.*1A)/>Y'=96?#LCT?.;0$H 9V.;R3@'>SX/" DV.8B47QO*._;4NPE
MP:DU/#'*0!H-]>T+T 2B2 GU;Q '%S>419$UVFJH*0?^#$BBC2)*((-"26MB
M\L5-WZ)3MB1J?_1BE<31J73AN),JMUO"GJ?4SQ;(&KGSD<*]*IF#S"N$E[4U
MNK?)_W,'4['&\YF4^V#.R+J!%4SJ=4FFOEA#OF.6+-TCNZ6IRH]PVUMWCP41
M8*\!\$<]_C#H5 %!X%&Z$ 2],4WZ5PJ^]-[@.(!]Z'A 0OU-M3$?56F*&5C#
M^[1>)' P8,A4P/AF)7)[T['+ HL>>$!6-\O_!61/<+Q@=<9BFC:$B#0/UO=<
M[IFTS0?8^?R!T-A#OR3W58,,U#)G+MP&6,1*VP S#!LG*2=9#7.A=AE=C'1&
M0I+319(1'::B3#OBIH#" "1.B;TLM0_(U N^0@E+;>GNDZCR[UTF%'H!*U_S
MAQ0BXQH"HM647<(H6[K!3&-Q#J![<'LT'#+HX<\SWG-Y<'ZVX9G<G*>-?K9%
M [M0X)G09:6R?C!7( T'?N:,,0QFX0KG+8TFA<]]MWE(L#^DI>,W)::(I34#
M4(/E!:9NF7EA8F6_OD#S#-97+ '(UIFWW(<TU5LG(6!*?,1\"*Z5C&AV&]%)
M8GN<T*C_:SV[H3^(>:= P2T:BX8)XRG_T00?D[-O!'5VE^IPK.)M+C^F$SD2
MHTW 7I0.+2X8N_(:.$X8)2B/W!2$NGG@R#_HV'9NW'>:VAA8;'QZ+#;NN]CX
MXEAL/)A=LZ](Z(='BH2\L@[*JD@'#,D"+4%*NM:\X1LNP&T3,JG<$5HX$XNJ
M.7#P@!Y.>-VIORY*?DJUYB1E.C(763C[:IIP?-N-Z<<Y-9A(S<"PMI:RTOF4
M3<YP3S _U!L+O@&(0*;,^^1\]E)\JU^R%&2^M/C9SIIX212C(DX=4[X-R,HE
M&\_5+1Z$J(,_8@:G*(.Q0;@I^CDS!+ET]!4%U!(@E(XLMGU0O.9T028X?(+F
M], C8+>N]!^/1\QXS%?M("_[\]75A]YZW^$?D_O:\#\^TH8'(2Q@XZ8X\)!2
M'N"EMV(=316H:2%MI/)S6A.(S%H:2CX#'[K$N4S;YK<D9@G<NZYG&5F!!>EG
M5[=I6F_?P)B+QZ!)K%;_<V/(RN5J*C@J+(TY ;K-E_09=9LKL9&V-PGMI'C3
M]T! 0.F)=$8="XBM:]Y[MSDY'8].X"N-#/![?/4/>OLP^]MA3*T5 *M::7U2
MR1]);Q%B _Q"I&S@TOB!%>MHX^9GMDXMX3Y]?VX3&S#P,S!:SH591I^2+RD%
M0_SKR @\!XSWD+#!F_D6,#=%R2;V/:QND7 UR/ECZ^6DI#Y3##AF!=[%4/(D
MM,@-ZT,9L68,I[VTNTS8Z7W$QF5U^ 0OD\[H;QARN7A(Y]K<, />?T-I[G5F
MH"XCP2_?5*@@A>F>""&6 '1(O7A=5E(J4 ZH.6\W]Q$./8) '_/5HRUO[LZF
M0:^N@C=1A]Z-C$=?UNL#YC_AH=Z8-1#L N*%U%1B1BUJT'*1IK(E,#^(PN!I
M1>SLNPS53G_#%AW07F'8_%5&*!ID@^8%B0'*%B 5NR^KS#/59Z7PF';;H=/H
MA"3/F\,11W8"/"MJIPVB]N)6J8JD*/68,_/S(#,%K]D]ZPR=PT*D,[@5"01T
MK'+GO<*,*'()7W?&VD+HXL8>X>8'Q"/\I+],P";^A\*Z(\MK1_6,OEB4)CL+
MQM6D P=6WZ TFBXYXVQRMII"-*>GF8C#]_\&IDF>'=,D^TZ3_'!,DQS,KME7
MU/3RT=(D=8KGT;H=/>T$*$.\H HPU#%*1P'X1">61Z0O'1$>3:#(MW"/81]*
M+6R4I]"U"DZ]L(7TP5@2JT?#7TIG#PP'"7W]C>)!'$M3'_8.VM8S;<T,*S!4
MW8.R5>UV5G",D.5SB#O<0RZS*EG!"5YF7!_WCB=K8U&PJ:&";X,C_X_<@F9R
MI"DW3XL!'(1JG9 04]@GUU7_4Y].GT 64W, _%*-6]3O_+2$]G+.0UF'0!QQ
M ]&W&Z#HIJ,W:PX?J2JU!I">OWN^_+B2\\[]A;X^W[L>_(L!BN?6K<,TOV'T
M#CX?]='E77,JE2>E$WD@S\V6!:@I S<-_TL;QUFVN9]:!"=-40%=D,SFXK!(
M[P VZ5D,:*F2PX<5T(C(&1[V(EM6*#WW#KUK8DV!;&-:3H7%5BJWI"L(\1L\
MS%V1,:G_Q%U/D"!-_L%USJ!2PW\+?OVV]S S$<M$<LS'K\B[N94Z?0M)!_#K
M*PZ,&SR+/ASIO+^)2$"]%EX4"*X@L>6FG;73(OXGQ!L VT^61,L%&N"0SBA
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MB+27!"'8=%'PD)AGL#1QF;5U-B=+SD!:PQ%%MS_\5,">@IHG%X]6"EJ0/?^
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MZP"Y&.)1 ETH0WCC_N8V\>QL412?&=?(65^YHL]01(';$^2'83M#PI?[:Q8
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MKB5BXMH;%+91]7)NVT6E[V2RS:J5J$3E_J*AY]D34\?1D%O[]=SY%*?61+8
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M999S-RZ<ITDYR6KFH6%I3+_@8\I20?9(F@ EI<#\$;[5N4#BB* +D[(-XY$
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MO#\2Y7)ASJQRMTR(,=>S+2ZSFE'CV+;:$&%H+7UW7[^H:$F5Z1*[%*"[E9(
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M]61Z"RW$O.H?T*CXY,>+/P>]=\>#9,=!\J_]);NW%8.#"A-NN+*HJK/UBDQ
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M<_)*Y761W,_7V \$JA:=1XN1N<<BY'WNKGZ;K<37"+_-< >LYD@+6SX3!(=
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MCM"%+R40;D^)YB[4JI@E "A0<:&^Y0__XKQ6:A5ZE>2?S;?045-= L8U0&*
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M,GYWO2NFEZE.C&\L0V8:J,"4.,]BC>0VK8$-M9FWCVTVAT8XTD$"$Z&=.?U
MU^]DSP\LB;P\ED3V71)Y<BR)',RNV?=)F?TN)^6#7%ZKY,T$Q[[NS>W106E<
M3[=7R ]=1Q^X4&VL</!1^B6C$GYGR;G9Y >H88_!Y:/!A;,5D)QGU:W[_JQ8
MU;$FY9EW)UN1;PE$9NUS>XH!9O.;^&YRW+=>;#S:\68*&5OA/[A0;R1C8CW.
M8F%OAE] +NR&NRC\*3?1TZTQL'"0]PXN*O1V'60RNN:T/_GB2QQ?4W\8CP+
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M+1D[E^I,2U2W2GY_W[5TA8WG-YZ"?51=T;C=5JWPL*&83HWEQ_?*2I'UU,'
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MK_/T"ZB<MV@,UEJ:^8814OR%D\-#KE8W%;)SZ^6>[CRCQ!S,J?G1LYUGX!+
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M=X4Z++:7LT*$ 4207V0Q?BUPM8R)H.$R,8D9<'9>4;'Z+TF/6^XT-8Y+^8&
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MFP"A14B:4V:<QS4<!0O-HD( ,9AGOF),(PIKEPT0:^".UQ5_L;#'3+"NRC;
M0^O0-?WT76QZMMGHAL:>U[&XYVXI8YX(OK+\MI@@MQ[5>SHI<&%,(V-M;')@
MR]FW70D,A2 ::XL.5X4@35J8FX1/CS7+A!>#:=_=;Y8H,]<26VU4NL[CIIA?
M;[]@#YGJF6!MUE<QDTF_8%JB8I+F9D)%4^)>(ERQDL$E%3X!!()AH@Y6E$NJ
MS!YQ_\D.C6A!I<X?U]_J7/7UN8JV$[\19Z-SQ9 N:.X=;FCS3HA,)4:R0,?!
MD0"- 6N1PGIFDI1V>Q<R#)F0W*P*6PR7W1YUB**QD7K_LW4E%R :33$$$7^
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M3AW@PXC5GFY'\+,+5YPNIM2!09.R3K:?7F3R]4SLL1UZXG[KB=&W/?!I\U2
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M*^FIK$TG,T-4%&CCZ[MJ=!;@4P^9&-V0#II@W01K(?#!6BW+,'.-AQ2VX:Z
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MR"\WYLGZ B8#YLD#*LOQMDJU=]X#YZ[?6WCPFNEO.%&FU/2NB#JN\R:ICWW
M^IO-2X97]S;AU96'5Y]MPJMK<VQ6K<Y7B(!<*V^3=;WQ.;^'M^E[1Q(ZM"]>
MRN?TG_%0GF>_9US/KJO*VP1G%-_H?_H95/![Y[BA"R__!_5"65:[P4_?SQ?=
MYUAFV!F=@UM_!%\4%[/?NY\;&CV2%PKN[1)NJ+-MKJ?V\+ZHX[<LXXQ&R_NB
M3?#: H]4FG;?RR6-EO9(F=X[8.TVW5/R<GTS^6'\RM'&K_QW,$16"'K]"K]R
MJ5LD=3W*%N143T\[DA,X*O\_>I2KELC5(TX?-^!Q.2?@T6Q;M%2P$4S':S K
M:QMP)-/'M5(-&F]4#*<X Q@U4L/F%:GL(25R]<+/T\NBSN3BOBFQ70K_ TLA
MB0J/.1LFV!]":*@L!V'('3"<67@]Z-4='B#S,^ SQX97+QG=9A6:](W@Z8!G
MT.^=IMGU!2P[O<YKVQ(ZJGI"S0PT :.W;6"1_F)P"7$D9:I.;5AX($[U,$,J
MH__<PQ@PQ8&;!4,;O;#&:-QC'R^ -4@=@ $NT..6@II'H[:"]&6$RQ(9H";L
MJ0@,G@'>)A*N=,$!?!IPI#_!*B:!=V3<H0+1+;=6ZL0)XS=<F$:"9-:2I@G<
M:]=8Q4YEP 4R0&\D<H%$7JU.(@<)LO]W89^'&!N9I".2'5523H5^&];2"<(A
M_D3T8=++,IF8DLPF[(APT09WQ 7C+0A.Q+R43GZY<H?%QE;AR"U7-Y("15^*
M72G_P>+,),-A4>+9G&!A;=:,T BNJ[*%>DS@%E/I(X'.KF\DWJ.G0RY5I%1P
MK_1YRT6SI--(@6VJR!.&("GZG/%B-"?*%25#\G6K:59+@2,[[.14)2#5HTOV
M& 7<3W=UD3^!I]JBY+&4G303B[%[447^/250-@3 9^S38E,S(?!OO<&Q5DCS
M5<( 8>P)A<0Y\]MR6#.3NB[*/)U5<N=CKM1_PG8(Z$:#P;7!%H9@$G!$ARHC
M[K?7O,5LX?$>5_@'BMXLO]%DO;DT%V95\*P@=16&!YA:$S0[2I&^# .N$?&.
MWJ",)'D^O;:VFV/BW&!#._JF^L$42:RN!!UY]-,Y?/DW?/%9#>>ACOY63$MD
MW<* JT0GV ?1O@^N&$9WB6VN2[)Z(:%5%2(I/A7I#+2_(^42F"0]NH"[#CG
M)K.H20B=""Y3FNHY0Q7>C] SL7'9L.:2:WH"EOM.)S] [\<EDW3[FR3=RI-T
MSS=)NM4?&Y[P;F#"]+=5$0 C^OCKZ7]_'AP/3@_>1Q]/3WX].CLZ.3[;\/YV
MF=:O5\3[:SJV"^OOF>V1B=27$S8RF-OC!OXY)*MADMRU2A*$(#BY9@XB:2B
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M>=NI2O!6S>R(8J5M97&-YEOF8&ZCN)U8A*? ?[45: W7,[LB;@EP+(STEKQ
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MCO2&)Z/+BGO#T]$HY<5<*'1WIZ,WR-MSL75SG&_"N?A9Q)1A!?Q&>+ %3H@
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M+GAS9%!+ 0(4 Q0    ( !>(;%-P'HP( 0L  .*'   5              "
M 7 #  !C8G1X+3(P,C$Q,3 U7VQA8BYX;6Q02P$"% ,4    "  7B&Q39=PV
MEE4'   O60  %0              @ &D#@  8V)T>"TR,#(Q,3$P-5]P<F4N
M>&UL4$L! A0#%     @ %XAL4S3',9\:+0  3-D  !(              ( !
M+!8  '1M,C$S,3DV-&0X7SAK+FAT;5!+ 0(4 Q0    ( !>(;%.J]ZH:UA8
M #25   6              "  79#  !T;3(Q,S$Y-C1D.%]E>#$P+3$N:'1M
M4$L! A0#%     @ %XAL4W:V*/['(@  ![H  !8              ( !@%H
M '1M,C$S,3DV-&0X7V5X,3 M,BYH=&U02P$"% ,4    "  7B&Q3]\9D_5Z3
M 0#?6PH %0              @ %[?0  =&TR,3,Q.38T9#A?97@R+3$N:'1M
64$L%!@     '  < T $   P1 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
